日本臨牀　72/増刊3　最新関節リウマチ学

出版社： 日本臨牀社
発行日： 2014-03-28
分野： 臨床医学：一般  >  雑誌
ISSN： 00471852
雑誌名：
特集： 最新関節リウマチ学―寛解・治癒を目指した研究と最新治療
電子書籍版： 2014-04-20 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

19,800 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

19,800 円(税込)

購入する

目次

  • 日本臨牀　72/増刊3　最新関節リウマチ学

    ―目次―

    特集　最新関節リウマチ学―寛解・治癒を目指した研究と最新治療

    1．総　論
    2．関節リウマチの疫学
    3．関節リウマチの発症要因と発症メカニズム
    4．関節リウマチの病理・病態
    5．関節リウマチの基礎研究
    6．関節リウマチの検査・診断
    7．類縁疾患
    8．関節リウマチの治療
    9．関節リウマチの合併症
    10．関節リウマチの予後因子
    11．ガイドライン策定の意義
    12．トランスレーショナル リサーチ ―基礎から臨床応用まで―
    13．特　論

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

序文

P.6 掲載の参考文献
1) Fuchs HA, et al:Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol 16:585-591, 1989.
 
2) Goekoop-Ruiterman YP, et al:Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the Best study):a randomized, controlled trial. Arthritis Rheum 52:3381-3390, 2005.
PubMed
3) 高崎芳成:関節リウマチに対する治療法. 日医会誌 135:1047-1051, 2006.
 
4) Arnett FC, et al:The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324, 1988.
PubMed
5) 日本リウマチ学会新基準検証委員会コホート解析作業部会報告. [http://www.ryumachi-jp.com/info/news120115.html]
 
6) Aletaha D, et al:2010 rheumatoid arthritis classification criteria:an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69:1580-1588, 2010.
PubMed
7) Singh JA, et al:2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 64:625-639, 2012.
PubMed
8) Smolen JS, et al:EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs:2013 update. Ann Rheum Dis 73:492-509, 2014.
PubMed
9) Gabay C, et al:Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA):a randomised, double-blind, controlled phase 4 trial. Lancet 381:1541-1550, 2013.
PubMed
10) Schiff M, et al:Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis:two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis 73:86-94, 2014.
PubMed
11) Felson DT, et al:American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 63:573 -586, 2011.
 

I 総論

P.13 掲載の参考文献
1) Entezami P, et al:Historical perspective on etiology of rheumatoid arthritis. Hand Clin 27:1-10, 2010.
 
2) McInnes IB, Schett G:The pathogenesis of rheumatoid arthritis. N Engl J Med 365:2205-2219, 2011.
PubMed
3) Aletaha D, et al:2010 Rheumatoid arthritis classification criteria. Arthritis Rheum 62:2569-2581, 2010.
PubMed
4) O'Dell JR et al:Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med 369:307-318, 2013.
PubMed
5) Smolen JS, et al:EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease modifying antirheumatic drugs. Ann Rheum Dis 69:964-975, 2010.
PubMed
6) Felson DT, et al.:American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 63:573-586, 2011.
PubMed
P.17 掲載の参考文献
1) Zyrianova Y:Rheumatoid arthritis:a historical and biopsychosocial perspective. In:Rheumatoid Arthritis-Etiology, Consequences and Co-Morbidities (ed by Lemmey AB), p189-214, InTech, Rijeka, 2012.
 
2) Appelboom T, et al:Rubens and the question of antiquity of rheumatoid arthritis. JAMA 245:483-486, 1981.
PubMed
3) Ollier WE, et al:What is the natural history of rheumatoid arthritis? Best Pract Res Clin Rheum 15:27-48, 2001.
 
4) Welsing PM, et al:Is the disease course of rheumatoid arthritis becoming milder? Arthritis Rheum 52:2616-2624, 2005.
PubMed
5) Welsing PM, et al.:The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 44:2009-2017, 2001.
PubMed
6) Young A, et al:How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5 years of follow-up in 732 patients from the Early RA Study (ERAS). Rheumatology 39:603-611, 2000.
PubMed
7) Naz SM, Symmons DP:Mortality in established rheumatoid arthritis. Best Pract Res Clin Rheumatol 21:871-883, 2007.
PubMed
8) Sokka T, et al:Mortality in rheumatoid arthritis:2008 update. Clin Exp Rheumatol 26:S35-61, 2008.
PubMed
9) Toledano E, et al:A meta-analysis of mortality in rheumatic diseases. Reumatol Clin 8:334-341, 2012.
PubMed
10) Hakoda M, et al:Mortality of rheumatoid arthritis in Japan:a longitudinal cohort study. Ann Rheum Dis 64:1451-1455, 2005.
PubMed
11) Nakajima A, et al:Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, 10RRA. Scand J Rheumatol 39:360-367, 2010.
PubMed
12) Smitten AL, et al:A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 10:R45, 2008.
PubMed
13) Yamada T, et al:Incidence of malignancy in Japanese patients with rheumatoid arthritis. Rheumatol Int 31:1487-1492, 2011.
PubMed
14) Kuriya B, et al:Efficacy of initial methotrexate monotherapy versus combination therapy with a biological agent in early rheumatoid arthritis:a meta-analysis of clinical and radiographic remission. Ann Rheum Dis 69:1298-1304, 2010.
PubMed
15) Jacobsson LT, et al:Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 66:670-675, 2007.
PubMed
16) Carmona L, et al:All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 66:880-885, 2007.
 
17) Lunt M, et al:No evidence of association between anti-tumor necrosis factor treatlnent and mortality in patients with rheumatoid arthritis:results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 62:3145-3153, 2010.
PubMed
18) Simard JF, et al:Mortality rates in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors:drug-specific comparisons in the Swedish Biologics Register. Arthritis Rheum 64:3502-3510, 2012.
PubMed
19) Dixon WG, et al:Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therap.:results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 56:2905-2912, 2007.
 
20) Wolfe F, Michaud K:Biologic treatment of rheumatoid arthritis and the risk of malignancy:analyses from a large US observational study. Arthritis Rheum 56:2886-2895, 2007.
PubMed
21) Strangfeld A, et al:Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 12:R5, 2010.
 
22) Askling J, et al:Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies:does the risk change with the time since start of treatment? Arthritis Rheum 60:3180-3189, 2009.
PubMed
23) Takeuchi T, et al:Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 67:189-194, 2008.
PubMed
24) Koike T, et al:Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol 36:898-906. 2009.
PubMed
25) Koike T, et al:Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. Mod Rheumatol 21:343-351, 2011.
PubMed
26) Koike T, et al:Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan:interim analysis of 3881 patients. Ann Rheum Dis 70:2148-2151, 2011.
PubMed

II 関節リウマチの疫学

P.24 掲載の参考文献
1) Shichikawa K, et al:Changes in the incidence and prevalence of rheumatoid arthritis in Kamitonda, Wakayama, Japan, 1965-1996. Ann Rheum Dis 58:751-756, 1999.
PubMed
2) Yamanaka H, et al:Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort. Mod Rheumatol 24:33-40, 2014.
PubMed
3) Yamada T, et al:Incidence of malignancy in Japanese patients with rheumatoid arthritis. Rheumatol Int 31:1487-1492, 2011.
PubMed
4) Zink A, et al:European biologicals registers:methodology, selected results and perspectives. Ann Rheum Dis 68:1240-1246, 2009.
PubMed
5) Curtis JR, et al:Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 56:1125-1133, 2007.
PubMed
6) Hajjaj-Hassouni N, et al:The practical value of biologics registries in Africa and Middle East:challenges and opportunities. Clin Rheumatol 31:407-416, 2012.
PubMed
7) Takeuchi T, et al:Post-marketing surveillance of the safety profile of infliXimab in 5,000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 67(2):189-194, 2008.
 
8) Koike T, et al:Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol 36:898-906, 2009.
PubMed
9) Koike T, et al:Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients:postmarketing surveillance report of the first 3,000 patients. Mod Rheumatol 22:498-508, 2012.
PubMed
10) Koike T, et al:Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan:interim analysis of 3881 patients. Ann Rheum Dis 70:2148-2151, 2011.
PubMed
11) Yamanaka H, Tohma S:Potential impact of observational cohort studies in Japan on rheumatoid arthritis research and practice. Mod Rheumatol 16:75-76, 2006.
PubMed
12) Komano Y, et al:Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors:a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety. J Rheumatol 38:1258-1264, 2011.
PubMed
13) Yamanaka H, et al:Management of rheumatoid arthritis:the 2012 perspective. Mod Rheumatol 23:1-7, 2013.
PubMed
14) Saeki Y, et al:Current treatments of rheumatoid arthritis:from the 'NinJa' registry. Expert Rev Clin Immunol 8:455-465, 2012.
PubMed
15) Sakai R, et al:Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 64:1125-1134, 2012.
PubMed
P.28 掲載の参考文献
1) Carmona L, et al:Rheumatoid arthritis. Best Pract Res Clin Rheumatol 24:733-745, 2010.
PubMed
2) Peschken C, Esdaile JM:Rheumatic diseases in North America's indigenous peoples. Semin Arthritis Rheum 28:368-391, 1999.
PubMed
3) Minaur N, et al:Rheumatic diseases in an Australian Aboriginal community in North Queensland, Australia. A WHO-ILAR COPCORD survey. J Rheumatol 31:965-972, 2004.
 
4) Silman AJ, et al:Absence of rheumatoid arthritis in a rural Nigerian population. J Rheumatol 20:618-622, 1993.
 
5) Shichikawa K, et al:Changes in the incidence and prevalence of rheumatoid arthritis in Kamitonda, Wakayama, Japan, 1965-1996. Ann Rheum Dis 58:751-756, 1999.
PubMed
6) Kuo CF, et al:Rheumatoid arthritis prevalence, incidence, and mortality rates:anationwide population study in Taiwan. Rheumatol Int 33:355-360, 2013.
 
7) Sung YK et al:Prevalence and incidence of rheumatoid arthritis in South Korea. Rheumatol Int 33:1525-1532, 2013.
PubMed
8) Dadoun S, et al:Mortality in rheumatoid arthritis over the last fifty years:systemic review and meta-analysis. Joint Bone Spine 80:29-33, 2013.
 
9) van Nies JAB, et al:Improved treatment strategies reduce the increased mortality risk in early RA patients. Rheumatology (Oxford) 49:2210-2216, 2010.
PubMed
10) Nakajima A, et al:No increased mortality in patients with rheumatoid arthritis treated with biologics:results from the biologics register of six rheumatology institutes in Japan. Mod Rheumatol 23:945-952, 2013.
PubMed
11) Young G, et al:Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology (Oxford) 46:350-357, 2007.
 
12) Radovits BJ, et al:Excess mortality emerges after 10 years in an inception cohort of early rheumatoid arthritis. Arthritis Care Res (Hoboken) 62:362-370, 2010.
 
13) Lassere MN, et al:How many life years are lost in patients with rheumatoid arthritis? Secular cause -specific and all-cause mortality in rheumatoid arthritis, and their predictors in a long-term Australian cohort study. Intern Med J 43:66-72, 2013.
 
14) Nakajima A, et al:Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, IORRA. Scand J Rheumatol 39:360-367, 2010.
PubMed
15) Kim YJ, et al:Mortality and incidence of malignancy in Korean patients with rheumatoid arthritis. J Rheumatol 39:226-232, 2012.
PubMed
P.32 掲載の参考文献
1) Saevarsdohir S, et al:Predictors of response to methotrexate in early DMARD naive rheumatoid arthitis:results from the initial open-label phase of the SWEFOT trial. Ann Rheum Dis 70(3):469-475, 2011.
 
2) Saevarsdottir S, et al:Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors:observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts. Arthritis Rheum 63(1):26-36, 2011.
PubMed
3) Andersson ML, et al:The Effect of Stopping Smoking on Disease Activity in Rheumatoid Arthritis (RA). Data from BARFOT, a Multicenter Study of Early RA. Open Rheumatol J 6:303-309, 2012.
PubMed
4) Turesson C, et al:Association of HLA-C3 and smoking with vasculitis in patients with rheumatoid arthritis. Arthritis Rheum 54(9):2776-2783, 2006.
PubMed
5) Maxwell JR, et al:Alcohol consumption is inversely associated with risk and severity of rheumatoid arthritis. Rheumatology (Oxford) 49(11):2140-2146, 2010.
PubMed
6) Jonsson IM, et al:Ethanol prevents development of destructive arthritis. Proc Natl Acad Sci USA 104(1):258-263, 2007.
PubMed
7) Khoruts A, et al:Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients. Hepatology 13(2):267-276, 1991.
PubMed
8) Szabo G, et al:Regulation of human monocyte fUnctions by acute ethanol treatment:decreased tumor necrosis factor-alpha, interleukin-1 beta and elevated interleukin-10, and transforming growth factor-beta production. Alcohol Clin Exp Res 20(5):900-907, 1996.
PubMed
9) Bergman S, et al:Alcohol consumption is associated with lower self-reported disease activity and better health-related quality of life in female rheumatoid arthritis patients in Sweden:data from BARFOT, a multicenter study on early RA. BMC Musculoskelet Disord 14:218, 2013.
PubMed
10) Nissen MJ, et al:The effect of alcohol on radiographic progression in rheumatoid arthritis. Arthritis Rheum 62(5):1265-1272, 2010.
PubMed
11) Salliot C, van der Heijde D:Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis:asystematic literature research. Ann Rheum Dis 68(7):1100-1104, 2009.
 
12) El-Shinnawi U, Soory M:Associations between periodontitis and systemic inflammatory diseases:response to treatment. Recent Pat Endocr Metab Immune Drug Discov 7(3):169-188, 2013.
PubMed
13) Park YJ, et al:LDL cholesterolemia as a novel risk factor for radiographic progression of rheumatoid arthritis:a single-center prospective study. PLoS One 8(7):e68975, 2013.
PubMed
14) Evers AW, et al:Does stress affect the joints? Daily stressors, stress vulnerability, immune and HPA axis activity, and short-term disease and symptom fluctuations in rheumatoid arthritis. Ann Rheum Dis, 2013. [Epub ahead of print]
 
15) Amari W, et al:Non-melanoma and melanoma skin cancer risk in a national cohort of veterans with rheumatoid arthritis [abstract] . Arthritis Rheum 60(Suppl 10):1379, 2009.
 
16) Merlino LA, et al:Vitamin D intake is inversely associated with rheumatoid arthritis:results from the Iowa Wbmen's Health Study. Arthritis Rheum 50(1):72-77, 2004.
PubMed
17) Furuya T, et al:Prevalence of and factors associated with vitamin D deflciency in 4, 793 Japanese patients with rheumatoid arthritis. Clin Rheumatol 32(7):1081-1087, 2013.
 
18) Jamison RN, et al:Weather changes and pain:perceived influence of local climate on pain complaint in chronic pain patients. Pain 61(2):309-315, 1995.
PubMed
19) Patberg WR, Rasker JJ:Weather effects in rheumatoid arthritis:from controversy to consensus. A review. J Rheumatol 31 (7):1327-1334, 2004.
PubMed
20) Abbasi M, et al:Sleep disturbances in patients with rheumatoid arthritis. Niger J Med 22(3):181-186, 2013.
PubMed

III 関節リウマチの発症要因と発症メカニズム

P.39 掲載の参考文献
1) Astorga GP, Williams RC Jr:Altered reactivity in mixed lymphocyte culture of lymphocytes from patients with rheumatoid arthritis. Arthritis Rheum 12:547 -554, 1969.
 
2) Stastny P:Mixed lymphocyte cultures in rheumatoid arthritis. J Clin Invest 57:1148-1157, 1976.
PubMed
3) Stastny P:Association of the B-cell alloantigen DRw4 with rheumatoid arthritis. N Engl J Med 298:869-871, 1978.
 
4) Gregersen PK, et al:The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 30:1205-1213, 1987.
PubMed
5) Shibue T, et al:Tumor necrosis factor alpha 5'-flanking region, tumor necrosis factor receptor II, and HLA-DRB1 polymorphisms in Japanese patients with rheumatoid arthritis. Arthritis Rheum 43:753-757, 2000.
PubMed
6) Huizinga TW, et al:Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum 52:3433-3438, 2005,
PubMed
7) Klareskog L, et al:A new model for an etiology of rheumatoid arthritis:smoking may trigger HLADR (shared epitope) -restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 54:38-46, 2006.
PubMed
8) Klareskog L, et al:Smoking, citrullination and genetic variability in the immunopathogenesis of rheumatoid arthritis. Semin Immunol 23:92-98, 2011.
PubMed
9) Suzuki A, et al:Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 34:395-402, 2003.
PubMed
10) Plenge RM, et al:Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden:association of susceptibility with PTPN22, CTLA4, and PADI4. Am J Hum Genet 77:1044-1060, 2005.
PubMed
11) Farquharson D, et al:Periodontitis Porphyromonas, and the pathogenesis of rheumatoid arthritis. Mucosal Immunol 5:112-120, 2012.
PubMed
12) Raychaudhuri S, et al:Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis, Nat Genet 44:291-296, 2012.
PubMed
13) McInnes IB, Schett G:The pathogenesis of rheumatoid arthritis. N Engl J Med 365:2205-2219, 2011.
PubMed
14) Kochi Y, et al:A regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility. Nat Genet 42:515-519, 2010.
PubMed
15) Eyre S, et al:High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat Genet 44:1336-1340, 2012.
PubMed
16) Bottini N, Firestein GS:Duality of fibroblast-like synoviocytes in RA:passive responders and imprinted aggressors. Nat Rev Rheumatol 9:24-33, 2013.
PubMed
P.43 掲載の参考文献
1) MacGregor AJ, et al:Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum 43:30-37, 2000.
PubMed
2) Raychaudhuri S, et al:Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat Genet 44:291-296, 2012.
PubMed
3) Gregersen PK, et al:The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 30:1205-1213, 1987.
PubMed
4) van Gaalen FA, et al:Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum 50:2113-2121, 2004.
PubMed
5) Kallberg H, et al:Gene-gene and gene-environment interactions involving HLA-DRB1, FTPN22, and smoking in two subsets of rheumatoid arthritis. Am J Hum Genet 80:867-875, 2007.
 
6) Okada Y, et al:Meta-analysis identifies nine new loci associated with rheumatoid arthritis in the Japanese population. Nat Genet 44:511-516, 2012.
PubMed
7) Okada Y, et al:Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 506:376-381, 2014.
PubMed
8) Suzuki A, et al:Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 34:395-402, 2003.
PubMed
9) Klareskog L, et al:Immunity to citrullinated proteins in rheumatoid arthritis. Annu Rev Immunol 26:651-675, 2008.
PubMed
10) Kochi Y, et al:A regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility. Nat Genet 42:515-519, 2010.
PubMed
11) Plenge RM, et al:Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nat Genet 39:1477-1482, 2007.
PubMed
12) Remmers EF, et al:STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 357:977-986, 2007.
PubMed
13) Myouzen K, et al:Functional variants in NFKBIE and RTKN2 involved in activation of the NF-κB pathway are associated with rheumatoid arthritis in Japanese. PLoS Genet 8:e1002949, 2012.
 
P.47 掲載の参考文献
1) Klareskog L, et al:A new model for an etiology of rheumatoid arthritis:smoking may trigger HLADR (shared epitope) -restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 54(1):38-46, 2006.
PubMed
2) Linn-Rasker SP, et al:Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles. Ann Rheum Dis 65(3):366-371, 2006.
PubMed
3) Padyukov L et al:A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum 50(10):3085-3092, 2004.
PubMed
4) Hill JA, et al:Cutting edge:the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol 171(2):538-541, 2003.
PubMed
5) Scher JU, et al:Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis, Arthritis Rheum 64(10):3083-3094, 2012.
PubMed
6) Mikuls TR, et al:Porphyromonas gingivalis and disease-related autoantibodies in individuals at increased risk of rheumatoid arthritis. Arthritis Rheum 64(11):3522-3530, 2012.
PubMed
7) Lundberg K, et al:Periodontitis in RA-the citrullinated enolase connection. Nat Rev Rheumatol 6(12):727-730, 2010.
PubMed
8) Wegner N, et al:Peptidylarginine deiminase from Porphyromonas gingivalis citrullinates human fibrinogen and α-enolase:implications for autoimmunity in rheumatoid arthritis. Arthritis Rheum 62(9):2662-2672, 2010.
 
9) Bonfil JJ, et al:A "case control" study on the role of HLA DR4 in severe periodontitis and rapidly progressive periodontitis. Identification of types and subtypes using molecular biology (PCR. SSO) J Clin Periodontol 26(2):77-84, 1999,
PubMed
10) Kobayashi S, et al:Molecular aspects of rheumatoid arthritis:role of environmental factors. FEBS J 275(18):4456-4462, 2008.
PubMed
11) Lunemann JD, et al:Increased frequency of EBV-specific effector memory CD8+ T cells correlates with higher viral load in rheumatoid arthritis. J Immunol 181(2):991-1000, 2008.
PubMed
12) Karlson EW, Deane K:Environmental and gene-environment interactions and risk of rheumatoid arthritis. Rheum Dis Clin North Am 38(2):405-426, 2012.
PubMed
13) Oliver JE, Silman AJ:Why are women predisposed to autoimmune rheumatic diseases? Arthritis Res Ther 11(5):252, 2009.
PubMed
14) Lahiri M, et al:Using lifestyle factors to identify individuals at higher risk of inflammatory polyarthritis (results from the European Prospective Investigation of Cancer-Norfolk and the Norfolk Arthritis Register-the EPIC-2-NOAR Study). Ann Rheum Dis 73:219-226, 2014.
PubMed
P.52 掲載の参考文献
1). 大村浩一郎, 三森経世:抗シトルリン化蛋白抗体 (抗CCP抗体). リウマチ科 36:8-15, 2006.
 
2) Wegner N, et al:Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunol Rev 233:34-54, 2010.
 
3) Gyorgy B, et al:Citrullination:a posttranslational modification in health and disease. Int J Biochem Cell Biol 38:1662-1677, 2006.
PubMed
4) Lundberg K, et al:Periodontitis in RA-the citrullinated enolase connection. Nat Rev Rheumatol 6:727-730, 2010.
PubMed
5) 橋本求, 大村浩一郎:関節リウマチの発症における歯周病の役割. リウマチ科 49:109-114, 2013.
 
6) van Venrooij WJ, et al:Anti-CCP antibodies:the past, the present and the future. Nat Rev Rheumatol 7:391-398, 2011.
PubMed
7) Andrade F, et al:Autocitrullination of human peptidyl arginine deiminase type 4 regulates protein citrullination during cell activation. Arthritis Rheum 62:1630-1640, 2010.
PubMed
8) Wang Y, et al:Human PAD4 regulates histone arginine methylation levels via demethylimination. Science 306:279-283, 2004.
PubMed
9) Jang B, et al:Subcellular localization of peptidylarginine deiminase 2 and citrullinated proteins in brains of scrapie-infected mice:nuclear localization of PAD2 and membrane fraction-enriched citrullinated proteins. J Neuropathol Exp Neurol 70:116-124, 2011.
PubMed
10) Ohmura K, et al:Anti-citrullinated peptide antibody-negative RA is a genetically distinct subset:a definitive study using only bone-erosive ACPA-negative rheumatoid arthritis. Rheumatology (Oxford) 49:2298-2304, 2010.
PubMed
11) Hill JA, et al:Cutting edge:the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol 171:538-541, 2003.
PubMed
12) Suzuki A, et al:Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 34:395-402, 2003.
PubMed
13) Rantapaa-Dahlqvist S, et al:Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 48:2741-2749, 2003.
PubMed
P.57 掲載の参考文献
1) Morita Y, et al:Expression of interleukin-12 in synovial tissue from patients with rheumatoid arthritis. Arthritis Rheum 41:306-314, 1998.
PubMed
2) Murphy CA, et al:Divergent pro-and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 198:1951-1957, 2003.
PubMed
3) Chabaud M, et al:Human interleukin-17:A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 42:963-970, 1999.
 
4) Yao Z, et al:Human IL-17:a novel cytokine derived from T cells. J Immunol 155:5483-5486, 1995.
 
5) Harrington LE, et al:Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6:1123-1132, 2005.
 
6) Kurebayashi Y, et al:Recent advances in understandillg the molecular mechanisms of the development and function of Th17 cells. Genes Cells 18:247-265, 2013.
PubMed
7) Ghoreschi K, et al:Generation of pathogenic T (H) 17 cells in the absence of TGF-beta signalling. Nature 467:967-971, 2010.
 
8) O'Connor W, et al:A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol 10:603-609, 2009.
 
9) Hirota K, et al.:Fate mapping of IL-17-producing T cells in inflammatory responses. Nat Immunol 12:255-263, 2011.
PubMed
10) Voo KS, et al:Identification of IL-17-producing FOXP3+ regulatory T cells in humans. Proc Natl Acad Sci USA 106:4793-4798, 2009.
PubMed
11) Miossec P, Kolls JK:Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov 11:763-776, 2012.
PubMed
12) Nakae S, et al:IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci USA 100:5986-5990, 2003.
PubMed
13) Kirkham BW, et al:Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis:a two-year prospective study (the DAMAGE study cohort). Arthritis Rheum 54:1122-1131, 2006.
PubMed
14) Raza K, et al:Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res Ther 7:R784-795, 2005.
PubMed
15) Kellner H:Targeting interleukin-17 in patients with active rheumatoid arthritis:rationale and clinical potential. Ther Adv Musculoskelet Dis 5:141-152, 2013.
PubMed
P.63 掲載の参考文献
1) Stanszyk J, et al:Altered expression of MicroRNA in synovial丘broblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum 58(4):1001-1009, 2008.
 
2) Nakasa T, et al:Expression of microRNA-146 in rheumatoid arthritis synovial tissue. Arthritis Rheum 58(5):1284-1292, 2008.
PubMed
3) Tanaka Y, Asahara H:Joint and microRNA. Nihon Rinsho Meneki Gakkai Kaishi 35(6):447-454, 2012.
 
4) Nagata Y, et al:Induction of apoptosis in the synovium of mice with autoantibody-mediated arthritis by the intraarticular injection of double-strand MicroRNA-15a. Arthritis Rheum 60(9):2677-2683, 2009.
PubMed
5) Filkova M, et al:Association of circulating miR-223 and miR-16 with disease activity in patients with early rheumatoid arthritis. Ann Rheum Dis, 2013. [Epub ahead of print]
 
6) Zhu S, et al:The microRNA miR-23b suppressed IL-17-associated autoimmune by targeting TAB2, TAB3 and IKK-α. Nat Med 18(7):1077-1086, 2012.
 
7) Murata K, et al:Comprehensive microRNA analysis identifies miR-24 and miR-125a-5p as plasma biomarkers for rheumatoid arthritis. PLoS One 8(7):e69118, 2013.
PubMed
8) Niederer F, et al:Down-regulation of microRNA-34* in rheumatoid arthritis synovial fibroblasts promotes apoptosis resistance. Arthritis Rheum 64(6):1771-1779, 2012.
PubMed
9) NakamachiY, et al:MicroRNA-124a is a key regulator and monocyte c hemoattractant protein 1 secretion in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Arthritis Rheum 60(5):1294-1304, 2009.
 
10) Pandis I, et al:Identification of microRNA-221/222 and microRNA-323-323p association with rheumatoid arthritis via predictions using the human tumor necrosis factor transgenic mouse model. Ann Rheum Dis 71(10):1716-1723, 2012.
 
11) Semaan N, et al:miR-346 controls release of TNF-α protein and stability of its mRNA in rheumatoid arthritis via tristetraprolin stabilization. PLoS One 6(5):e19827, 2011.
 
12) Li J, et al:Altered microRNA expression profile with miR-146a upregulation in CD4+ T cells from patients with rheumatoid arthritis. Arthritis Res Ther 12(3):R81, 2010.
PubMed
13) Zhu S, et al.:MicroRNA in immunity and autoimmunity. J Mol Med 91(9):1039-1050, 2013.
PubMed
14) Hu R, O'Connell RM:MicroRNA control in the development of systemic autoimmunity. Arthritis Res Ther 15(1):202, 2013.
PubMed
15) Jinnin M:microRNA in autoimmune disorders. Nihon Rinsho Meneki Gakkai Kaishi 34(6):439-446, 2011.
PubMed
P.67 掲載の参考文献
1) Corrigal VM, et al:The human endoplasmic reticulum molecular chaperone BiP is an autoantigen for rheumatoid arthritis and prevents the induction of experimental arthritis. J Immunol 166:1492-1498, 2001.
 
2) Yoo SA, et al:A novel pathogenic role of the ER chaperone GRP78/BiP in rheumatoid arthritis. J Exp Med 209:871-886, 2012.
PubMed
3) Lu MC, et al:Anti-citrullinated protein antibodies bind surface-expressed citrullinated Grp78 on monocyte/macrophages and stimulate tumor necrosis factor alpha production. Arthritis Rheum 62:1213-1223, 2010.
PubMed
4) Shoda H, et al:Detection of autoantibody to citrullinated BiP in rheumatoid arthritis patients and pro-inflammatory roles of citrullinated BiP in collagen-induced arthritis. Arthritis Res Ther 13:R191, 2011.
PubMed
5) Blass S, et al:The stress protein BiP is overexpressed and is a major B and T cell target in rheumatoid arthritis. Arthritis Rheum 44:761-771, 2001.
 
6) Brownlie RJ, et al:Treatment of murine collagen-induced arthritis by the stress protein BiP via interleukin-4-producing regulatory T cells:a novel function for an ancient protein. Arthritis Rheum 54:854-863, 2006.
PubMed
7) Yoshida K, et al:Binding immunoglobulin protein resolves rheumatoid synovitis:a xenogeneic study using rheumatoid arthritis synovial membrane transplants in SCID mice. Arthritis Rheum 13:R149. 2011.
 
8) Bodman-Smith MD, et al:BiP, a putative autoantigen in rheumatoid arthritis, stimulates IL-10-producing CD8-positive T cells from normal individuals. Rheumatology 42:637-644, 2003.
PubMed
9) Corrigall VM, et al:Binding immunoglobulin protein-treated peripheral blood monocyte-derived dendritic cells are refractory to maturation and induce regulatory T-cell development. Immunology 128:218-226, 2009.
PubMed
10) Shields AM, et al:A neu-age for biologic therapies:long-term drug-free therapy with BiP? Front Immunol 3:17, 2012.
 
P.70 掲載の参考文献
1) Pitti RM, et al:Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396:699-703, 1998.
PubMed
2) Bai C, et al:Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster. Proc Natl Acad Sci USA 97:1230-1235, 2000.
 
3) Yu KY, et al:A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J Biol Chem 274:13733-13736, 1999.
PubMed
4) Migone TS, et al:TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 16:479-492, 2002.
 
5) Yang CR, et al:Decoy receptor 3 (DcR3) induces osteoclast formation from monocyte/macrophage lineage precursor cells. Cell Death Differ 11:S97-S107, 2004.
PubMed
6) Hayashi S, et al:DcR3 induces cell proliferation through MAPK signaling in chondrocytes of osteoarthritis. Osteoarthritis Cartilage 19:903-910, 2011.
 
7) Chou CT, et al:Apoptosis in rheumatoid arthritis-expression of Fas, Fas-L, p53, and Bcl-2 in rheumatoid synovial tissues. J Pathol 193:110-116, 2001.
 
8) Hayashi S, et al:Decoy receptor 3 expressed in rheumatoid synovial fibroblasts protects the cells against Fas-induced apoptosis. Arthritis Rheum 56:1067-1075, 2007.
PubMed
9) Hayashi S, et al:Decoy receptor 3 is highly expressed in patients with rheumatoid arthritis. Mod Rheumatol 20:63-68, 2010.
PubMed
10) Athanasou NA:Synovial macrophages. Ann Rheum Dis 54:392 -394, 1995.
 
11) Tateishi K, et al:DcR3 protects THP-1 macrophages from apoptosis by increasing integrin alpha4. Biochem Biophys Res Commun 389:593-598, 2009.
PubMed
12) Takahashi M, et al:DcR3-TL1A signalling inhibits cytokine-induced proliferation of rheumatoid synovial fibroblasts. Int J Mol Med 28:423-427, 2011.
PubMed
13) Fukuda M, et al:Decoy receptor 3 regulates the expression of various genes in rheumatoid arthritis synoVial fibroblasts. Int J Mol Med 32:910-916, 2013.
 
P.76 掲載の参考文献
1) Davis BN, et al:SMAD proteins control DROSHA-mediated microRNA maturation. Nature 454:56-61, 2008.
PubMed
2) Suzuki HI, et al:Modulation of microRNA processing by p53. Nature 460:529-533, 2009.
PubMed
3) Heo I, et al:TUT4 in concert with Lin28 suppresses microRNA biogenesis through pre-microRNA uridylation. Cell 138:696-708, 2009.
PubMed
4) Yang W, et al:Modulation of microRNA processing and expression through RNA editing by ADAR deaminases. Nat Struct Mol Biol 13:13-21, 2006.
PubMed
5) Ota H, et al:ADARI forms a complex with Dicer to promote microRNA processing and RNAinduced gene silencing. Cell 153:575-589, 2013.
 
6) Stanczyk J, et al.:Altered expression of MicroRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum 58:1001-1009, 2008.
PubMed
7) Taganov KD, et al:NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 103:12481-12486, 2006.
PubMed
8) Boldin MP, et al:miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J Exp Med 208:1189-1201, 2011.
PubMed
9) Zhao JL, et al:NF-kappaB dysregulation in microRNA-146a-deficient mice drives the development of myeloid malignancies. Proc Natl Acad Sci USA 108:9184-9189, 2011.
PubMed
10) Pauley KM, et al:Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Res Ther 10:R101, 2008.
PubMed
11) Nakasa T, et al:Expression of microRNA-146 in rheumatoid arthritis synovial tissue. Arthritis Rheum 58:1284-1292, 2008.
PubMed
12) Li J, et al:Altered microRNA expression profile with miR-146a upregulation in CD4+ T cells from patients with rheumatoid arthritis. Arthritis Res Ther 12:R81, 2010.
PubMed
13) Murata K, et al:Plasma and synovial fluid microRNAs as potential biomarkers of rheumatoid arthritis and osteoarthritis. Arthritis Res Ther 12:R86, 2010.
PubMed
14) Niimoto T, et al:MicroRNA-146a expresses in interleukin-17 producing T cells in rheumatoid arthritis patients. BMC Musculoskelet Disord 11:209, 2010.
PubMed
15) Nakasa T, et al:The inhibitory effect of microRNA-146a expression on bone destruction in collagen-induced arthritis. Arthritis Rheum 63:1582-1590, 2011.
 
P.82 掲載の参考文献
1) Mclnnes IB, Shcett G:The pathogenesis of rheumatoid arthritis. N Engl J Med 365:2205-2219, 2011.
 
2) Sallusto F, et al:Central memory and effector memory T cell subsets:function, generation, and maintenance. Annu Rev Immunol 22:745-763, 2004.
PubMed
3) Appay V:The physiological role of cytotoxic CD4+ T-cells:the holy grail? Clin Exp Immunol 138:10-13, 2004.
PubMed
4) Okada R, et al.:Phenotypic classification of human CD4+ T cell subsets and their differentiation. Int Immunol 20:1189-1199, 2008.
PubMed
5) Matsuki F, et al:CD45RA-Foxp3 (high) activated/effector regulatory T cells in the CCR7+ CD45RA-CD27+ CD28+ central memory subset are decreased in peripheral blood from patients with rheumatoid arthritis. Biochem Biophys Res Commun 438(4):778-783, 2013.
PubMed
6) Campbell DJ, Koch MA:Phenotypical and functional specialization of FOXP3+ regulatory T cells. Nat Rev Immunol 11:119-130, 2011.
PubMed
7) Wing K, et al:CTLA-4 control over Foxp3+ regulatory T cell function. Science 322:271-275, 2008.
PubMed
8) Rubtsov YP, et al:Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity 28:546-558, 2008.
PubMed
9) Miyara M, et al:Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 30:899-911, 2009.
PubMed
10) Buckner JH:Mechanisms of impaired regulation T cells in human autoimmune diseases. Nat Rev Immunol 10:849-859, 2010.
PubMed

IV 関節リウマチの病理・病態

P.93 掲載の参考文献
1) 澤井高志ほか:慢性関節リウマチ滑膜初期病変の免疫組織化学的検討-モノクロナル抗体を用いた炎症性細胞の定性ならびに定量的解析-. リウマチ 30:247-254, 1990.
 
2) Gardner DL:Chapter 2 Articular tissues:Gross and Microscopic Pathology. In:The Pathology of Rheumatoid Arthritis, p7-37, Edward Arnold, London, 1972.
 
3) 澤井高志:VII. リウマチ性疾患の病理. 慢性関節リウマチ (井村裕夫ほか編), p89-107, 中山書店, 1993.
 
4) 須田立雄:VII. 骨と軟骨の有機成分, 骨の科学 (須田立雄ほか編). p110-119, 医歯薬出版, 1985.
 
5) 鈴木不二男:5. 軟骨基質. 骨はどのようにしてできるか-軟骨分化の謎を探る- (鈴木不二男編), p8-18, 大阪大学出版会, 2000.
 
6) Ouchi N, et al:Cartilage destruction is partly induced by the internal proteolytic enzymes and apoptotic phenomenon of chondrocytes in relapsing polychondritis. J Rheumatol 38:730-737, 2011.
PubMed
7) 竹内勤:関節リウマチの治療の進歩. 日内会誌 101:647-653, 2012.
 
P.97 掲載の参考文献
1) Schett G, Gravallese E:Bone erosion in rheumatoid arthritis:mechanisms, diagnosis and treatment. Nat Rev Rheumatol 8:656-664, 2012.
PubMed
2) Dimitroulas T, et al:Biologic therapies and systemic bone loss in rheumatoid arthritis. Autoimmun Rev 12:958-966, 2013.
PubMed
3) Niki Y, et al:Clinical significance of cartilage biomarkers for monitoring structural joing damage in rheumatoid arthritis patients treated with anti-TNF therapy. PLoS One 7:e37447, 2012.
 
4) Grauw JC, et al:Inflammatory mediators and cartilage biomarkers in synovial fluid after a single inflammatory insult:a longtidunal experimental study. Arthritis Res Therapy 11:R35, 2009.
 
5) Conaghan PG, et al:Assessment by MRI of infiammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab:results of the GO-FORWARD trial. Ann Rheum Dis 70:1968-1974, 2011.
 
6) Denny JC:Chapter 13:Mining electronic health records in the genomics era. PLoS Comput Biol 8:e1002823, 2012.
PubMed
P.101 掲載の参考文献
1) Sharp JT, et al:Methods of scoring the progression of radiologic changes in rheulnatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. Arthritis Rheum 14:706-720, 1971.
PubMed
2) van der Heijde DM, et al:Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1:1036-1038. 1989.
PubMed
3) 岡敬之:MRIを用いた軟骨定量ソフトウエア. 別冊整形外科 62:64-69, 2012.
 
4) Larsen A:A radiological method for grading the severity of rheumatoid arthritis. Scand J Rheumatol 4:225-233, 1975.
 
P.106 掲載の参考文献
1) Muller-Ladner U, et al:Mechanisms of disease:the molecular and cellular basis of joint destruction in rheumatoid arthritis. Nat Rev Rheum 1:102-110, 2005.
 
2) McInnes IB. Schett G:Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 7:429-442. 2007.
PubMed
3) Keller B, et al:Interaction of TGFβ and BMP signaling pathways during chondrogenesis. PLoS One 6:e16421, 2011.
 
4) Gibson G, Asahara H:microRNAs and cartilage. J Orthop Res 31:1333-1344, 2013.
PubMed
5) Taganov KD, et al:NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 103:12481-12486, 2006.
 
6) Boldin MP, et al:miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J Exp Med 208:1189-1201, 2011.
PubMed
7) Bluml S, et al:Essential role of microRNA-155 in the pathogenesis of autoimmune arthritis in mice. Arthritis Rheum 63:1281-1288, 2011.
PubMed
8) Nakamachi Y. et al:MicroRNA-124a is a key regulator of proliferation and monocyte chemoattractant protein 1 secretion in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Arthritis Rheum 60:1294-1304, 2009.
PubMed
9) Stanczyk J, et al:Altered expression of microRNA-203 in rheumatoid arthritis synovial fibroblasts and its role in fibroblast activation. Arthritis Rheum 63:373-381, 2011.
PubMed
10) Philippe L, et al:TLR2 expression is regulated by microRNA miR-19 in rheumatoid fibroblast-like synoviocytes. J Immunol 188:454-461, 2012.
 
11) Philippe L, et al:MiR-20a regulates ASK1 expression and TLR4-dependent cytokine release in rheumatoid fibroblast-like synoviocytes. Ann Rheum Dis 72:1071-1079, 2013.
PubMed
12) Shibuya H, et al:Overexpression of microRNA-223 in rheumatoid arthritis synovium controls osteoclast differentiation. Mod Rheumatol 23:674-685, 2013.
PubMed
13) Haneklaus M, et al:Cutting edge:miR-223 and EBV miR-BART15 regulate the NLRP3 inflammasome and IL-1β production. J Immunol 189:3795-3799, 2012.
 
14) Semaan N, et al:miR-346 controls release of TNF-α protein and stability of its mRNA in rheumatoid arthritis via tristetraprolin stabilization. PLoS One 6:e19827. 2011.
 
15) Niederer F, et al:Down-regulation of microRNA-34a in rheumatoid arthritis synovial fibroblasts promotes apoptosis resistance. Arthritis Rheum 64:1771-1779, 2011.
PubMed
P.111 掲載の参考文献
1) Miyamoto T, Suda T:Differentiation and function of osteoclasts. Keio J Med 52:1-7, 2003.
PubMed
2) Takahashi N, et al:Osteoblastic cells are involved in osteoclast formation. Endocrinology 123:2600-2602, 1998.
 
3) Tsuda E, et al:Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 234:137-142, 1997.
PubMed
4) Simonet WS, et al:Osteoprotegerin:a novel secreted protein involved in the regulation of bone density. Cell 89:309-319, 1997.
PubMed
5) Yasuda H, et al:Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesisinhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597-3602, 1998.
PubMed
6) Lacey DL, et al:Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176, 1998.
PubMed
7) Kong YY, et al:OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315-323, 1999.
PubMed
8) Dougall WC, et al.:RANK is essential for osteoclast and lymph node development. Genes Dev 13:2412-2424, 1999.
PubMed
9) Yoshida H, et al:The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 345:442-444, 1990.
PubMed
10) Arai F, et al:Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med 190:1741-1754. 1999.
PubMed
11) Takayanagi H, et al:Induction and activation of the transcription factor NEATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3:889-901. 2002.
PubMed
12) Yagi M, et al:DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J Exp Med 202:345-351, 2005.
PubMed
13) Miyamoto H, et al:Osteoclast stimulatory transmembrane protein and dendritic cell-specific transmembrane protein cooperatively modulate cell-cell fusion to form osteoclasts and foreign body giant cells. J Bone Miner Res 27:1289-1297, 2012.
PubMed
14) Miyauchi Y, et al:The Blimp1-Bcl6 axis is critical to regulate osteoclast differentiation and bone homeostasis. J Exp Med 207:751-762, 2010.
PubMed
15) Mori T, et al:IL-1β and TNFα-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis. Int Immunol 23:701-712, 2011.
 
P.115 掲載の参考文献
1) Erlebacher A, et al:Toward a molecular understanding of skeletal development. Cell 80(3):371-378, 1995.
 
2) Karsenty G, Wagner EF:Reaching a genetic and molecular understanding of skeletal development. Dev Cell 2(4):389-406, 2002.
PubMed
3) Zaidi M:Skeletal remodeling in health and disease. Nat Med 13(7):791-801, 2007.
PubMed
4) Long F:Building strong bones:molecular regulation of the osteoblast lineage. Nat Rev Mol Cell Biol 13(1):27-38, 2012.
 
5) Boyce BF:Advances in osteoclast biology reveal potential new drug targets and new roles for osteoclasts. J Bone Miner Res 28(4):711-722, 2013.
PubMed
6) Dallas SL, et al:The osteocyte:an endocrine cell... and more. Endocr Rev 34(5):658-690, 2013.
PubMed
7) Xiong J, O'Brien CA:Osteocyte RANKL:new insights into the control of bone remodeling. J Bone Miner Res 27(3):499-505, 2012.
PubMed
8) Tang Y, et al:TGF-betal-induced migration of bone mesenchymal stem cells couples bone resorption with formation, Nat Med 15(7) 1757-765, 2009.
 
9) Martin TJ, Sims NA:Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med 11(2):76-81, 2005.
PubMed
10) Wysolmerski JJ:Osteocytes remove and replace perilacunar mineral during reproductive cycles. Bone 54(2):230-236, 2013.
PubMed
P.119 掲載の参考文献
1) Takayanagi H:New developments in osteoimmunology. Nat Rev Rheumatol 8(11):684 -689, 2012.
 
2) Takayanagi H:Osteoimmunology and the effects of the immune system on bone. Nat Rev Rheumatol 5(12):667-676, 2009.
 
3) Pettit AR, et al:TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 159(5):1689-1699, 2001.
 
4) Redlich K, et al:Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 110(10):1419-1427, 2002.
PubMed
5) Kadono Y, et al.:Rheumatoid arthritis associated with osteopetrosis. Mod Rheumatol 19(6):687-690, 2009.
 
6) Harre U, et al:Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest 122(5):1791-1802, 2012.
PubMed
7) Sato K et al:Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 203(12):2673-2682, 2006.
 
8) Komatsu N, et al:Inflammation and bone destruction in arthritis:synergistic activity of immune and mesenchymal cells in joints. Front Immunol 3:77, 2012.
PubMed
9) Smolen JS, et al:Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement:a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 52(4):1020-1030, 2005.
PubMed
10) Genovese MC, et al:Efficacy and safety of secukinumab in patients with rheumatoid arthritis:a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis 72(6):863-869, 2013.
PubMed
11) Komatsu N, et al:Pathogenic conversion of Foxp3+ T cells into Th17 cells in autoimmune arthritis. Nat Med 20:62-68, 2014.
PubMed
12) Diarra D, et al:Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13(2):156-163, 2007.
PubMed
13) Hayashi M, et al:Osteoprotection by semaphorin 3A. Nature 485(7396):69-74, 2012.
PubMed
14) Sherlock JP, et al:IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+ CD4- CD8- entheseal resident T cells. Nat Med 18(7):1069-1076, 2012.
 

V 関節リウマチの基礎研究

P.129 掲載の参考文献
1) Haynes BF, et al:Introduction to the immune system. In:Harrison'sPrinciples of Internal Medicine, 18th ed (ed by Fauci AS, et al), p2650-2685, McGraw-Hill, Columbus, 2011.
 
2) Lipsky PE:Rheumatoid arthritis, In:Harrison's Principles of Internal Medicine, 18th ed (ed by Fauci AS, et al), p2738-2752, McGraw-Hill, Columbus, 2011.
 
3) McInnes IB, Schett G:The pathogenesis of rheumatoid arthritis. N Engl J Med 365:2205-2219, 2011.
PubMed
4) Scott DL, et al:Rheumatoid arthritis. Lancet 376:1094-1108, 2010.
PubMed
5) Eyre S, et al:High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat Genet 44:1336-1340, 2012.
PubMed
6) Nakayamada S, et al:Early Th1 cell differentiation is marked by a Tfh cell-like transition. Immunity 35:919-931, 2011.
PubMed
7) Maeshima K, et al:AJAK inhibitor tofacitinib regulates synovitis through inhibition of IFN-γ and IL-17 production by human CD4+ T cells. Arthritis Rheum 64:1790-1798, 2012.
 
8) Tanaka Y, et al.:In vitro and in vivo analysis of a Jak inhibitor in rheumatoid arthritis. Ann Rheum Dis 71(Suppl 2):i70-74, 2012.
 
9) Redlich K, Smolen JS:Inflammatory bone loss:pathogenesis and therapeutic intervention. Nat Rev Drug Discov 11:234-250, 2012.
PubMed
10) Iwata S, et al:Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in longterm remission after B cell depletion therapy with rtuximab. J Rheumatol 38:633-641, 2011,
PubMed
11) Iwata S, et al:B cell or T cell-dominant recurrence after rituximab therapy in patients with SLE. Ann Rheum Dis 71:1749-1750, 2012.
 
12) Weinblatt ME, et al:An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med 363:1303-1312, 2010.
PubMed
13) Iwata S, et al:Amplification of Toll-like receptor-mediated signaling through spleen tyrosine kinase in human B-cell activation. J Allergy Clin Immunol 129:1594-1601, 2012.
 
14) Ochi S, et al:Pathological role of osteoclast costimulation in arthritis-induced bone loss. Proc Natl Acad Sci USA 104:11394-11399, 2007.
PubMed
15) Shinohara M, et al:Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals. Cell 32:794-806, 2008.
 
16) Miossec P, Kolls JK:Targeting IL-17 and TH17 cells in chronic innammation. Nat Rev Drug Discov 11:763-776, 2012.
 
17) Catrina AI, et al:Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis. Arthritis Rheum 54:76-81, 2006.
PubMed
18) Tanaka Y:Next stage of RA treatment:is TNF inhibitor-free remission a possible treatment goal? Ann Rheum Dis 72:ii124-ii127, 2013.
PubMed
19) Tanaka Y:Intensive treatment and treatment holiday of TNF-inhibitors in rheumatoid arthritis. Curr Opin Rheumatol 24:319-326, 2012.
PubMed
P.134 掲載の参考文献
1) Abell K Watson CJ:The Jak/Stat pathway:a novel way to regulate PI3K activity. Cell Cycle 4:897-900, 2005.
PubMed
2) Cantley LC:The phosphoinositide 3-kinase pathway. Science 296:1655, 2002.
PubMed
3) Foster JG, et al:Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies. Pharmacol Rev 64:1027-1054, 2012.
PubMed
4) Zhang H, et al:Regulation of tumor necrosis factor alpha-mediated apoptosis of rheumatoid arthritis synovial fibroblasts by the protein kinase Akt. Arthritis Rheum 44:1555-1567, 2001.
PubMed
5) Pap T, et al:Activation of synovial fibroblasts in rheumatoid arthritis:lack of expression of the tumor suppressor PTEN at sites of invasive growth and destruction. Arthritis Res 2:59-64, 2000.
PubMed
6) Kim KW, et al:Increased interleukin-17 production via a phosphoinositide 3-kinase/Akt and nuclear factor kappaB-dependent pathway in patients with rheumatoid arthritis. Arthritis Res Ther 7:139, 2005.
 
7) Toyama S, et al:Inhibitory effects of ZSTK474, a novel phosphoinositide-3 kinase on osteoclasts and collagen-induced arthritis in mice. Arthritis Res Ther 12:R92, 2010.
PubMed
8) Flores-Borja F, et al:Decreased Lyn expression and translocation to lipid raft signaling domains in Blymphocytes from patients with systemic lupus erythematosus, Arthritis Rheum 52:3955-3966, 2005.
 
9) Borlado LR, et al:Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo. FASEB J 14:895-903, 2000.
PubMed
10) Barber DF, et al:PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat Med 11:933-935, 2005.
 
11) Taher TE, et al:Protein phosphorylation and kinome profiling reveal altered regulation of multiple signaling pathways in B lymphocytes form patients with sysytemic lupus erythematosus. Arthritis Rheum 62:2412-2423, 2010.
 
12) Suarez-Fueyo A, et al:Enhanced phosphoinositide 3-kinaseδactivity is a frequent event in systemic lupus erythematosus that confers resistance to activation-induced T cell death. J Immunol 187:2376-2385, 2011.
 
13) Yamane K, et al:Epidermal growth factor up-regulates expression of transforming growth factor beta receptor type II in human dermal fibroblasts by phosphoinositide 3-kinase/Akt signaling pathway:Resistance to epidermal growth factor stimulation in scleroderma fibroblasts. Arthritis Rheum 48:1652-1666, 2003.
 
14) Mori S, et al:ZSTK474, a phosphatidylinositol 3-kinase inhibitor, ameliorates ankylosing enthesitis in DBA/1 mice. Arthritis Rheum 60(Suppl 10):1442, 2009.
 
P.142 掲載の参考文献
1) Kim TH, et al:Soluble triggering receptor expressed on myeloid cells-1 as a new therapeutic molecule in rheumatoid arthritis. Med Hypotheses 78:270-272, 2011.
PubMed
2) Derive M, et al:Triggering receptor expressed on myeloid cells-1 as a new therapeutic target during inflammatory diseases. Self Nonself 1:225-230, 2010.
PubMed
3) Feldmann M:Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2:364-371, 2002.
PubMed
4) Bresnihan B:Pathogenesis of joint damage in rheumatoid arthritis. J Rheumatol 26:717-719, 1999.
PubMed
5) Firestein GS:Immunologic mechanisms in the pathogenesis of rheumatoid arthritis. J Clin Rheumatol 11:S39-44, 2005.
PubMed
6) Feldmann M, et al:Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14:397-440, 1996.
PubMed
7) van Vollenhoven RF:Unresolved issues in biologic therapy for rheumatoid arthritis. Nat Rev Rheumatol 7:205-215, 2011.
PubMed
8) Harigai M, et al:Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med 357:1874-1876, 2007.
PubMed
9) Winthrop KL:Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2:602-610, 2006.
PubMed
10) Bouchon A et al:Cutting edge:innammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol 164:4991-4995, 2000.
 
11) Daws MR, et al:Cloning and characterization of a novel mouse myeloid DAP12-associated receptor family. Eur J Immunol 31:783-791, 2001.
PubMed
12) Colonna M:TREMs in the immune system and beyond. Nat Rev Immunol 3(6):445-453, 2003.
PubMed
13) Bouchon A, et al:A DAP12-mediated pathway regulates expression of CC chemokine receptor 7 and maturation of human dendritic cells. J Exp Med 194:1111-1122, 2001.
PubMed
14) Bouchon A, et al:TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature 410:1103-1107, 2001.
PubMed
15) Colonna M, Facchetti F:TREM-1 (triggering receptor expressed on myeloid cells):a new player in acute inflammatory responses. J Infect Dis 187(Suppl 2):S397-401, 2003.
 
16) Collins CE, et al:Elevated synovial expression of triggering receptor expressed on myeloid cells 1 in patients with septic arthritis or rheumatoid arthritis. Ann Rheum Dis 68:1768-1774, 2009.
PubMed
17) Kuai J, et al:TREM-1 expression is increased in the synovium of rheumatoid arthritis patients and induces the expression of pro-inflammatory cytokines. Rheumatology (Oxford) 48:1352-1358, 2009.
PubMed
18) Murakami Y, et al:Intervention of an inflammation amplifier, triggering receptor expressed on myeloid cells 1, for treatment of autoimmune arthritis. Arthritis Rheum 60:1615-1623, 2009.
PubMed
19) Murakami Y, et al:Induction of triggering receptor expressed on myeloid cells 1 in murine resident peritoneal macrophages by monosodium urate monohydrate crystals, Arthritis Rheum 54:455-462, 2006.
PubMed
20) Schenk M, et al:TREM-1-expressing intestinal macrophages crucially amplify chronic inflammation in experimental colitis and inflammatory bowel diseases. J Clin Invest 117:3097-3106, 2007.
PubMed
21) Wang DY, et al.:Expression of TREM-1 mRNA in acute pancreatitis. World J Gastroenterol 10:2744-2746, 2004.
PubMed
22) Gibot S, et al:A soluble form of the triggering receptor expressed on myeloid cells-1 modulates the inflammatory response in murine sepsis. J Exp Med 200:1419-1426, 2004.
PubMed
23) Gomez-Pina V, et al:Metalloproteinases shed TREM-1 ectodomain from lipopolysaccharide-stimulated human monocytes. J Immunol 179:4065-4073, 2007.
PubMed
24) Sharif O, Knapp S:From expression to signaling:roles of TREM-1 and TREM-2 in innate immunity and bacterial infection. Immunobiology 213:701-713, 2008.
PubMed
25) Fortin CF, et al:Effects of TREM-1 activation in human neutrophils:activation of signaling pathways, recruitment into lipid rafts and association with TLR4. Int Immunol 19:41-50, 2007.
 
26) Haselmayer P, et al:TREM-1 ligand expression on platelets enhances neutrophil activation. Blood 110:1029-1035, 2007.
PubMed
27) McVicar DW, et al:DAP12-mediated signal transduction in natural killer cells. A dominant role for the Syk protein-tyrosine kinase. J Biol Chem 273:32934-32942, 1998.
PubMed
28) Tessarz AS, Cerwenka A:The TREM-1/DAP12 pathway. Immunol Lett 116:111-116, 2008.
PubMed
29) Bleharski JR, et al.:A role for triggering receptor expressed on myeloid cells-1 in host defense during the early-induced and adaptive phases of the immune response. J Immunol 170:3812-3818, 2003.
PubMed
30) Radsak MP, et al:Triggering receptor expressed on myeloid cells-1 in neutrophil innammatory responses:differential regulation of activation and survival. J Immunol 172:4956-4963, 2004.
 
31) Dower K, et al:Innate immune responses to TREM-1 activation:overlap. divergence, and positive and negative cross-talk with bacterial lipopolysaccharide. J Immunol 180:3520-3534, 2008.
PubMed
32) Ornatowska M, et al:Functional genomics of silencing TREM-1 on TLR4 signaling in macrophages. Am J Physiol Lung Cell Mol Physiol 293:L1377-1384, 2007.
PubMed
33) Knapp S, et al.:Cutting edge:expression patterns of surface and soluble triggering receptor expressed on myeloid cells-1 in human endotoxemia. J Immunol 173:7131-7134, 2004.
PubMed
34) Ramanathan B, et al:Cloning of porcine triggering receptor expressed on myeloid cells-1 (TREM-1) and its induction by lipopolysaccharide, peptidoglycan, and Salmonella enterica serovar Typhimurium infection. Dev Comp Immunol 29:1-7, 2005.
PubMed
35) Gibot S, et al:Surface and soluble triggering receptor expressed on myeloid cells-1:expression patterns in murine sepsis. Crit Care Med 33:1787-1793, 2005.
PubMed
36) Zheng H, et al:MYD88-dependent and-independent activation of TREM-1 via specific TLR ligands. Eur J Immunol 40:162-171, 2010.
PubMed
37) Gibot S, et al:Modulation of the triggering receptor expressed on myeloid cells-1 pathway during pneumonia in rats. J Infect Dis 194:975-983, 2006.
PubMed
38) Wiersinga WJ, et al:Expression profile and function of triggering receptor expressed on myeloid cells-1 during melioidosis. J Infect Dis 196:1707-1716, 2007.
PubMed
39) Gibot S, et al:Modulation of the triggering receptor expressed on the myeloid cell type 1 pathway in murine septic shock. Infect Immun 74:2823-2830. 2006.
PubMed
40) Kelker MS, et al:Crystal structure of human triggering receptor expressed on myeloid cells 1 (TREM-1) at 1.47 A. J Mol Biol 342:1237-1248, 2004.
 
41) Kelker MS, et al:Crystal structure of mouse triggering receptor expressed on myeloid cells 1 (TREM-1) at 1.76 A. J Mol Biol 344:1175-1181, 2004.
 
P.146 掲載の参考文献
1) Matsumoto I, et al:Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science 286:1732-1735, 1999.
 
2) Matsumoto I, et al:How antibodies to a ubiquitous cytoplasmic enzyme may provoke joint specific autoimmune disease. Nat Immunol 3:360-365, 2002.
PubMed
3) Schubert D, et al.:Immunization with glucose-6-phosphate isomerase induces T cell-dependent peripheral polyarthritis in generally unaltered mice. J Immunol 172:4503-4509, 2004.
 
4) Matsumoto I, et al:Therapeutic effects of antibodies to TNF alpha and IL-6 and CTLA-4 Ig in mice with glucose-6-phosphate isomerase-induced arthritis. Arthritis Res Ther 10:R66, 2008.
 
5) Iwanami K, et al:Crucial role of IL-6/IL-17 cytokine axis in the induction of arthritis by glucose-6-phosphate-isomerase. Arthritis Rheum 58:754-763, 2008.
PubMed
6) Inoue A, et al:Tumor necrosis factor alpha-induced adipose-related protein expression in experimental arthritis and in rheumatoid arthritis. Arthritis Res Ther 11:R118, 2009.
PubMed
7) Ramadoss P, et al:Regulation of hepatic six transmembrane epithelial antigen of prostate 4 (STEAP4) expression by STAT3 and CCAAT/enhancer-binding protein alpha. J Biol Chem 285(22):16453-16466, 2010.
PubMed
8) Inoue A, et al:Murine tumor necrosis factor α-induced adipose-related protein (tumor necrosis factor α-induced protein 9) deficiency leads to arthritis via interleukin-6 overproduction with enhanced NF-κB, STAT-3 signaling, and dysregulated apoptosis of macrophages. Arthritis Rheum 64:3877-3885, 2012.
 
9) Wellen KE, et al:Coordinated regulation of nutrient and inflammatory response by STAMP2 is essential for metabolic homeostasis. Cell 129:537-548, 2007.
PubMed
10) Grunewald TG, et al:The STEAP protein family:versatile oxidoreductases and targets for cancer immunotherapy with overlapping and distinct cellular functions. Biol Cell 104:641-657, 2012.
PubMed
11) Tanaka Y, et al:Six-transmembrane epithelial antigen of prostate 4 (STEAP4) is TNFalphainduced protein that regulates IL-6, IL-8, and cell proliferation in synovium from patients with rheumatoid arthritis. Mod Rheumatol 22:128-136, 2012.
 
12) Tanaka Y, et al:Six-transmembrane epithelial antigen of prostate 4 (STEAP4) is expressed on monocytes/neutrophils, and is regulated by TNF antagonist in patients with rheumatoid arthritis. Clin Exp Rheumatol 30:99-102, 2012.
PubMed
P.153 掲載の参考文献
1) Sekigawa I, et al:Protein biomarker analysis by mass spectrometry in patients with rheumatoid arthritis receiving anti-tumor necrosis factor-α antibody therapy. Clin Exp Rheumatol 26:261-267, 2008.
 
2) Nozawa K, et al:Connective tissue growth factor promotes articular damage by increased osteoclastogenesis in patients with rheumatoid arthritis. Arthritis Res Ther 11(6):R174, 2009.
PubMed
3) Nozawa K, et al:INFLIXIMAB pharmacology. In:Uses and Limitations (ed by Fox RI, Fox CM), p167-176, Nova Science Publishers, 2012.
 
4) Nozawa K, et al:Inhibition of connective tissue growth factor ameliorates disease in a murine model of rheumatoid arthritis. Arthritis Rheum 65(6):1477-1486, 2013.
 
5) Fujishiro M, et al:The detection of plasma levels of connective tissue growth factor in rheumatoid arthritis patients. Clin Exp Rheumatol 30(1):145-146, 2012.
PubMed
6) Bradham DM, et al:Connective tissue growth factor:a cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10. J Cell Biol 114:1285-1294, 1991.
 
7) 久保田聡, 滝川正春:結合組織成長因子 (CTGF/CCN2) と軟骨形成. 骨粗鬆症治療 9(4):287-290, 2010.
Medical*Online
8) Rico MC, et al:Amelioration of inflammation, angiogenesis and CTGF expression in an arthritis model by a TSP1-derived peptide treatment. J Cell Physiol 211(2):504-512, 2007.
 
9) Pierce CW, et al:Connective tissue groWth factor (ctgf) expression in the tenosynovium of patients with carpal tunnel syndrome-biomed 2009. Biomed Sci Instrum 45:30-35, 2009.
PubMed
P.158 掲載の参考文献
1) Taniguchi K, et al:Induction of p16INK4a senescence gene as a new therapeutic strategy for the treatment of rheumatoid arthritis, Nat Med 5:760-767, 1999.
PubMed
2) Nonomura Y, et al:Direct modulation of rheumatoid infiammatory mediator expression in retinoblastoma protein-dependent and-independent pathways by cyclin-dependent kinase 4/6. Arthritis Rheum 54:2074-2083, 2006.
 
3) Sekine C, et al:Successful treatment of animal models of rheumatoid arthritis with small-molecule cyclin-dependent kinase inhibitors. J Immunol 180:1954-1961, 2008.
PubMed
P.163 掲載の参考文献
1) Provot S, Schipani E:Molecular mechanisms of endochondral bone development. Biochem Biophys Res Commun 328:658-665, 2005.
PubMed
2) Akiyama H:Control of chondrogenesis by the transcription factor Sox9. Mod Rheumatol 18:213-219, 2008.
PubMed
3) Han Y, Lefebvre V:L-Sox5 and Sox6 drive expression of the aggrecan gene in cartilage by securing binding of Sox9 to a far-upstream enhancer. Mol Cell Biol 28:4999-5013, 2008.
PubMed
4) Inada M, et al.:Maturational disturbance of chondrocytes in Cbfa1-deficient mice. Dev Dyn 214:279-290, 1999.
PubMed
5) Kim IS, et al:Regulation of chondrocyte differentiation by Cbfa1. Mech Dev 80:159-170, 1999.
PubMed
6) Orfanidou T, et al:Involvement of SOX-9 and FGF-23 in RUNX-2 regulation in osteoarthritic chondrocytes. J Cell Mol Med 13:3186-3194, 2009.
PubMed
7) Hirao M, et al:Oxygen tension regulates chondrocyte differentiation and function during endochondral ossification. J Biol Chem 281:31079-31092, 2006.
PubMed
8) Hellemans J, et al:Homozygous inactivating mutations in the NKX3-2 gene result in spondylo-megaepiphyseal-metaphyseal dysplasia. Am J Hum Genet 85:916-922, 2009.
PubMed
9) Lengner CJ, et al:Nkx3.2-mediated repression of Runx2 promotes chondrogenic differentiation. J Biol Chem 280:15872-15879, 2005.
PubMed
10) Lettice LA, et al:The mouse bagpipe gene controls development of axial skeleton, skull, and spleen. Proc Natl Acad Sci USA 96:9695-9700, 1999.
PubMed
11) Tribioli C, Lufkin T:The murine Bapx1 homeobox gene plays a critical role in embryonic development of the axial skeleton and spleen. Development 126:5699-5711, 1999.
 
12) Zeng L, et al:Shh establishes an Nkx3.2/Sox9 autoregulatory loop that is maintained by BMP signals to induce somitic chondrogenesis. Genes Dev 16:1990-2005, 2002.
PubMed
13) Akazawa H, et al.:Targeted disruption of the homeobox transcription factor Bapxl results in lethal skeletal dysplasia with asplenia and gastroduodenal malformation. Genes Cells 5:499-513, 2000.
 
14) Aszodi A, et al:Collagen II is essential for the removal of the notochord and the formation of intervertebral discs. J Cell Biol 143:1399-1412, 1998.
PubMed
15) Provot S, et al:Nkx3.2/Bapxl acts as a negative regulator of chondrocyte maturation. Development 133:651-662, 2006.
 
P.167 掲載の参考文献
1) Sakaguchi N, et al:Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature 426(6965):454-460, 2003.
PubMed
2) Hirota K, et al:T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis. J Exp Med 204(1):41-47, 2007.
PubMed
3) Yoshitomi H, et al:A role for fungal β-glucans and their receptor Dectin-1 in the induction of autoimmune arthritis in genetically susceptible mice. J Exp Med 201(6):949-960, 2005.
 
4) Hashimoto M, et al:Complement drives Th17 cell differentiation and triggers autoimmune arthritis. J Exp Med 207(6):1135-1143, 2010.
PubMed
5) Kouskoff V, et al:Organ-specific disease provoked by systemic autoimmunity. Cell 87(5):811-822, 1996.
PubMed
6) Matsumoto I, et al:Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science 286(5445):1732-1735, 1999.
 
7) Ji H, et al:Arthritis critically dependent on innate immune system players. Immunity 16(2):157-168, 2002.
PubMed
8) Wu HJ, et al:Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 32(6):815-827, 2010.
PubMed
9) Lee DM, et al:Mast cells:a cellular link betWeen autoantibodies and inflammatory arthritis. Science 297(5587):1689-1692, 2002.
PubMed
10) Horai R, et al:Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 191(2):313-320, 2000.
PubMed
11) Nakae S, et al:IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci USA 100(10):5986-5990, 2003.
PubMed
12) Atsumi T, et al:A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis. J Exp Med 196(7):979-990, 2002.
PubMed
13) Ogura H, et al:Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. Immunity 29(4):628-636, 2008.
PubMed
14) Fujikado N, et al:Dcir deficiency causes development of autoimmune diseases in mice due to excess expansion of dendritic cells. Nat Med 14(2):176-180, 2008.
PubMed
15) Kawane K, et al:Chronic polyarthritis caused by mammalian DNA that escapes from degradation in macrophages. Nature 443(7114):998-1002, 2006.
PubMed
P.173 掲載の参考文献
1) Silman AJ, et al:Twin concordance rates for rheumatoid arthritis:results from a nationwide study. Br J Rheumatol 32(10):903-907, 1993.
PubMed
2) Jarvinen P, Aho K:Twin studies in rheumatic diseases. Semin Arthritis Rheum 24(1):19-28, 1994.
 
3) Bottini N:Duality of fibroblast-like synoviocytes in RA:passive responders and imprinted aggressors. Nat Rev Rheumatol 9(1):24-33, 2013.
PubMed
4) Muller-Ladner U, et al:Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am J Pathol 149(5):1607-1615, 1996.
PubMed
5) 中野和久, 田中良哉:関節リウマチにおけるゲノムワイドDNAメチル化解析. リウマチ科 49(5):589-594, 2013.
 
6) Nakano K, et al:DNA methylome signature in rheumatoid arthritis. Ann Rheum Dis 72(1):110-117, 2013.
PubMed
7) Whitaker J, et al:An imprinted rheumatoid arthritis methylome signature reflects pathogenic phenotype. Genome Med 5(4):40, 2013.
PubMed
8) de la Rica L, et al:Identification of novel markers in rheumatoid arthritis through integrated analysis of DNA methylation and microRNA expression. J Autoimmun 41(0):6-16, 2013.
 
9) Nakano K, et al:Regulation of DNA methylation in rheumatoid arthritis synoviocytes. J Immunol 190(3):1297-1303, 2013.
PubMed
P.177 掲載の参考文献
1) Klein K, et al:Epigenetic contributions in the development of rheumatoid arthritis. Arthritis Res Ther 14:227, 2012.
PubMed
2) Grabiec AM, Reedquist KA:The ascent of acetylation in the epigenetics of rheumatoid arthritis. Nat Rev Rheumatol 9:311-318, 2013.
PubMed
3) Horiuchi M, et al:Expression and function of histone deacetylases in rheumatoid arthritis synovial fibroblasts. J Rheumatol 36:1580-1589, 2009.
PubMed
4) Kawabata T, et al.:Increased activity and expression of histone deacetylase 1 in relation to tumor necrosis factor-alpha in synovial tissue of rheumatoid arthritis. Arthritis Res Ther 12:R133, 2010.
PubMed
5) Grabiec AM, et al:Histone deacetylase inhibitors suppress rheumatoid arthritis fibroblast-like synoviocyte and macrophage IL-6 production by accelerating mRNA decay. Ann Rheum Dis 71:424-431, 2012.
PubMed
6) Morinobu A, et al.:Trichostatin A cooperates with Fas-mediated signal to induce apoptosis in rheumatoid arthritis synovial fibroblasts. J Rheumatol 33:1052-1060, 2006,
PubMed
7) Bolden JE, et al:Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5:769-784, 2006.
PubMed
8) Grabiec AM, et al:Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue. J Immunol 184:2718-2728, 2010.
 
9) Arlt A, Schafer H:Role of the immediate early response 3 (IER3) gene in cellular stress response, inflammation and tumorigenesis. Eur J Cell Biol 90:545-552, 2011.
PubMed
10) Sasada T, et al:Prognostic significance of the immediate early response gene X-1 (IEX-1) expression in pancreatic cancer. Ann Surg Oncol 15:609-617, 2008.
 
11) Steensma DP, et al:Rearrangements and amplification of IER 3 (IEX-1) represent a novel and recurrent molecular abnormality in myelodysplastic syndromes. Cancer Res 69:7518-7523, 2009.
 
12) Zhi L, et al:Enhanced Th17 differentiation and aggravated arthritis in IEX-1-deficient mice by mitochondrial reactive oxygen species-mediated signaling. J Immunol 189:1639-1647, 2012.
PubMed
P.182 掲載の参考文献
1) Denk W, et al:Two-photon laser scanning fluorescence microscopy. Science 248:73-76, 1990.
PubMed
2) Denk W, Svoboda K:Photon upmanship:why multiphoton imaging is more than a gimmick. Neuron 18:351-357, 1997.
PubMed
3) Ishii M, et al:Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis. Nature 458:524-528, 2009.
PubMed
4) Ishii M, et al:Chemorepulsion by blood SIP regulatcs osteoclast precursor mobilization and bone remodeling in vivo. J Exp Med 207:2793-2798, 2010.
 
5) Kikuta J, et al:Dynamic visualization of RANKL and Th17-mediated osteoclast function. J Clin Invest 123:866-873, 2013.
PubMed
6) Toyomura T, et al:Three subunit a isoforms of mouse vacuolar H (+) -ATPase. Preferential expression of thc a3 isoform during osteoclast differentiation. J Biol Chem 275:8760-8765, 2000.
 
7) Toyomura T, et al:From lysosomes to the plasma membrane:localization of vacuolar-type H+ -ATPase with the a3 isoform during osteoclast differentiation. J Biol Chem 278:22023-22030, 2003.
 
8) Sun-Wada GH, et al:Direct recruitment of H+ -ATPase from lysosomes for phagosomal acidification. J Cell Sci 122:2504-2513, 2009.
PubMed
9) Kowada T et al:In vivo fluorescence imaging of bone-resorbing osteoclasts. J Am Chem Soc 133:17772-17776, 2011.
PubMed
10) Sato K, et al:Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 203:2673-2682, 2006.
 

VI 関節リウマチの検査・診断

P.195 掲載の参考文献
1) Aletaha D, et al:2010 rheumatoid arthritis classification criteria:an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69:1580-1588, 2010.
PubMed
2) 袴田康弘:関節リウマチ. Medicina 49:1508-1512, 2012.
 
3) Stern S, et al:I have a patient with joint pain. How do I determine the cause? In:Symptom to Diagnosis-An Evidence Based Guide, 2nd ed, p365-385, McGraw-Hill, New York, 2009.
 
4) Meeham RT:History and physical examination. In:Rheumatology Secret, 2nd ed, Hanley & Belfus, Philadelphia, 2002.
 
5) Imboden JB:Approach to the adolescent with arthritis. In:Current Diagnosis and Treatment:Rheumatology, McGraw-Hill, New York, 2013.
 
6) Klippel JH, et al:History and physical examination. In:Primer on the Rheumatic Diseases, 13th ed, p6-41, Springer. New York, 2008.
 
7) McInnes IB, Schett G:The pathogenesis of rheumatoid arthritis. N Engl J Med 365:2205-2219, 2011.
PubMed
8) 高杉潔:リウマチ性疾患の診療・診断法. C. 関節のみかた. リウマチ基本テキスト (第2版), p160-180, 日本リウマチ財団, 2002.
 
9) Smolen JS, et al:A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 42:244-257, 2003.
PubMed
P.199 掲載の参考文献
1) Smoren JS, et al.:Treating rheumatoid arthritis to target:recommendations of an international task force. Ann Rheum Dis 69:631-637, 2010.
 
2) Felson DT, et al:American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 63:573-586, 2011.
PubMed
3) Arnett FC, et al:The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324, 1988.
PubMed
4) Aletha D, et al:2010 rheumatoid arthritis classification criteria:an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569-2581, 2010.
 
5) Pinals RS, et al:Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 24:1308-1315, 1981.
PubMed
6) Prevoo ML, et al:Modified disease activity scores that include twenty-eight-joint counts:development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44-48, 1995.
 
7) Smolen JS, et al:A simplified disease activity index for rheumatoid arthritis use in clinical practice. Rheumatology (Oxford) 42:244-257, 2003.
PubMed
8) Aletaha D, et al:Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis:validation of a clinical activity score. Arthritis Res Ther 7:R796-R806, 2005.
PubMed
9) Engstrom-Laurent A, et al:Circulating hyaluronic acid levels vary with physical activity in healthy subjects and in rheumatoid arthritis patients. Relationship to synovitis mass and morning stiffness. Arthritis Rheum 30:1333-1338, 1987.
PubMed
P.203 掲載の参考文献
1) Singh JA, et al:2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 64:625-639, 2012.
PubMed
2) Cortet B, et al:Pulmonary function tests and high resolution computed tomography of the lungs in patients with rheumatoid arthritis. Ann Rheum Dis 56:596-600, 1997.
PubMed
3) Turesson C, et al:Severe extra-articular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis, Ann Rheum Dis 66:70, 2007.
PubMed
4) McGavin DD, et al:Episcleritis and scleritis. A study of their clinical manifestations and association with rheumatoid arthritis. Br J Ophthalmol 60:192, 1976.
PubMed
5) Foster CS, et al:Mortality rate in rheumatoid arthritis patients developing necrotizing scleritis or peripheral ulcerative keratitis. Effects of systemic immunosuppression. Ophthalmology 91:1253, 1984.
PubMed
6) Watson PG, Hayreh SS:Scleritis and episcleritis. Br J Ophthalmol 60:163, 1976.
PubMed
7) Fujita M, et al:Correlation between dry eye and rheumatoid arthritis activity. Am J Ophthalmol 140:808, 2005.
PubMed
8) Spurlock RG, Richman AV:Rheumatoid meningitis. A case report and review of the literature. Arch Pathol Lab Med 107:129-131, 1983.
PubMed
9) Campion G, et al:The Felty syndrome:a case-matched study of clinical manifestations and outcome, serologic features, and immunogenetic associations. Medicine (Baltimore) 69:69-80, 1990.
PubMed
10) Tan N, et al:Oral methotrexate in the treatment of Felty's syndrome. J Rheumatol 20:599, 1993.
PubMed
11) Tiitinen S, et al:Amyloidosis-incidence and early risk factors in patients with rheumatoid arthritis. Scand J Rheumatol 22:158-161, 1993.
PubMed
12) 奥田恭章, 高杉潔:アミロイドーシスの診療 リウマチ科 27:933-938, 2002.
 
13) Okuda Y, Takasugi K:Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum 54:2997-3000, 2006.
PubMed
P.208 掲載の参考文献
1) Arnett FC, et al:The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324, 1988.
PubMed
2) Wiles N, et al:Estimating the incidence of rheumatoid arthritis trying to hit a moving target ? Arthritis Rheum 42:1339-1346, 1999.
PubMed
3) Aletaha D, et al:2010 Rheumatoid arthritis classification criteria:an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69:1580-1588, 2010.
PubMed
4) Aletaha D, et al:2010 Rheumatoid arthritis classification criteria:an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569-2581, 2010.
PubMed
5) Funovits J, et al:The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis:methodological report phase I. Ann Rheum Dis 69:1589-1595, 2010.
PubMed
6) van der Heijde D, et al:EULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteria. Ann Rheum Dis 72:479-481, 2013.
PubMed
7) van der Linden MP, et al:Classification of rheumatoid arthritis comparison of the 1987 American College of Rheumatology criteria and the 2010 American College of Rheumatology/European League Against Rheumatism criteria. Arthritis Rheum 63:37-42, 2011.
PubMed
8) Berglin E, et al:Comparison of the 1987 ACR and 2010 ACR/EULAR classification criteria for rheumatoid arthritis in clinical practice:a prospective cohort study. Scand J Rheumatol 42:362-368, 2013.
PubMed
9) Kaneko Y, et al.:Sensitivity and specificity of 2010 rheumatoid arthritis classification criteria. Rheumatology 50:1268-1274, 2011.
PubMed
10) Radner H, et al:Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis:a systemic literature review. Ann Rheum Dis 73:114-123, 2014.
 
11) Colebatch AN, et al:EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Ann Rheum Dis 72:804 -814, 2013.
 
12) Nakagomi D, et al:Ultrasound can improve the accuracy of the 2010 American College of Rheumatology/European League against rheumatism classification criteria for rheumatoid arthritis to predict the requirement for methotrexate treatment. Arthritis Rheum 65:890-898, 2013.
PubMed
13) de Hair MJ, et al:The clinical picture of rheumatoid arthritis according to the 2010 American College of Rheumatology/European League Against Rheumatism criteria:is this still the same disease? Arthritis Rheum 63:389-393, 2012.
 
14) Inoue K, et al:Older age onset rheumatoid arthritis with or without osteoarthritis. Ann Rheum Dis 46:908-911, 1987.
 
P.213 掲載の参考文献
1) Arnett FC, et al:The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324, 1988.
PubMed
2) Aletaha D, et al:2010 rheumatoid arthritis classhication criteria:an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569-2581, 2010.
PubMed
3) Humphreys JH, et al:The incidence of rheumatoid arthritis in the UK:comparisons using the 2010 ACR/EULAR classification criteria and the 1987 ACR classification criteria. Results from the Norfolk Arthritis Register. Ann Rheum Dis 72:1315-1320, 2013.
PubMed
4) Banal F, et al:Sensitivity and specificity of the American College of Rheumatology 1987 criteria for the diagnosis of rheumatoid arthritis according to disease duration:asystematic literature review and meta-analysis. Ann Rheum Dis 68:1184-1191, 2009.
 
5) van der Linden MP, et al:Classification of rheumatoid arthritis:comparison of the 1987 American College of Rheumatology criteria and the 2010 American College of Rheumatology/European League Against Rheumatism criteria. Arthritis Rheum 63:37-42, 2011.
PubMed
6) Cader MZ, et al:Performance of the 2010 ACR/EULAR criteria for rheumatoid arthritis:comparison with 1987 ACR criteria in a very early synovitis cohort. Ann Rheum Dis 70:949-955, 2011.
 
7) Britsemmer K et al:Validation of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis:slight improvement over the 1987 ACR criteria. Ann Rheum Dis 70:1468-1470, 2011.
PubMed
P.217 掲載の参考文献
1) Brigden ML:Clinical utility of the erythrocyte sedimentation rate. Am Fam Physician 60(5):1443-1450, 1999.
PubMed
2) Thompson D, et al:The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure 7(2):169-177, 1999.
 
3) Mold C, Clos TW:C-reactive protein inhibits plasmacytoid dendritic cell interferon responses to autoantibody immune complexes. Arthritis Rheum 65(7):1891-1901, 2013.
PubMed
4) Paffen E, DeMaat MP:C-reactive protein in atherosclerosis:A causal factor? Cardiovasc Res 71(1):30-39, 2006.
PubMed
5) Sasaki T, Tsukamoto S:ESR, CRP, SAA. Nihon Naikagakkai Zasshi 87(12):10-15, 1998.
 
6) Figueredo MA, et al:Autoantibodies against C-reactive protein:clinical associations in systemic lupus erythematosus and primary antiphospholipid syndrome. J Rheumatol 33(10):1980-1986, 2006.
PubMed
7) Sjowall C, et al:High prevalence of autoantibodies to C-reactive protein in patients with chronic hepatitis C infection:association with liver fibrosis and portal inflammation. Hum Immunol 73(4):382-388, 2012.
 
8) Jonsen A, et al:Association between SLE nephritis and polymorphic variants of the CRP and FcgammaRIIIa genes. Rheumatology (Oxford) 46(9):1417-1421, 2007.
PubMed
9) Rodriguez W, et al:Prevention and reversal of nephritis in MRL/lpr mice with a single injection of C-reactive protein. Arthritis Rheum 54(1):325-335, 2006.
PubMed
10) Galarraga B, et al.:C-reactive protein:the underlying cause of microvascular dysfunction in rheumatoid arthritis. Rheumatology (Oxford) 47(12):1780-1784, 2008.
PubMed
11) Schwedler SB, et al:C-reactive protein:a family of proteins to regulate cardiovascular function. Am J Kidney Dis 47(2):212-222, 2006.
PubMed
12) Eisenhardt SU, et al:Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques. Circ Res 105(2):128-137, 2009.
PubMed
13) Matsui T, et al:Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan. Ann Rheum Dis 66(9):1221-1226, 2007.
 
14) Inoue E, et al:Comparison of Disease Activity Score (DAS) 28-erythrocyte sedimentation rate and DAS28-C-reactive protein threshold values. Ann Rheum Dis 66(3):407-409, 2007.
PubMed
15) Wells G, et al:Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate, Ann Rheum Dis 68(6):954-960, 2009.
 
P.221 掲載の参考文献
1) Parekh RB, et al.:Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature 316:452-457, 1985.
PubMed
2) Aho K et al:Rheumatoid factors antedating clinical rheumatoid arthritis. J Rheumatol 18:1282-1284, 1991.
PubMed
3) Bukhari M, et al:Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis:results from the Norfolk Arthritis Register Study, a large inception cohort. Arthritis Rheum 46:906-912, 2002.
PubMed
4) Schellekens GA, et al:Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 101:273 -281, 1998.
 
5) Schellekens GA, et al.:The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 43:155-163, 2000.
PubMed
6) van Venrooij WJ, et al:Anticitrullinated protein/peptide antibody and its role in the diagnosis and prognosis of early rheumatoid arthritis. Neth J Med 60:383-388, 2002.
PubMed
7) Nishimura K, et al:Meta-analysis:diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 146:797-808, 2007.
PubMed
8) Rantapaa-Dahlqvist S, et al:Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 48:2741-2749, 2003.
PubMed
9) Smolen JS, et al:EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69:964-975, 2010.
PubMed
10) Barra L, et al:Anticitrullinated protein antibodies and rheumatoid factor fluctuate in early inflammatory arthritis and do not predict clinical outcomes. J Rheumatol 40:1259-1267, 2013.
 
11) Matsui T, et al.:Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis. J Rheumatol 33:2390-2397, 2006.
PubMed
12) Matsui T, et al:Anti-cyclic citrullinated peptide antibody in rheumatic diseases other than rheumatoid arthritis. Clin Rheumatol 25:610-611, 2006.
PubMed
13) Linn-Rasker SP, et al:Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles. Ann Rheum Dis 65:366-371, 2006.
PubMed
14) Wegner N, et al:Peptidylarginine deiminase from Porphyromonas gingivalis citrullinates human fibrinogen and alpha-enolase:implications for autoimmunity in rheumatoid arthritis. Arthritis Rheum 62:2662-2672, 2010.
PubMed
P.226 掲載の参考文献
1) Visse R, Nagase H:Matrix metalloproteinases and tissue inhibitors of metalloproteinases:structure, fUnction, and biochemistry. Circ Res 92(8):827-839, 2003.
PubMed
2) Curry TE Jr, Osteen KG:The matrix metalloproteinase system:changes, regulation, and impact throughout the ovarian and uterine reproductive cycle. Endocr Rev 24(4):428-465, 2003.
PubMed
3) Hashizume K:Analysis of uteroplacental-specific molecules and their functions during implantation and placentation in the bovine. J Reprod Dev 53(1):1-11, 2007.
PubMed
4) Okada Y, et al:Localization of matrix metalloproteinase 3 (stromelysin) in osteoarthritic cartilage and synovium. Lab Invest 66(6):680-690, 1992.
PubMed
5) Yoshihara Y, et al:Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann Rheum Dis 59(6):455-461, 2000.
 
6) Ii M, et al:Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Exp Biol Med (Maywood) 231(1):20-27, 2006.
PubMed
7) Amalinei C, et al:Biology of metalloproteinases. Rom J Morphol Embryol 48(4):323-334, 2007.
PubMed
8) Sato H, et al:A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 370(6484):61-65, 1994.
 
9) Van Wart HE, Birkedal-Hansen H:The cysteine switch:a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci USA 87(14):5578-5582, 1990.
 
10) Okada Y, et al:A metalloproteinase from human rheumatoid synovial fibroblasts that digests connective tissue matrix components. Purification and characterization. J Biol Chem 261(30):14245-14255, 1986.
PubMed
11) Okada Y, et al:Matrix metalloproteinase 9(92-kDa gelatinase/type IV collagenase) from HT 1080 human fibrosarcoma cells. Purification and activation of the precursor and enzymic properties. J Biol Chem 267(30):21712-21719, 1992.
PubMed
12) Takizawa M, et al:Production of tissue inhibitor of metalloproteinases 3 is selectively enhanced by calcium pentosan polysulfate in human rheumatoid synovial fibroblasts. Arthritis Rheum 43(4):812-820, 2000.
PubMed
13) 山中寿:血清MMP-3 (matrix metalloproteinase-3). 日本臨牀 60(12):2325-2330, 2002.
Medical*Online
14) Yamanaka H, et al:Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum 43(4):852-858, 2000.
PubMed
15) 大内英子ほか:関節リウマチにおける血清MMP-3測定の有用性. Inflammation and Regeneration 24(3):154-160, 2004.
 
P.232 掲載の参考文献
1) Karstila K, et al:Prognosis of clinical renal disease and incidence of new renal findings in patients with rheumatoid arthritis:follow-up of a population-based study. Clin Rheumatol 26(12):2089-2095, 2007.
PubMed
2) Nakano M, et al:Analysis of renal pathology and drug history in 158 Japanese patients with rheumatoid arthritis. Clin Nephrol 50(3):154-160, 1998.
PubMed
3) Sihvonen S, et al:Renal disease as a predictor of increased mortality among patients with rheumatoid arthritis. Nephron Clin Pract 96(4):107-114, 2004.
 
4) Nakano M, et al:Renal disorders in rheumatoid arthritis. Nihon Rinsho 50(3):576-580, 1992.
PubMed
5) Paydas S:Report on 59 patients with renal amyloidosis. Int Urol Nephrol 31(5):619-631, 1999.
PubMed
6) Schiff MH, Whelton A:Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis. Semin Arthritis Rheum 30(3):196-208, 2000.
PubMed
7) Obayashi M, et al.:Clinical course of bucillamine-induced nephropathy in patients with rheumatoid arthritis. Clin Exp Nephrol 7(4):275-278, 2003.
PubMed
8) Hoshino J, et al:Outcome and treatment of bucillamine -induced nephropathy. Nephron Clin Pract 104(1):15-19, 2006.
 
9) Shimizu T, et al:Clinical and histological analysis of acute tacrolimus (TAC) nephrotoxicity in renal allografts. Clin Transplant 13(Suppl 1):48-53, 1999.
 
10) Shimizu T, et al:Clinical and histological analysis of chronic tacrolimus nephrotoxicity in renal allografts. Transplant Proc 40(7):2370-2372, 2008.
PubMed
11) Williams EL, et al:Anti-TNF-induced lupus. Rheumatology (Oxford) 48(7):716-720, 2009.
PubMed
12) Stokes MB, et al:Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant 20(7):1400-1406, 2005.
PubMed
13) Simms R, et al:ANCA-associated renal vasculitis following anti-tumor necrosis factor alpha therapy. Am J Kidney Dis 51(3):11-14, 2008.
 
14) Kaneko K, et al:Etanercept-induced necrotizing crescentic glomerulonephritis in two patients with rheumatoid arthritis. Mod Rheumatol 20(6):632-636, 2010.
PubMed
P.236 掲載の参考文献
1) Zordo TD, et al:US guided injections in arthritis. Eur J Radiol 71:197-203, 2009.
 
2) Ted RM:Synovial fluid analysis. In:Arthritis and Allied Conditions (ed by Koopmann WJ, Moreland LW), p81-96, Lippincott Williams & Wilkins, Baltimore, 2004.
 
3) Pascual E, et al:Synovial fluid analysis for crystals. Curr Opin Rheumatol 23:161-169, 2011.
PubMed
4) Sato M, et al:Clinical significance of anti-CCP antibodies in the knee joint fluids of patients with rheumatoid arthritis. Clin Rheumatol 18:158-162, 2006.
 
5) Neidhart M, et al:Small fragments of cartilage oligomeric protein in synovial fluid and serum as markers for cartilage degradation. Br J Rheumatol 36:1151-1160, 1997.
PubMed
6) Yoshihara Y, et al:Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann Rheum Dis 59:455-461, 2000.
 
7) Carrasco R Barton A:Biomarkers of outcome in rheumatoid arthritis. Rheumatology Reports 2:26-38, 2010.
 
8) Raza K, et al:Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res Ther 7:784 -795, 2005.
 
9) Liao H, et al:Use of mass spectrometry to identify protein biomarkers of disease severity in the synovial fluid and serum of patients with rheumatoid arthritis. Arthritis Rheum 50:3792-3803, 2004.
PubMed
P.251 掲載の参考文献
1) Arnett FC, et al:The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315-324, 1988.
PubMed
2) Aletaha D, et al:Rheumatoid arthritis classification criteria:an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62(9):2569-2581, 2010.
PubMed
3) Steinbrocker O, et al:Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc 140(8):659-662, 1949.
PubMed
4) Larsen A, et al:Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn 18(4):481-491, 1977.
PubMed
5) Larsen A:How to apply Larsen score in evaluating radiographs of rheumatoid arthritis in long-term studies. J Rheumatol 22(10):1974-1975, 1995.
PubMed
6) Scott DL, et al:Long term progression of joint damage in rheumatoid arthritis. Ann Rheum Dis 45(5):373-378, 1986.
PubMed
7) Sharp JT, et al:Reproducibility of multiple-observer scoring of radiologic abnormalities in the hands and wrists of patients with rheumatoid arthritis. Arthritis Rheum 28(1):16-24, 1985.
PubMed
8) van der Heijde DM, et al:Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1(8646):1036-1038, 1989.
PubMed
9) van der Heijde D:How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 26(3):743-745, 1999.
 
10) van der Heijde DM:Plain X-rays in rheumatoid arthritis:overview of scoring methods, their reliability and applicability. Baillieres Clin Rheumatol 10(3):435-453, 1996.
PubMed
11) Genant HK, et al:Abatacept inhibits progression of structural damage in rheumatoid arthritis:results from the long-term extension of the AIM trial. Ann Rheum Dis 67(8):1084-1089, 2008.
 
12) Kaneko A, et al:Development and validation of a new radiographic scoring system to evaluate bone and cartilage destruction and healing of large joints with rheumatoid arthritis:ARASHI (Assessment of rheumatoid arthritis by scoring of large joint destruction and healing in radiographic imaging) study. Mod Rheumatol 23:1053-1062, 2013.
PubMed
13) Landewe R, van der Heijde D:Radiographic progression depicted by probability plots:presenting data with optimal use of individual values. Arthritis Rheum 50(3):699-706, 2004.
PubMed
14) van der Heijde D:Use of imaging as an outcome measure in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis in clinical trials. In:Rheumatology, fifth edition (ed by Hochberg MC, et al), p413-424, ELSEVIER MOSBY, Philadelphia, 2011.
 
15) Bruynesteyn K, et al:Minimal clinically important ditiference in radiological progression of joint damage over 1 year in rheumatoid arthritis:preliminary results of a validation study with clinical experts. J Rheumatol 28(4):904-910, 2001.
PubMed
16) Bruynesteyn K, et al:Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference. Arthritis Rheum 46(4):913-920, 2002.
 
17) Bruynesteyn K, et al:Detecting radiological changes in rheumatoid arthritis that are considered important by clinical experts:influence of reading with or without known sequence. J Rheumatol 29(11):2306-2312, 2002.
PubMed
18) Vastesaeger N, et al:A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology (Oxford) 48(9):1114-1121, 2009.
PubMed
19) Flury M, et al.:Rheumatoid arthritis of the wrist. Classification related to the natural course. Clin Orthop Relat Res (366):72-77, 1999.
 
20) Murakoshi K, et al:Prediction of wrist prognosis in patients with early rheumatoid arthritis according to radiographic classification. J Hand Surg Am 34(5):824-831, 2009.
PubMed
21) Lehtinen JT, et al:Subacromial space in the rheumatoid shoulder:aradiographic 15-year follow-up study of 148 shoulders. J Shoulder Elbow Surg 9(3):183-187, 2000.
 
22) Lehtinen JT, et al:Valgus deformity and proximal subluxation of the rheumatoid elbow:a radiographic 15 year follow up study of 148 elbows. Ann Rheum Dis 60(8):765-769, 2001.
PubMed
23) Lehtimaki MY, et al:Hip involvement in seropositive rheumatoid arthritis. Survivorship analysis with a 15-year follow-up. Scand J Rheumatol 27(6):406-409, 1998.
PubMed
24) HARDY RH, CLAPHAM JC:Observations on hallux valgus ; based on a controlled series. J Bone Joint Surg Br 33-B (3):376-391, 1951.
 
25) Bouysset M, et al:Flattening of the rheumatoid foot in tarsal arthritis on X-ray. Scand J Rheumatol 16(2):127-133, 1987.
PubMed
26) HINCK VC, HOPKINS CE:Measurement of the atlanto-dental interval in the adult. Am J Roentgenol Radium Ther Nucl Med 84:945-951, 1960.
PubMed
27) Ranawat CS, et al:Cervical spine fusion in rheumatoid arthritis. J Bone Joint Surg Am 61(7):1003-1010, 1979.
PubMed
28) Redlund-Johnell I, Pettersson H:Radiographic measurements of the cranio-vertebral region. Designed for evaluation of abnormalities in rheumatoid arthritis. Acta Radiol Diagn 25(1):23-28, 1984.
PubMed
29) 骨粗鬆症の予防と治療ガイドライン (2011年度版) (骨粗鬆症の予防と治療ガイドライン作成委員会編, ライフサイエンス出版, 2011.
 
30) 折茂肇ほか:原発性骨粗鬆症の診断基準 (2000年度改訂版). 日骨代謝誌 18:76-82, 2001.
 
31) Genant HK, et al:Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137-1148, 1993.
PubMed
P.256 掲載の参考文献
1) Colebatch A, et al:EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Ann Rheum Dis 72:803-814, 2013.
 
2) Tamai M, et al:Magnetic resonance imaging (MRI) detection of synovitis and bone lesions of the wrists and finger joints in early-stage rheumatoid arthritis:comparison of the accuracy of plain MRI-based findings and gadolinium-diethylenetriamine pentaacetic acid-enhanced MRI-based findings. Mod Rheumatol 22:654-658, 2012.
PubMed
3) McQueen F, et al:Pitfalls in scoring MR images of rheumatoid arthritis wrist and metacarpophalangeal joints. Ann Rheum Dis 64(Suppl 1):i48-55, 2005.
 
4) Ostergaard M, et al:New radiographic bone erosions in the wrists of patients with rheumatoid arthritis are detectable with magnetic resonance imaging a median of two years earlier. Arthritis Rheum 48:2128-2131, 2003.
PubMed
5) McQueen FM, et al:Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals progression of erosions despite clinical improvement Ann Rheum Dis 58(3):156-163, 1999.
PubMed
6) Brown AK, et al:Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission:evidence from an imaging study may explain structural progression. Arthritis Rheum 54:3761-3773, 2006.
PubMed
7) Brown AK, et al:An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum 58:2958-2967, 2008.
PubMed
8) Kawashiri SY, et al.:Musculoskeletal ultrasonography assists the diagnostic performance of the 2010 classification criteria for rheumatoid arthritis. Mod Rheumatol 23(1):36-43, 2013.
PubMed
9) Lillegraven S, et al:Tenosynovitis of the extensor carpi ulnaris tendon predicts erosive progression in early rheumatoid arthritis. Ann Rheum Dis 70(11):2049-2050, 2011.
PubMed
10) McQueen F, et al:Magnetic resonance imaging evidence of tendinopathy in early rheumatoid arthritis predicts tendon rupture at six years. Arthritis Rheum 52(3):744-751, 2005.
PubMed
11) ScireCA, et al:Ultrasonographic evaluation of joint involvement in early rheumatoid arthritis in clinical remission:power Doppler signal predicts short-term relapse. Rheumatology (Oxford) 48:1092-1097, 2009.
PubMed
12) Dohn UM, et al:Are bone erosions detected by magnetic resonance imaging and ultrasonography true erosions? A comparison with computed tomography in rheumatoid arthritis metacarpophalangeal joints. Arthritis Res Ther 8:R110, 2006.
PubMed
13) Wakefield RJ, et al:The value of sonography in the detection of bone erosions in patients with rheumatoid arthritis:a comparison with conventional radiography. Arthritis Rheum 43:2762-2770, 2000.
PubMed
14) Scheel AK, et al:Prospective 7 year follow up imaging study comparing radiography, ultrasonography, and magnetic resonance imaging in rheumatoid arthritis finger joints. Ann Rheum Dis 65:595-600, 2006.
PubMed
P.261 掲載の参考文献
1) Smolen JS, et al:EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69:964-975, 2010.
PubMed
2) Klarlund M, et al:Finger joint synovitis in rheumatoid arthritis ; quantitative assessment by magnetic resonance imaging. Rheumatology (Oxford) 38(1):66-72, 1999.
PubMed
3) Backhaus M, et al:Guidelines for musculoskeletal ultrasound in rheumatology. Ann Rheum Dis 60:641-649, 2001.
PubMed
4) 佐藤正夫ほか:超音波3Dイメージングを用いた関節リウマチの手指関節炎評価. 日整外超音波研会誌 23:40-43, 2011.
 
5) Watanabe T, et al:Quantitative analysis of vascularization in the finger joints in patients with rheumatoid arthritis using three-dimensional volumetric ultrasonography with power Doppler. Clin Rheumatol 31:299-307, 2012.
PubMed
6) 佐藤正夫ほか:超音波三次元イメージングを用いた手指関節内血流数量化の試み. 別冊整形外科 62:188-193, 2012.
 
7) Kamishima T, et al:Semi-quantitative analysis of rheumatoid finger joint synovitis using power Doppler ultrasonography:when to perform follow-up study after treatment consisting mainly of antitumor necrosis factor alpha agent. Skeletal Radiol 39:457-465, 2010.
PubMed
8) Weidekamm C, et al:Diagnostic value of high-resolution B-mode and Doppler sonography for imaging of hand and finger joints in rheumatoid arthritis. Arthritis Rheum 48:325-333, 2003.
PubMed
P.265 掲載の参考文献
1) Nakajima A. et al:No increased mortality in patients with rheumatoid arthritis treated with biologics:results from the biologics register of six rheumatology institutes in Japan. Mod Rheumatol 23:945-952, 2013.
PubMed
2) 徳田均:関節リウマチの肺病変. Evidence Based Medicineを活かす膠原病リウマチ診療 (山中寿編), 第3版, p224-235, メディカルビュー社, 2013.
 
3) Mori S, et al:Comparison of pulmonary abnormalities on high-resolution computed tomography in patients with early versus longstanding rheumatoid arthritis. J Rheumatol 35:1513-1521, 2008.
PubMed
4) Mori S, et al:Small airway obstruction in patients with rheumatoid arthritis. Mod Rheumatol 21:164-173, 2011.
PubMed
5) Gabbay E, et al:Interstitial lung disease in recent onset rheumatoid arthritis. Am J Respir Crit Care Med 156:528-535, 1997.
PubMed
6) Winthrop KL, et al:Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis 72:37-42, 2013.
PubMed
7) Mori S, et al:Radiological features and therapeutic responses of pulmonary nontuberculous mycobacterial disease in rheumatoid arthritis patients receiving biological agents:a retrospective multicenter study in Japan. Mod Rheumatol 22:727-737, 2012.
PubMed
8) Tasaka S, Tokuda H:Pneumocystis jirovecii pneumonia in non-HIV-infected patients in the era of novel immunosuppressive therapies. J Infect Chemother 18:793-806, 2012.
PubMed
9) Tokuda H, et al:Clinical and radiological features of Pneumocystis pneumonia in patients with rheumatoid arthritis, in comparison with methotrexate pneumonitis and Pneumocystis pneumonia in acquired immunodeficiency syndrome:amulticenter study. Intern Med 47:915-923, 2008.
 
P.269 掲載の参考文献
1) 荒武正人ほか:PETによる関節炎の評価. リウマチ科 36:381-385, 2006.
 
2) Matsui T, et al.:Inflammatory cytokines and hypoxia contribute to 18F-FDG uptake by cells involved in pannus formation in rheumatoid arthritis. J Nucl Med 50:920-926, 2009.
PubMed
3) Beckers CX, et al:18F-FDG PET imaging of rheumatoid knee synovitis correlates with dynamic magnetic resonance and sonographic assessments as well as with the serum level of metalloproteinase-3. Eur J Nucl Med Mol Imaging 33:275-280, 2006.
 
4) Palmer WE, et al:Quantification of inflammation in the wrist with gadolinium-enhanced MR imaging and PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 196:647-655, 1995.
 
5) 岡邨興一ほか:関節リウマチ患者評価におけるFDG-PET/CTの応用. 映像情報Medical 45:415-420, 2013.
Medical*Online
6) Goerres GW, et al:F-18 FDG whole-body PET for the assessment of disease activity in patients with rheumatoid arthritis. Clin Nucl Med 31:386-390, 2006.
PubMed
7) Kubota K, et al:Whole-body FDG-PET/CT on rheumatoid arthritis of large joints. Ann Nucl Med 23:783-791, 2009.
PubMed
8) Okamura K, et al:The assessment of biological treatment in patients with rheumatoid arthritis using FDG-PET/CT. Rheumatology (Oxford) 51:1484-1491, 2012.
PubMed
9) 高木英希ほか:関節リウマチ治療の効果判定におけるFDG-PETの応用. 関節外科 27:73-78, 2008.
 
10) Beckers C, et al:Assessment of disease activity in rheumatoid arthritis with 18F-FDG PET. J Nucl Med 45:956-964, 2004.
 
11) 岡邨興一ほか:リウマチ画像診断の進歩 関節リウマチ患者評価におけるFDG-PET/CTの応用. 関節外科 32:368-373, 2013.
Medical*Online
12) Roivainen A, et al:Correlation of 18F-FDG PET/CT assessments with disease activity and markers of inflammation in patients with early rheumatoid arthritis following the initiation of combination therapy with triple oral antirheumatic drugs. Eur J Nucl Med Mol Imaging 40:403-410, 2012.
 
13) 公文義雄:脊椎関節炎の診断におけるFDG-PET/CTの有用性. リウマチ科 48:562-568, 2012.
 
14) Taniguchi Y, et al:Positron emission tomography/computed tomography:aclinical tool for evaluation of enthesitis in patients with spondyloarthritides. Rheumatology (Oxford) 49:348-354, 2010.
 
15) Yamashita H, et al:Similarities and differences in fluorodeoxyglucose positron emission tomography/computed tomography findings in spondyloarthropathy, polymyalgia rheumatica and rheumatoid arthritis. Joint Bone Spine 80:171-177, 2013.
PubMed
P.272 掲載の参考文献
1) 守屋秀繁ほか:鏡視下手術における合併症に関する全国アンケート調査報告 ; 2003年度版. 関節鏡 30:239-243, 2005.
Medical*Online
P.275 掲載の参考文献
1) 石田剛, 今村哲夫:慢性関節リウマチとその関連疾患. 非腫瘍性骨関節疾患の病理, p21-29, 文光堂, 2003.
 
2) 宇月美和ほか:各論-臓器病変と鑑別診断- 4. 関節・骨, 膠原病の病理診断マニュアル. 病理と臨床 23(臨時増刊号):106-110, 2005.
 
3) Rooney M, et al:Analysis of the histologic variation of synovitis in rheumatoid arthritis. Arthritis Rheum 31:956-963, 1988.
PubMed
4) Koizumi E et al:Synovitis in rheumatoid arthritis:Scoring of characteristic histopathological features. Pathol Int 49:298-304, 1999.
 
5) Matsuno H, et al:Relationship between histological findings and clinical findings in rheumatoid arthritis. Pathol Int 52:527-533, 2002.
PubMed
P.279 掲載の参考文献
1) Paleolog EM:Angiogenesis in rheumatoid arthritis. Arthritis Res 4:S81-S90, 2002,
PubMed
2) Marrelli A, et al:Angiogenesis in rheumatoid arthritis:a disease specific process or a common response to chronic inflammation? Autoimmun Rev 10:595-598, 2011.
PubMed
3) Szekanecz Z, et al:Angiogenesis in rheumatoid arthritis. Autoimmunity 42:563-573, 2009.
PubMed
4) Isozaki T, et al:Evidence that CXCL16 is a potent mediator of angiogenesis and is involved in endothelial progenitor cell chemotaxis:studies in mice with K/BxN serum-induced arthritis. Arthritis Rheum 65:1736-1746, 2013.
 
5) Vblin MV, et al.:Fractalkine:A novel angiogenic chemokine in rheumatoid arthritis. Am J Pathol 159:1521-1530, 2001.
 
6) Moran EM, et al:Interleukin-17A induction of angiogenesis, cell migration, and cytoskeletal rearrangement. Arthritis Rheum 63:3263-3273, 2011.
PubMed
7) Kurosaka D, et al:Clinical significance of serum levels of vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in patients with rheumatoid arthritis. J Rheumatol 37:1121-1128, 2010.
PubMed
8) Wang CH, et al:CD147 induces angiogenesis through a vascular endothelial growth factor and hypoxia-inducible transcription factor 1α-mediated pathway in rheumatoid arthritis. Arthritis Rheum 64:1818-1827, 2012.
 
9) Pickens SR, et al.:IL-17 contributes to angiogenesis in rheumatoid arthritis. J Immunol 184:3233-3241, 2010.
PubMed
10) Fearon U, et al:Oncostatin M induces angiogenesis and cartilage degradation in rheumatoid arthritis synovial tissue and human cartilage cocultures. Arthritis Rheum 54:3152-3162, 2006.
PubMed
11) Koch AE, et al:Regulation of angiogenesis by C-X-C chemokines interleukin-8 and epithelial neutrophil activating peptide 78 in the rheumatoid joint. Arthritis Rheum 44:31-40, 2001.
 
12) Watanabe K, et al:Pathogenic role of CXCR7 in rheumatoid arthritis. Arthritis Rheum 62:3211-3220. 2010.
PubMed
13) Pickens SR, et al:Role of the CCL21 and CCR7 pathways in rheumatoid arthritis angiogenesis. Arthritis Rheum 64:2471-2481, 2012.
PubMed
14) Saber T, et al:Toll-like receptor 2 induced angiogenesis and invasion is mediated through the Tie2 signalling pathway in rheumatoid arthritis. Plos One 6:e23540, 2011.
PubMed
P.285 掲載の参考文献
1) 宇月美和ほか:RAにおける骨・軟骨破壊の病理学的特徴. Rheumatology Clinical Update 15:7-10, 2008,
 
2) 宇月美和, 澤井高志:生検による病理学的検査. 日本臨牀 68(増刊号5):270-275, 2010.
Medical*Online
3) Yamakawa H, et al:Scoring evaluation for histopathological features of synovium in patients with rheumatoid arthritis during anti-tumor necrosis factor therapy. Rheumatol Int 30:409-413, 2010.
 
4) Haringman JJ, et al:Synovial tissue macrophages:asensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis 64:834-838, 2005.
 
5) 宇月美和ほか:特集 関節リウマチ (RA):診断と治療の進歩 II. 病態 1. 病理. 日内会誌 101(10):2830-2838, 2012.
 
6) Ouchi N, et al:Cartilage destruction is partly induced by the internal proteolytic enzymes and apoptotic phenomenon of chondrocytes in relapsing polychondritis. J Rheumatol 38:730-737, 2011.
PubMed
7) 村上賢也ほか:関節破壊の病理学的特徴. 日本臨牀 68(増刊号5):65-70, 2010.
 
8) 澤井高志ほか:炎症における蛋白分解酵素・サイトカインの発現について. 病理と臨床 10:1033-1040, 1992.
 
9) Mimata Y, et al:Interleukin-6 upregulates expression of ADAMTS-4 in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Int J Rheum Dis 15:36-44, 2012.
PubMed
10) Firestein GS:Cartilage and bone destruction, Rheumatoid Arthritis. In:Textbook of Rheumatology, 8th ed (ed by Firestein GS, et al), p1075-1079, Saunders, Philadelphia, 2009.
 
P.294 掲載の参考文献
1) 京極方久:慢性関節リウマチ (2) 再び. 滑膜細胞とは何ぞや? 免疫・Immunology Frontier 3(5):65-72, 1993.
 
2) Seemayer CA, et al:Rheumatoid arthritis:new developments in the pathogenesis with special reference to synovial fibroblasts. Z Rheumatol 60(5):309-318, 2001.
PubMed
3) 越智隆弘:関節リウマチの病因に迫る:腸骨骨髄の場で, ナース細胞とCD14(+)細胞を焦点にあてて. 厚生省労働科学研究班 報告書 (平成22年度まで), 関節リウマチ骨髄血中の疾患誘導因子解明と根治治療法開発研究班, 2011.
 
4) Bartok B, Firestein GS:Fibroblast-like synoviocytes:key effector cells in rheumatoid arthritis. Immunol Rev 233 (1):233-255, 2010.
PubMed
5) Hirohata K. Kobayashi I:Fine structures of the synovial tissues in rheumatoid arthritis. Kobe J Med Sci 10:195-225, 1964.
PubMed
6) 澤井高志ほか:慢性関節リウマチ滑膜初期病変の免疫組織化学的検討-モノクロナル抗体を用いた炎症性細胞の定性ならびに定量的解析-. リウマチ 30(4):247-254, 1990.
 
7) Wekerle H, et al:Thymic nurse cells. Lymphoepithelial cell complexes in murine thymuses:morphological and serological characterization. J Exp Med 151(4):925-944, 1980.
PubMed
8) Hiai H, et al:Differentiation-associated cellular complex formation of murine thymocytes with thymic stromal cells. Cancer Res 44(12 Pt 1):5771-5775, 1984.
 
9) Iwagami S, et al:Establishment and characterization of nurse cell-like clones from human skin. Nurse cell-like clones can stimulate autologous mixed lymphocyte reaction. J Immunol 153(7):2927-2938, 1994.
PubMed
10) Sawai T, et al:Serial block-face scanning electron microscopy combined with double-axis electron beam tomography provides new insight into cellular relationships. Microscopy (Oxf) 62(2):317-320, 2013.
PubMed
11) Davis DM:Intercellular transfer of cell-surface proteins is common and can affect many stages of an immune response. Nat Rev Immunol 7(3):238-243, 2007.
PubMed
12) Rechavi O, et al:Intercellular transfer of oncogenic H-Ras at the immunological synapse. PLoS One 2(11):e1204, 2007.
PubMed
13) Osborne DG, Wetzel SA:Trogocytosis results in sustained intracellular signaling in CD4 (+) T cells. J Immunol 189(10):4728-4739, 2012.
PubMed
14) 村上賢也ほか:関節リウマチにおけるCD14陽性細胞の役割-蛍光二重染色および電子顕微鏡学的解析-. 東日整災外会誌 23(1):15-24, 2011.
 
15) Burger JA, et al:Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 96(8):2655-2663, 2000.
PubMed
16) Tsukada N, et al:Distinctive features of "nurse like" cells that differentiate in the context of chronic lymphocytic leukemia. Blood 99(3):1030-1037, 2002.
 
17) Shimaoka Y, et al:Nurse-like cells from bone marrow and synovium of patients With rheumatoid arthritis promote survival and enhance function of human B cells. J Clin Invest 102(3):606-618, 1998.
 
18) Ochi T, et al:Mesenchymal stromal cells. Nurse-like cells reside in the synovial tissue and bone marrow in rheumatoid arthritis. Arthritis Res Ther 9(1):201, 2007.
PubMed
19) Ochi T, et al:The presence of a myeloid cell population showing strong reactivity with monoclonal antibody directed to difucosyl type 2 chain in epiphyseal bone marrow adjacent to joints affected with rheumatoid arthritis (RA) and its absence in the corresponding normal and non-RA bone marrow. J Rheumatol 15(11):1609-1615, 1988.
PubMed
P.298 掲載の参考文献
1) Neal S, et al:Parvovirus B19. N Engl J Med 350:586-597, 2004.
 
2) Scroggie DA, et al:Parvovirus arthropathy outbreak in southwestern United States. J Rheumatol 27(10):2444-2448, 2000,
PubMed
3) Fawaz-Estrup F:Human parvovirus infection:rheumatic manifestations, angioedema, C1 esterase inhibitor deficiency, ANA positivity, and possible onset of systemic lupus erythematosus. J Rheumatol 23(7):1180-1185, 1996.
PubMed
4) Kozireva SV, et al:Incidence and clinical significance of parvovirus B19 infection in patients with rheumatoid arthritis. J Rheumatol 35(7):1265-1270, 2008.
PubMed
5) Cohen BJ, et al:Human parvovirus infection in rheumatoid and inflammatory arthritis. Ann Rheum Dis 45(10):832-838, 1986,
PubMed
6) Naides SJ, et al:Transient rheumatoid factor positivity in acute human parvovirus B19 infection. Arch Intern Med 148(12):2587-2589, 1998.
 
7) Von Landenberg P, et al:Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B 19 infection. Arthritis Rheum 48(7):1939-1947, 2003.
 
8) Grahame R, et al:Chronic arthritis associated with the presence of intrasynovial rubella virus. Ann Rheum Dis 42(1):2-13, 1983.
PubMed
9) Mitchell IA, et al:Chronic rubella vaccine-associated arthropathy. Arch Intern Med 153(19):2268-2274, 1993.
 
10) Tingle AJ, et al:Rubella-associated arthritis. I. Comparative study of joint manifestations associated with natural rubella infection and RA 27/3 rubella immunisation. Ann Rheum Dis 45(2):110-114, 1986.
PubMed
11) Tingle AJ, et al:Prospective immunological assessment of arthritis induced by rubella vaccine. Infect Immun 40(1):22-28, 1983.
PubMed
12) Mitchell LA, et al:HLA-DR class II associations with rubella vaccine-induced joint manifestations. J Infect Dis 177(1):5-12, 1998.
PubMed
13) Calabrese LH, Naides SJ:Viral arthritis, Infect Dis Clin North Am 19:963-980, 2005.
 
14) Grahame R, et al:Isolation of rubella Virus from synovial fluid in five cases of seronegative arthritis. Lancet 2(8248):649-651, 1981.
PubMed
P.304 掲載の参考文献
1) Sumida T, et al:Functional role of M3 muscarinic acetylcholine receptor (M3R) reactive T cells and anti-M3R autoantibodies in patients with Sjogren's syndrome. Autoimmun Rev 9:615-617, 2010.
PubMed
2) 住田孝之:厚生労働科学研究費補助金難治性疾患克服研究事業自己免疫疾患に関する調査研究平成23年度 総括・分担研究報告書, p3-10, 2012.
 
3) 藤林孝司ほか:厚生省特定疾患自己免疫疾患調査研究班, 平成10年度研究報告書, p135-138, 1999.
 
4) Fujibayashi T, et al:Revised Japanese criteria for Sjogren's syndrome (1999):availability and validity. Mod Rheumatol 14:425-434, 2004.
PubMed
5) Adler S, et al:Evaluation of histological, serological and clinical changes in response to abatacept treatment of primary Sjogren's syndrome:A pilot study. Arthritis Care Res, 2013. [Epub ahead of print]
 
6) Tsuboi H, et al:Efficacy and safety of abatacept for patients with Sjogren's syndrome associated with rheumatoid arthritis:Messages from ROSE trial (Rheumatoid Arthritis with Orencia Trial Toward Sjogren's syndrome Endocrinopathy), 12th International Symposium on Sjogren's Syndrome (Suppl), 2013.
 
P.308 掲載の参考文献
1) 渡邊紀彦, 高林克日己:主要疾患における研究動向 SLE. 日本臨牀 67(3):500-505, 2009.
 
2) Hahn BH:Systemic lupus erythematosus. In:Harrison's Principle of Internal Medicine, 17th ed (ed by Fauci AS, et al), p2075-2083, McGraw-Hill, Columbus, 2008.
 
3) D'Cruz DP, et al:Systemic lupus erythematosus. Lancet 369:587-596, 2007.
PubMed
4) Hochberg MC:Updating the American College of Rheumatology revised criteria of the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725, 1997.
PubMed
5) 高崎芳成:特集膠原病:診断と治療の進歩 I. 新しい検査の意義と使い方 1. 抗核抗体. 日内会誌 96:2124-2131, 2007.
 
6) Bombardier C, et al:Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35 (6):630-640, 1992.
 
7) Grossman JM:Lupus arthritis. Best Pract Res Clin Rheumatol 23(4):495-506, 2009.
PubMed
8) Labowitz R, Schumacher Jr HR:Articular manifestations of systemic lupus erythematosus. Ann Intern Med 74(6):911-921, 1971.
 
9) van Vugt RM, et al:Deforming arthropathy or lupus and rhupus hands in systemic lupus erythematosus. Ann Rheum Dis 57:540-544, 1998.
 
10) Pipili C, et al:Deforming arthropathy in systemic lupus erythematosus. Eur J Intern Med 19(7):482-487, 2008.
 
11) Reilly PA, et al:Arthropathy of hands and feet in systemic lupus erythematosus. J Rheumatol 17(6):777-784, 1990.
PubMed
12) Panush RS, et al:'Rhupus' syndrome. Arch Intern Med 148(7):1633-1636, 1988.
PubMed
13) Tani C, et al:Rhupus syndrome:assessment of its prevalence and its clinical and instrumental characteristics in a prospective cohort of 103 SLE patients. Autoimmun Rev 12(4):537-541, 2013.
 
14) Iagnocco A, et al:Wrist joint involvement in systemic lupus erythematosus. An ultrasonographic study. Clin Exp Rheumatol 22(5):621-624, 2004.
PubMed
15) Boutry N, et al:MR imaging findings in hands in early rheumatoid arthritis:comparison with those in systemic lupus erythematosus and primary Sjogren syndrome. Radiology 236(2):593-600, 2005.
PubMed
P.314 掲載の参考文献
1) Sharp GC, et al:Mixed connective tissue disease-an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigens (ENA). Am J Med 52:148-159, 1972.
 
2) 混合性結合組織病の診療ガイドライン (改訂第3版) (三森経世編), 厚生労働科学研究費補助金 難治性疾患克服研究事業 混合性結合組織病の病態解明と治療法の確立に関する研究班, p1-63, 2011.
 
3) Nimelstein SH, et al:Mixed connective tissue disease:a subsequent evaluation of the original 25 patients. Medicine (Baltimore) 59:239-248, 1980.
PubMed
4) 粕川禮司:混合性結合組織病診断の手引きと治療指針. 厚生省特定疾患混合性結合組織病調査研究班昭和62年度研究報告, p5-15, 1988.
 
5) 近藤啓文:混合性結合組織病の病態, 治療と関連する遺伝的因子, 自己抗体の研究. 厚生労働科学研究費補助金 難治性疾患克服研究事業 混合性結合組織病に関する研究班平成16年度研究報告書, p1-6, 2005.
 
6) 東條毅ほか:膠原病四疾患における肺高血圧症の頻度に関する全国疫学調査. 厚生省特定疾患皮膚・結合組織疾患調査研究班混合性結合組織病分科会平成10年度研究報告書, p3-6, 1999.
 
7) 吉田俊治ほか:混合性結合組織病 (MCTD) の肺動脈性肺高血圧症 (PAH) 診断の手引き改訂について. 厚生労働科学研究費補助金 難治性疾患克服研究事業 混合性結合組織病の病態解明と治療法の確立に関する研究班平成22年度報告書, p7-13, 2011.
 
8) 吉田俊治:肺高血圧症. 混合性結合組織病の診療ガイドライン (改訂第3版) (三森経世編), 厚生労働科学研究費補助金 難治性疾患克服研究事業 混合性結合組織病の病態解明と治療法の確立に関する研究班, p27-32, 2011.
 
P.319 掲載の参考文献
1) Aggarwal R, et al.:Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis 73:227-232, 2014.
PubMed
2) Yoshifuji H, et al.:Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity 39:233-241, 2006.
PubMed
3) Kaneko Y, et al:Osteolytic change of distal interphalangeal joints and sacroiliac joints in subluxing arthropathy associated with anti-Jo-1 antibody. Joint Bone Spine 80:544-545, 2013.
PubMed
4) Oddis CV, et al:A subluxing arthropathy associated with the anti-Jo-1 antibody in polymyositis/dermatomyositis. Arthritis Rheum 33:1640-1645, 1990.
PubMed
5) Hervier B. et al:Hierarchical cluster and survival analyses of antisynthetase syndrome:phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. Autoimmun Rev 12:210-217, 2012.
PubMed
6) 圓谷理恵, 西野一三:炎症性筋疾患の病理. 炎症と免疫 20:34-38, 2012.
Medical*Online
7) Tjarnlund A, et al:Progress Report on Development of Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies. Arthritis Rheum (Suppl) 64:751, 2012.
 
P.324 掲載の参考文献
1) Hasegawa M, Takehara K:Potential immunologic targets for treating fibrosis in systemic sclerosis:a review focused on leukocytes and cytokines. Semin Arthritis Rheum 42:281-296, 2012.
PubMed
2) Cutolo M, et al:Raynaud's phenomenon and the role of capillaroscopy. Arthritis Rheum 48:3023-3030, 2003.
PubMed
3) Denton CP, Ong VH:Targeted therapies for systemic sclerosis. Nat Rev Rheumatol 9:451-464, 2013.
PubMed
P.329 掲載の参考文献
1) Barber HS:Myalgic syndrome with constitutional effects:polymyalgia rheumatica. Ann Rheum Dis 16:230-237, 1957.
PubMed
2) Kobayashi S, et al:Clinical and epidemiologic analysis of giant cell (temporal) arteritis from a nationwide survey in 1998 in Japan:the first government-supported nationwide survey. Arthritis Rheum 49:594-598, 2003.
PubMed
3) Bird HA, et al:An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis 28:434-439, 1979.
 
4) Brooks RC, McGee SR:Diagnostic dilemmas in polymyalgia rheumatica. Arch Intern Med 157:162-168, 1997.
PubMed
5) Nishioka J, et al:Symptomatological review of polymyaligia rheumatica in Japan:Induction to diagnostic criteria for Japanese patients. Jpn J Rheumatol 1:113-121, 1986.
 
6) Kyle V, Hazleman BL:The clinical and laboratory course of polymyalgia rheumatica/giant cell arteritis after the first two months of treatment. Ann Rheum Dis 52:847-850, 1993.
PubMed
7) Dasqupta B, et al:2012 Provisional classification criteria for polymyalgia rheumatica:a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheum 64:943-954, 2012.
 
8) Kimura M, et al:Clinical characteristics of patients with remitting seronegative symmetrical synovitis with pitting edema compared to patients with pure polymyalgia rheumatica. J Rheumatol 39:148-153, 2012.
PubMed
9) Sibilia J, et al:Remitting seronegative symmetrical synovitis with pitting edema (RS3PE):a form of paraneoplastic polyarthritis. J Rheumatol 26:115-120, 1999.
PubMed
10) Salvarani C, et al:Polymyalgia rheumatica and giant cell arteritis. N Engl J Med 347:261-270, 2002.
PubMed
11) 佐野統:リウマチ性多発筋痛症. 日内会誌 96:2214-2219, 2007.
 
12) Hunder GG, et al:The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 33:1122-1128, 1990.
PubMed
13) Jennette JC, et al:2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65(1):1-11, 2013.
 
14) Gabriel SE, et al:Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum 40:1873-1878, 1997.
PubMed
15) Macchioni P, et al:Tocilizumab for polymyalgia rheumatica:Report of two cases and review of the literature. Semin Arthritis Rheum 43(1):113-118, 2013.
PubMed
P.333 掲載の参考文献
1) Wright V, et al:Psoriatic arthritis. Bull Rheum Dis 21:627-632, 1971.
PubMed
2) McHugh NJ, et al:Progression of peripheral joint disease in psoriatic arthritis:a 5-yr prospective study. Rheumatology (Oxford) 42:778-783, 2003.
PubMed
3) Khan M, et al:Clinical and radiological changes during Psoriatic arthritis disease progression. J Rheumatol 30:1022-1026, 2003.
PubMed
4) Taylor W, et al.:Classification criteria for psoriatic arthritis:development of new criteria from a large international study. Arthritis Rheum 54:2665-2673, 2006.
 
5) Gossec L et al:European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 71:4-12, 2012.
PubMed
6) Salvarani C, et al:A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol 28:2274-2282, 2001.
PubMed
7) Fraser AD, et al:A randomized, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis 64:859-864, 2005.
PubMed
8) Antoni CE. et al:Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis:results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 52:1227-1236, 2005.
PubMed
9) Antoni C, et al:Infliximab improves signs and symptoms of psoriatic arthritis:results of the IMPACT 2 trial. Ann Rheum Dis 64:1150-1157, 2005.
PubMed
10) Kavanaugh A, et al:The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT):results of radiographic analyses after 1 year. Ann Rheum Dis 65:1038-1043, 2006.
PubMed
11) Mease PJ, et al:Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis:results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52:3279-3289, 2005.
PubMed
12) Gottlieb A, et al:Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis:randomised, double-blind, placebo-controlled, crossover trial. Lancet 373:633-640, 2009.
PubMed
13) Griffiths CE, et al:Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl Med 362:118-128, 2010.
PubMed
14) Ritchlin CT, et al:Treatment recommendation for psoriatic arthritis, Ann Rheum Dis 68:1387-1394, 2009.
PubMed
P.337 掲載の参考文献
1) Aletaha D, et al.:2010 Rheumatoid arthritis classification criteria:an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569-2581, 2010.
PubMed
2) Cader MZ, et al:Performance of the 2010 ACR/EULAR criteria for rheumatoid arthritis:comparison with 1987 ACR criteria in a very early synovitis cohort. Ann Rheum Dis 70:949-955, 2011.
 
3) Kaneko Y, et al:Sensitivity and specificity of 2010 rheumatoid arthritis classification criteria. Rheumatology (Oxford) 50:1268-1274, 2011.
PubMed
4) Shmerling RH, Delbanco TL:The rheumatoid factor:an analysis of clinical utility. Am J Med 91:528-534, 1991.
PubMed
5) van Venrooij WJ, et al.:Anti-CCP Antibody, a Marker for the Early Detection of Rheumatoid Arthritis. Ann N Y Acad Sci 1143:268-285, 2008.
PubMed
6) Bajocchi G, et al:Elderly onset rheumatoid arthritis:clinical aspects. Clin Exp Rheumatol 18:S49-50, 2000.
PubMed
7) Cutolo M, et al:Polymyalgia rheumatica vs late-onset rheumatoid arthritis. Rheumatology (Oxford) 48:93 -95, 2009.
 
8) Olivieri I, et al.:Management issues with elderly-onset rheumatoid arthritis:an update. Drugs Aging 22:809-822, 2005.
PubMed
9) Yamanaka H, et al:Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum 43:852-858, 2000.
PubMed
10) Soubrier M, et al:Elderly-onset rheumatoid arthritis. Joint Bone Spine 77:290-296, 2010.
PubMed
P.342 掲載の参考文献
1) Akhtar S, et al:Management and referral for trigger finger/thumb. Br Med J 331:30-33, 2005.
 
2) Pegoli L, et al:A comparison of endoscopic and open trigger finger release. Hand Surg 13:147-151, 2008.
PubMed
3) 吉田健治ほか:APL・EPB 両腱に対する腱鞘切開術. 臨床整形外科 41:123-129, 2006.
 
4) 湯浅勝則, 清重佳郎:de Quervain病に対する短母指伸筋腱開放術. 整形外科 57:223-226, 2006.
 
5) Jackson WT, et al:Anatomical variations in the first extensor compartment of the wrist. A clinical and anatomical study. J Bone Joint Surg 68:923-926, 1986.
 
6) 麻生邦一:de Quervain病の診断 徒手診断法の有用性. 臨床整形外科 41:103-108, 2006.
 
7) Jirarattanaphochai K, et al:Treatment of de Quervain disease with triamcinolone injection with or without nimesulide. A randomized, double-blind, placebo-controlled trial. J Bone Joint Surg 86:2700-2706, 2004.
PubMed
8) 井上久:我が国における強直性脊椎炎の実態. リウマチ科 28:137-141, 2002.
 
9) McGonagle D, et al:Heberden's nodes and what Heberden could not see:the pivotal role of ligaments in the pathogenesis of early nodal osteoarthritis and beyond. Rheumatology 47:1278-1285, 2008.
PubMed
10) 三笠元彦:五十肩の診断と治療. 日本医事新報 4128:10-15, 2003.
Medical*Online
11) 橋本卓, 信原克哉:肩関節疾患に伴う肩甲帯部痛 五十肩 (肩関節周囲炎). MB Orthopaedics 23:23-29, 2010.
Medical*Online
12) Grant JA, et al:Comparison of manipulation and arthroscopic capsular release for adhesive capsulitis:a systematic review. J Shoulder Elbow Surg 22:1135-1145, 2013.
PubMed
13) Salvarani C, et al.:Proximal bursitis in active polymyalgia rheumatica. Ann Intern Med 127:27-31, 1997.
PubMed
P.347 掲載の参考文献
1) 川崎拓, 七川勧次:住民検診による痛風の疫学調査. 痛風と核酸代謝 30:66, 2006.
 
2) 厚生労働省官房統計情報部 (編):平成22年国民生活基礎調査.
 
3) Campion EW, et al:Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med 82:421-426, 1987.
PubMed
4) Lin KC, et al:The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol 27:1501-1505, 2000.
 
5) Wallace SL et al:Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 20:895-900, 1977.
PubMed
6) Chen LX, Schumacher HR:Current trends in crystal identification. Curr Opin Rheumatol 18:171-173, 2006.
PubMed
7) Urano W, et al:The inflammatory process in the mechanism of decreased serum uric acid concentrations during acute gouty arthritis. J Rheumatol 29:1950-1953, 2002.
PubMed
8) Choi HK et al:Dual energy CT in gout:a prospective validation study. Ann Rheum Dis 71:1466-1471, 2012.
 
9) Grassi W, et al:'Crystal clear' -sonographic assessment of gout and calcium pyrophosphate deposition disease. Semin Arthritis Rheum 36:197-202, 2006.
PubMed
10) Thiele RG, Schlesinger N:Diagnosis of gout by ultrasound. Rheumatology 46:1116-1121, 2007.
PubMed
11) Ellman MH, Levin B:Chondrocalcinosis in elderly persons. Arthritis Rheum 18:43-47, 1975.
PubMed
12) Wilkins E, et al:Osteoarthritis and articular chondrocalcinosis in the elderly. Ann Rheum Dis 42:280-284, 1983.
PubMed
13) Zhang W, et al:European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I:terminology and diagnosis. Ann Rheum Dis 70:563-570, 2011.
PubMed
14) Zhang W, et al:EULAR recommendations for calcium pyrophosphate deposition. Part II:management. Ann Rheum Dis 70:571-575, 2011.
PubMed
P.352 掲載の参考文献
1) Yamaguchi A, et al:Association of HLA-B39 with HLA-B27-negative ankylosing spondylitis and pauciarticular juvenile rheumatoid arthritis in Japanese patients. Evidence for a role of the peptideanchoring B pocket. Arthritis Rheum 38:1672-1677, 1995.
PubMed
2) Sieper J, et al:New criteria for inflammatory back pain in patients with chronic back pain:a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis 68:784-788, 2009.
PubMed
3) Arnett FC Jr, et al:A new look at ankylosing spondylitis. Patient Care 30:82-101, 1989.
 
4) Rudwaleit M, et al:Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis:a consensual approach by the ASAS/OMERACT MRI group. Ann Rheum Dis 68:1520-1527, 2009.
PubMed
5) Rudwaleit M, et al:The development of Assessment of SpondyloArthritis international Society classincation criteria for axial spondyloarthritis (part I):classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis 68:770-776, 2009.
PubMed
6) Rudwaleit M. et al:The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 68:777-783, 2009.
 
7) Amor B, et al:Predictive factors for the longterm outcome of spondyloarthropathies. J Rheumatol 21:1883-1887, 1994.
PubMed
8) Dagfinrud H, et al:Physiotherapy interventions for ankylosing spondylitis. Cochrane Database Syst Rev (4):CD002822, 2004.
PubMed
9) Wanders A. et al:Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis:a randomized clinical trial. Arthritis Rheum 52:1756-1765, 2005.
PubMed
10) Clegg DO, et al:Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies:a Department of Veterans Affairs cooperative study. Arthritis Rheum 42:2325-2329. 1999.
PubMed
11) Chen J, et al:Methotrexate for ankylosing spondylitis. Cochrane I) atabase Syst Rev 2:CD004524, 2013.
 
12) Manadan AM, et al:New therapetltic approaches for spondyloarthritis. Curr Opin Rheulnatol 19:259-264, 2007.
 
13) Rudwaleit M, et al:Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 63:665-670, 2004.
 
14) Baraliakos X, et al:Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. Rheumatology (Oxford) 46:1450-1453, 2007.
PubMed
15) van der Heijde D, et al:Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 58:1324-1331, 2008.
PubMed
P.357 掲載の参考文献
1) Behget H, Matteson EL:On relapsing, aphthous ulcers of the mouth, eye and genitalia caused by a virus. 1937. Clin Exp Rheumatol 28(4 Suppl 60):S2-5, 2010.
 
2) 石ヶ坪良明:ベーチェット病の診断と治療の現状. 日本医事新報 4565号, 82-86, 2011.
 
3) Sakane T, et al:Behget's disease. N Engl J Med 341:1284-1291, 1999.
 
4) Hirohata T, et al:Epidemiologic study on Behget's disease in Hawaii-a comparison between Japanese-Hawaiian and Japanese in Japan. Nihon Eiseigaku Zasshi 30:190, 1975.
 
5) Ideguchi H, et al.:Behget disease:evolution of clinical manifestations, Medicine (Baltimore) 90:125-132, 2011.
 
6) Ono S, et al:Letter:HL-A5 and Behget's disease. Lancet 2:1383-1384, 1973.
 
7) Mizuki N, et al:Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behget's disease susceptibility loci. Nat Genet 42:703-706, 2010.
 
8) Kirino Y, et al:Genome-wide association analysis identifies new susceptibility loci for Behget's disease and epistasis between HLA-B*51 and ERAP1. Nat Genet 45:202-207, 2013.
 
9) Remmers EF, et al:Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behget's disease. Nat Genet 42:698-702, 2010.
 
10) Strange A, et al:A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet 42:985-990, 2010.
 
11) Evans DM, et al:Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet 43:761-767, 2011.
PubMed
12) Moll JM, et al.:Associations betwewn ankylosing spondylitis, psoriatic arthritis, Reiter's disease, the intestinal arthropathies, and Behget's syndrome. Medicine (Baltimore) 53:343-364, 1974.
 
13) Parkes M, et al:Genetic insights into common pathways and complex relationships among immunemediated diseases. Nat Rev Genet 14(9):661-673, 2013.
PubMed
14) Zhang F, et al:Identification of two new loci at IL23R and RAB32 that influence susceptibility to leprosy. Nat Genet 43:1247-1251, 2011.
PubMed
15) Kirino Y, et al:Targeted resequencing implicates the familial Mediterranean fever gene MEFV and the toll-like receptor 4 gene TLR4 in Behget disease. Proc Natl Acad Sci USA 110:8134-8139, 2013.
 
16) Yoshimi R, et al:Ultrasonography is a potent tool for the prediction of progressive joint destruction during clinical remission of rheumatoid arthritis. Mod Rheumatol 23:456-465, 2013.
PubMed
17) Hatemi G, et al:Increased enthesopathy among Behget's syndrome patients with acne and arthritis:an ultrasonography study. Arthritis Rheum 58:1539-1545, 2008.
 
18) Hatemi G, et al:Management of Behget disease:a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behget disease. Ann Rheum Dis 68:1528-1534, 2009.
 
19) Ohno S, et al:Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behget's disease with refractory uveoretinitis. J Rheumatol 31:1362-1368, 2004.
 
20) Iwata S, et al:Effects of anti-TNF-alpha antibody infliximab in refractory entero-Behget's disease. Rheumatology (Oxford) 48:1012-1013, 2009.
 
21) Yurdakul S, et al:A double-blind trial of colchicine in Behget's syndrome. Arthritis Rheum 44:2686-2692, 2001.
 
22) Remmers EF, et al:STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 357:977-986, 2007.
PubMed
P.370 掲載の参考文献
1) Jennette JC, et al:Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37:187-192, 1994.
PubMed
2) Jennette JC, et al:2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65:1-IL 2013.
 
3) 山村昌弘:RemIT-JAV研究. 日本臨牀 71(増刊号1):372-380, 2013.
Medical*Online
4) Comarmond C, et al:Eosinophilic granulomatosis with polyangiitis (Churg-Strauss):clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum 65:270-281, 2013.
 
5) Pedchenko V, et al:Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis. N Engl J Med 363:343-354, 2010.
PubMed
6) Lightfoot RW Jr, et al:The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum 33:1088-1093, 1990.
PubMed
7) Masi AT, et al:The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 33:1094-1100, 1990.
PubMed
8) Leavitt RV, et al:The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 33:1101-1107, 1990.
 
9) Calabrese LH, et al:The American College of Rheumatology 1990 criteria for the classification of hypersensitivity vasculitis. Arthritis Rheum 33:1108-1113, 1990.
PubMed
10) Mills JA, et al:The American College of Rheumatology 1990 criteria for the classification of Henoch-Schonlein purpura. Arthritis Rheum 33:1114-1121, 1990.
PubMed
11) Hunder GG, et al:The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 33:1122-1128, 1990.
PubMed
12) Arend WP, et al.:The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 33:1129-1134, 1990.
PubMed
13) Watts R, et al:Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 66:222-227, 2007.
PubMed
14) Mukhtyar C, et al:EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 68:310-317, 2009.
PubMed
15) Jones RB, et al:Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363:211 -220, 2010.
 
16) Stone JH, et al:Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363:221-232, 2010.
PubMed
P.376 掲載の参考文献
1) Giampietro C, Fautrel B:Anti-interleukin-1 agents in adult onset Still's disease. Int J Inflam 2012:317820, 2012.
PubMed
2) Mavragani CP, et al:Adult-onset Still's disease:from pathophysiology to targeted therapies. Int J Inflam 2012:879020, 2012.
PubMed
3) Pouchot J, Arlet JB:Biological treatment in adult-onset Still's disease. Best Pract Res Clin Rheumatol 26:477-487, 2012.
PubMed
4) Ohta A, et al:Adult Still's disease:a multicenter survey of Japanese patients. J Rheumatol 17:1058-1063, 1990.
PubMed
5) Yamaguchi M, et al:Preliminary criteria for classification of adult Still's disease. J Rheumatol 19:424-430, 1992.
 
6) Hoshino T, et al:Elevated serum IL-6, IFN-γ and TNF-α levels in patients with adult Still's disease. J Rheumatol 25:396-398, 1998.
 
7) Cosan F, et al:The association of TNFRSFIA gene and MEFV gene mutations with adult onset Still's disease. Rheumatol Int 33:1675-1680, 2013.
 
8) Chen DY, et al.:Involvement of TLR7 MyD88-dependent signaling pathway in the pathogenesis of adult-onset Still's disease. Arthritis Res Ther 15:R39, 2013.
PubMed
9) Chen DY, et al.:Predominance of Th1 cytokine in peripheral blood and pathological tissues of patients with active untreated adult onset Still's disease. Ann Rheum Dis 63:1300-1306, 2004.
PubMed
10) Chen DY, et al.:Potential role of Th17 cells in the pathogenesis of adult-onset Still's disease. Rheumatology (Oxford) 49:2305-2312, 2010.
PubMed
11) Fautrel B, et al:Corticosteroid sparing effect of low dose methotrexate treatment in adult Still's disease. J Rheumatol 26:373-378, 1999.
PubMed
12) Mitamura M, et al:Cyclosporin A treatment for Japanese patients with severe adult-onset Still's disease. Mod Rheumatol 19:57-63, 2009.
 
13) Kim YJ, et al:Clinical features and prognosis in 82 patients with adult-onset Still's disease. Clin Exp Rheumatol 32:28-33, 2014.
PubMed
14) Al-Homood IA:Biologic treatments for adult-onset Still's disease. Rheumatology (Oxford), 2013. [Epub ahead of print]
 
15) Suematsu R, et al:Therapeutic response of patients with adult Still's disease to biologic agents:multicenter results in Japan. Mod Rheumatol 22:712-719, 2012.
PubMed
P.379 掲載の参考文献
1) 加藤則人:皮膚科セミナリウム 第43回 蕁麻疹と紅斑症 3. 結節性紅斑と類症 (鑑別診断を含む). 日皮会誌 118:2403-2406, 2008.
 
2) 溝口昌子:結節性紅斑. 関節疾患. 最新内科学大系 74, p204 -207, 中山書店, 1995.
 
3) Kaneko F, et al:Immunological studies on aphthous ulcer and erythema nodosum-like eruptions in Behcet disease. Br J Dermatol 113:303-312, 1985.
PubMed
4) 山崎隻次:結節性紅斑. 最新皮膚化学大系 (玉置邦彦編), p11-15, 中山書店, 2003.
 
P.383 掲載の参考文献
1) Hench JJ, Rosenberg EF:Palindromic rheumatism. Arch Intern Med 73:293-321, 1944.
 
2) van de Laar M, et al:Miscellaneous inflammatory arthritis. In:Eular Compendium on Rheumatic Disease (ed by Bijlsma JWJ), BMJ publishing Group and European League Against Rheumatism, London, 2009.
 
3) Powell A, et al:Palindromic rheumatism is a common disease:comparison of new-onset palindromic rheumatism compared to new-onset rheumatoid arthritis in a 2-year cohort of patients. J Rheumatol 35:992-994, 2008.
 
4) Guerne PA Weisman MH:Palindromic rheumatism:part of or apart from the spectrum of rheumatoid arthritis. Am J Med 93:451 -460, 1992.
PubMed
5) Wajed MA, et al:Palindromic rheumatism. Clinical and serum complement study. Ann Rheum Dis 36:56-61, 1977.
PubMed
6) Hannonen P, et al:Palindromic rheumatism. A clinical survey of sixty patients. Scand J Rheumatol 16:413-420, 1987.
PubMed
7) Salvador G, et al:Prevalence and clinical significance of anti-cyclic citrullinated peptide and anti-keratin antibodies in palindromic rheumatism. An abortive form of rheumatoid arthritis? Rheumatology (Oxford) 42:972-975, 2003.
PubMed
8) Russell AS, et al:The role of anti-cyclic citrullinated peptide antibodies in predicting progression of palindromic rheumatism to rheumatoid arthritis. J Rheumatol 33:1240-1242, 2006.
PubMed
9) Koskinen E, et al:Palindromic rheumatism:longterm outcomes of 60 patients diagnosed in 1967-84. J Rheumatol 36(9):1873-1875, 2009.
PubMed
10) Chen HH, et al:Predicting the progression of palindromic rheumatism to rheumatoid arthritis:the role of ultrasonography and anti-cyclic citrullinated peptide antibodies. J Med Ultrasound 18:17-26, 2010.
 
11) Tamai M, et al:Contribution of anti-CCP antibodies, proximal interphalangeal joint involvement, HLA-DRB1 shared epitope, and PADI4 as risk factors for the development of rheumatoid arthritis in palindromic rheumatism. Scand J Rheumatol 39:287-291, 2010.
PubMed
12) Sanmarti R, et al.:Palindromic rheumatism with positive anticitrullinated peptide/protein antibodies is not synonymous with rheumatoid arthritis. A longterm followup study. J Rheumatol 39:1929-1933, 2012.
 
13) MaksymoWych WP, et al:HLA and cytokine gene polymorphisms in relation to occurrence of palindromic rheumatism and its progression to rheumatoid arthritis. J Rheumatol 29:2319-2326, 2002.
PubMed
14) Kim SK, et al.:Palindromic rheumatism:different genetic background implies a distinct disease entity. Ann Rheum Dis 65:1539-1540, 2006.
PubMed
15) Cafiete JD, et al:An unexpectedly high frequency of MEFV mutations in patients with anti-citrullinated protein antibody-negative palindromic rheumatism. Arthritis Rheum 56:2784-2788, 2007.
 
P.388 掲載の参考文献
1) 森本泰介ほか:2004年サルコイドーシス疫学調査. サルコイドーシス/肉芽腫性疾患 27:103-108, 2007.
Medical*Online
2) Sweiss NJ, et al:Rheumatol ogic manifestations of sarcoidosis. Semin Respir Crit Care Med 31:463-473, 2010.
 
3) Awada H, et al:Musculoskeletal and other extrapulmonary disorders in sarcoidosis. Best Pract Res Clin Rheumatol 17:971-987, 2003,
PubMed
4) Visser H, et al:Sarcoid arthritis:clinical characteristics, diagnostic aspects, and risk factors. Ann Rheum Dis 61:499-504, 2002.
PubMed
5) Barnard J, Newman LS:Sarcoidosis:immunology, rheumatic involvement, and therapeutics. Curr Opin Rheumatol 13:84-91, 2001.
PubMed
6) Ohta H, et al:Acute-onset sarcoidosis with erythema nodosum and polyarthralgia (Lofgren's syndrome) in Japan:a case report and a review of the literature. Intern Med 45:659-662, 2006.
 
7) Thelier N, et al:Osteoarticular involvement in a series of 100 patients with sarcoidosis referred to rheumatology departments. J Rheumatol 35:1622-1628, 2008.
 
8) Santoro F, Sloan SB:Nail dystrophy and bony involvement in chronic sarcoidosis. J Am Acad Dermatol 60:1050-1052, 2009.
PubMed
9) Judson MA, et al:Defining organ involvement in sarcoidosis:the ACCESS proposed instrument. ACCESS Research Group. A Case Control Etiologic Study of Sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 16:75-86, 1999.
 
10) Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 160:736-755, 1999.
PubMed
11) Mana J, et al:Periarticular ankle sarcoidosis:a variant of Lofgren's syndrome. J Rheumatol 23:874-877, 1996.
 
12) Kellner H, et al:Ultrasound findings in Lofgren's syndrome:is ankle swelling caused by arthritis, tenosynovitis or periarthritis? J Rheumatol 19:38-41, 1992.
 
13) Baughman RP, et al.:Methotrexate is steroid sparing in acute sarcoidosis:results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis 17:60-66, 2000.
PubMed
14) Migliore A, et al:Relevance of 99mTc-HYNIC-tir-octreotide scintigraphy in a patient affected by sarcoidosis with lung and joints involvement and secondary Sjogren's syndrome treated with infliximab:case report. Eur Rev Med Pharmacol Sci 12:127-130, 2008.
 
P.392 掲載の参考文献
1) McCarty DJ, et al:Remitting seronegative symmetrical synovitis with pitting edema. RS3PE syndrome. JAMA 254:2763-2767. 1985.
PubMed
2) Cantini F, et al:Remitting seronegative, symmetrical synovitis with pitting oedema (RS3PE) syndrome:a prospective follow up and magnetic resonance imaging study. Ann Rheum Dis 58:230-238, 1999.
PubMed
3) Klauser A, et al:Remitting seronegative symmetrical synovitis with pitting edema of the hands:ultrasound, color doppler ultrasound, and magnetic resonance imaging findings. Arthritis Care Res 53:226-233, 2005.
 
4) Pease C, Bhakta B:RS3PE syndrome. The relation with HLA-B7. Ann Rheum Dis 59:239-240, 2000.
PubMed
5) Toussirot E, et al:Lack of association between HLA-DRB1*alleles and RS3PE syndrome. Ann Rheum Dis 57:442, 1998.
PubMed
6) Arima K. et al:RS3PE syndrome presenting as vascular endothelial growth factor associated disorder. Ann Rheum Dis 64:214-219, 1997.
 
7) Deal CL, et al:The clinical features of elderly-onset rheumatoid arthritis. A comparison with younger-onset disease of similar duration. Arthritis Rheum 28:987-994, 1985.
PubMed
8) Cimmino MA, et al:Remitting seronegative symmetrical synovitis with pitting oedema (RS3PE) as recurrence of aborted PMR. Ann Rheum Dis 60:303, 2001.
PubMed
9) Sibilia J, et al:Remitting seronegative symmetrical synovitis with pitting edema (RS3 PE):a form of paraneoplastic polyarthritis? J Rheumatol 26:115-120, 1999.
 
10) Olive A, et al:The clinical spectrum of remitting seronegative symmetrical synovitis with pitting edema. The Catalan Group for the Study of RS3PE. J Rheumatol 24:333-336, 1997.
 
11) Tada Y, et al:Remitting seronegative symmetrical synovitis with pitting edema associated with gastric carcinoma. J Rheumatol 24:974-975, 1997.
PubMed
12) Bacaloiu ID, et al:Remitting seronegative symmetrical synovitis with pitting edema syndrome in a rural tertiary care practice:a retrospective analysis. Mayo Clin Proc 82:1510-1515, 2007.
 
13) Oide T, et al:Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome in Nagano, Japan:Clinical, radiological, and cytokine studies of 13 patients. Clin Exp Rheumatol 22:91-97, 2004.
PubMed
14) Kimura M, et al:Clinical characteristics of patients with remitting seronegative symmetrical synovitis with pitting edema compared to patients with pure polymyalgia rheumatica. J Rheumatol 39:148-153, 2012.
PubMed
15) Cantini F, et al:Paraneoplastic remitting seronegative symmetrical synovitis with pitting edema. Clin Exp Rheumatol 17:741-744, 1999.
PubMed

VII 類縁疾患

P.398 掲載の参考文献
1) Bevans M, et al:The systemic lesions of malignant rheumatoid arthritis. Am J Med 16(2):197-211, 1954.
PubMed
2) 橋本博史:厚生省特定疾患 難治性血管炎調査研究班 1995年度研究報告書, p9, 1996.
 
3) Scott DG, et al:Systemic rheumatoid vasculitis:a clinical and laboratory study of 50 cases. Medicine (Baltimore) 60(4):288-297, 1981.
PubMed
4) Watts RA, et al.:The incidence of rheumatoid vasculitis in the Norwich Health Authority. Br J Rheumatol 33(9):832-833, 1994.
PubMed
5) Turesson C, et al:Clustering of extraarticular manifestations in patients with rheumatoid arthritis. J Rheumatol 35(1):179-180, 2008.
PubMed
6) Turesson C, et al:Association of HLA-C3 and smoking with vasculitis in patients with rheumatoid arthritis. Arthritis Rheum 54(9):2776-2783, 2006.
PubMed
7) Gorman JD, et al:Particular HLA-DRB1 shared epitope genotypes are strongly associated with rheumatoid vasculitis. Arthritis Rheum 50(11):3476-3484, 2004.
PubMed
8) Radic M, et al:Drug-induced vasculitis:a clinical and pathological review. Neth J Med 70(1):12-17, 2012.
PubMed
9) Watts RA, et al:Isolated nail fold vasculitis in rheumatoid arthritis. Ann Rheum Dis 54(11):927-929, 1995.
PubMed
10) Geirsson AJ, et al:Clinical and serological features of severe vasculitis in rheumatoid arthritis:prognostic implications. Ann Rheum Dis 46(10):727-733, 1987.
PubMed
11) Pagnoux C, et al:Presentation and outcome of gastrointestinal involvement in systemic necrotizing vasculitides:analysis of 62 patients with polyarteritis nodosa, microscopic polyangiitis Wegener granulomatosis, Churg-Strauss syndrome, or rheumatoid arthritis-associated vasculitis. Medicine (Baltimore) 84(2):115-128, 2005.
PubMed
12) Turesson C, et al:Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis. Ann Rheum Dis 66(1):59-64, 2007.
PubMed
13) 三森明夫:RAの血管炎 (悪性関節リウマチ). 膠原病診療ノート, 第3版, p 513-515, 日本医事新報社, 2013.
 
14) 山路健, 橋本博史:悪性関節リウマチの治療. 医学と薬学 53(5):531-537, 2005.
Medical*Online
15) Puechal X, et al:Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis. Ann Rheum Dis 67(6):880-884, 2008.
PubMed
P.403 掲載の参考文献
1) Petty RE, et al:International League of Associations for Rheumatology classification of juvenile idiopathic arthritis:second revision, Edmonton 2001. J Rheumatol 31:390-392, 2004.
PubMed
2) 武井修治ほか:小慢データを利用した若年性特発性関節炎JIAの二次調査. 小児慢性特定疾患治療研究事業の登録・管理・評価・情報提供に関する研究. 平成19年度総括・分担研究報告書, p102-113, 2008.
 
3) 横田俊平:若年性関節リウマチの実態調査とQOL向上の医療・行政的政策立案. 平成12年度研究報告書, p1-18, 2001.
 
4) 武井修治, 加藤忠明:Capture-recapture法による若年性関節リウマチJRAの疾患頻度の推定. 小児慢性特定疾患治療研究事業を利活用した小児慢性疾患に関するデータベース作成とそれ以外の登録システムの統合に関する研究. 平成19年度総括・分担研究報告書, p129-133, 2008.
 
5) Shimizu M, et al:Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles. Cytokine 62:345-348, 2013.
 
6) 横田俊平ほか:若年性特発性関節炎 初期診療の手引き (2007年). 日小児会誌 111:1103-1112, 2007.
 
7) Kubota T, et al:Risk factors for radiographic progression in JIA treated with biologic agents. Arthritis Rheum 64(Suppl):S499, 2012.
 
P.406 掲載の参考文献
1) Felty AR:Chronic arthritis in the adult, associated with splenomegaly and leucopenia. A report of five cases of an unusual clinical syndrome. Bull Johns Hopkins Hosp 35:16-20, 1924.
 
2) Balint GP, Balint PV:Felty's syndrome. Best Pract Res Clin Rheumatol 18:631-645. 2004.
PubMed
3) Barnes CG, et al:Felty's syndrome. A clinical and pathological survey of 21 patients and their response to treatment. Ann Rheum Dis 30:359-374, 1971.
PubMed
4) Burks EJ, Loughran Jr TP:Pathogenesis of neutropenia in large granular lymphocyte leukemia and Felty syndrome. Blood Rev 20:245-266, 2006.
 
5) Shah A, et al:T cell large granular lymphocyte leukemia associated with rheumatoid arthritis and neutropenia. Clin Immunol 132:145-152, 2009.
 
6) Coakley G, et al:CD8+, CD57+ T cells from healthy elderly sublects suppress neutrophil development in vitro:implications for the neutropenia of Felty's and large granular lymphocyte syndromes. Arthritis Rheum 43:834-843, 2000,
 
7) Ditzel HJ, et al:Cloning and expression of a novel human antibody-antigen pair associated with Felty's syndrome. Proc Natl Acad Sci USA 97:9234-9239, 2000.
PubMed
8) van Gaalen FA. et al:Association of autoantibodies to glucose-6-phosphate isomerase with extraarticular complications in rheumatoid arthritis. Arthritis Rheum 50:395-399, 2004.
PubMed
9) Dwivedi N, et al:Felty's syndrome autoantibodies bind to deiminated histones and neutrophil extracellular chromatin traps. Arthritis Rheum 64:982-992, 2012.
PubMed
10) Hellmich B, et al:Autoantibodies against granulocyte colony-stimulating factor in Felty's syndrome and neutropenic systemic lupus erythematosus. Arthritis Rheum 46:2384-2391, 2002.
PubMed
11) Newman KA, Akhtari M:Management of autoimmune neutropenia in Felt y's syndrome and systemic lupus erythematosus. Autoimmun Rev 10:432-437, 2011.
 
12) Wassenberg S, et al:Methotrexate treatment in Felty's syndrome. Br J Rheumatol 37:908-911, 1998.
PubMed
13) Stanworth SJ, et al:Treatment of Felty's syndrome with the haemopoietic growth factor granulocyte colony-stimulating factor (G-CSF). Q J Med 91:49-56, 1998.
 
14) Narvaez J, et al:Biological agents in the management of Felty's syndrome:a systematic revlew. Semin Arthritis Rheum 41:658-668, 2012.
PubMed
15) Sordet C, et al:Lack of efficacy of rituximab in Felty's syndrome. Ann Rheum Dis 64:332-333, 2005.
PubMed
P.413 掲載の参考文献
1) Ahvonen P, et al:Arthritis associated with Yersinia enterocolitica. Acta Rheumatol Scand 15:232-253, 1969.
PubMed
2) Sieper J, et al:Report on the Fourth International Workshop on Reactive Arthritis. Arthritis Rheum 43:720-734, 2000.
PubMed
3) Braun J, et al:On the difficulties of establishing a consensus on the definition of and diagnostic investigations for reactive arthritis. Results and discussion of a questionnaire prepared for the 4th International Workshop on Reactive Arthritis, Berlin, Germany, July 3-6, 1999. J Rheumatol 27:2185-2192, 2000.
PubMed
4) Townes JM:Reactive arthritis after enteric infections in the United States:the problem of definition. Clin Infect Dis 50:247-254, 2010.
PubMed
5) Carter JD, et al:Chlamydiae as etiologic agents in chronic undifferentiated spondylarthritis. Arthritis Rheum 60:1311-1316, 2009.
PubMed
6) Carter JD, et al:Combination antibiotics as a treatment for chronic Chlamydia-induced reactive arthritis:a double-blind, placebo-. controlled, prospective trial. Arthritis Rheum 62:1298-1307, 2010.
PubMed
7) Mayer A, et al:Safety and efficacy of anti-TNFα therapy in 10 patients with recent-onset refractory reactive arthritis. Arthritis Rheum 63:1274-1280, 2011.
 
8) Tanaka T, et al:Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Arthritis Rheum 61:1762-1764, 2009.
PubMed
9) Goldsmith DP, Long SS:Streptococcal disease of childhood-a changing syndrome. Arthritis Rheum 25(Suppl):S18, 1982.
 
10) Kobayashi S, Ichikawa G:Reactive arthritis induced by tonsillitis:a type of "focal infection". Adv Otorhinolaryngol 72:79-82, 2011.
PubMed
11) Macke SL, Keat A:Poststreptococcal reactive arthritis:what is it and how do we know? Rheumatology (Oxford) 43:949-954, 2004.
 
12) Deighton C:Beta haemolytic streptococci and reactive arthritis in adults. Ann Rheum Dis 52:475-482, 1993.
PubMed
13) Ahmed S, Ayoub EM:Poststreptococcal reactive arthritis. Pediatr Infect Dis J 20:1081-1082, 2001.
 
14) Jansen TL, et al:Poststreptococcal reactive arthritis:a clinical and serological description, revealing its distinction from acute rheumatic fever. J Intern Med 245:261-267, 1999.
PubMed
15) Kobayashi S, et al:Uveitis in adult patients with poststreptococcal reactive arthritis:the first two cases reported associated with uveitis. Clin Rheumatol 21:533-535, 2002.
PubMed
16) Sobao Y, et al:Overlapping peptide-binding specificities of HLA-B27 and B39:evidence for a role of peptide supermotif in the pathogenesis of spondylarthropathies. Arthritis Rheum 42:175-181, 1999.
PubMed
P.418 掲載の参考文献
1) Clauw DJ:Fibromyalgia:an overview. Am J Med 122(12 Suppl):S3-S13, 2009.
 
2) Schmidt-Wilcke T, Clauw DJ:Fibromyalgia:from pathophysiology to therapy. Nat Rev Rheumatol 7(9):518-527, 2011.
PubMed
3) Wolfe F et al:The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Arthritis Rheum 33:160-172, 1990.
PubMed
4) Wolfe F, et al:The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken) 62(5):600-610, 2010.
PubMed

VIII 関節リウマチの治療

P.425 掲載の参考文献
1) Nakayama T, et al:Confusion about the concept of clinical practice guidelines in Japan:on the way to a social consensus. Int J Qual Health Care 15(4):359-360, 2003.
PubMed
2) Eddy DM:Chnical decision making:from theory to practice. Designing a practice policy. Standards, guidelines, and options. JAMA 263(22):3077, 3081, 3084, 1990.
 
3) Guidelines for the management of rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum 39(5):713-722, 1996.
 
4) Guidelines for monitoring drug therapy in rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum 39(5):723-731, 1996.
 
5) American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines:Guidelines for the management of rheumatoid arthritis:2002 Update. Arthritis Rheum 46(2):328-346, 2002.
PubMed
6) Gorter SL, et al:Current evidence for the management of rheumatoid arthritis with glucocorticoids:a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 69(6):1010-1014, 2010.
PubMed
7) Knevel R, et al:Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs:a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 69(6):987-994, 2010.
 
8) Nam JL, et al:Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs:a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 69(6):976-986, 2010.
PubMed
9) Gaujoux-Viala C, et al:Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs:a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 69(6):1004-1009, 2010.
PubMed
10) Schoels M, et al:Economic aspects of treatment options in rheumatoid arthritis:a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 69(6):995-1003, 2010.
PubMed
11) Smolen JS, et al:EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69(6):964-975, 2010.
PubMed
12) Colebatch AN, et al:EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Ann Rheum Dis 72(6):804-814, 2013.
PubMed
13) Saag KG, et al:American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59(6):762-784, 2008.
PubMed
14) Singh JA, et al:2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 64(5):625-639, 2012.
PubMed
15) 診断のマニュアルとEBMに基づく治療ガイドライン (越智隆弘ほか編), 日本リウマチ学会, 2004.
 
16) 関節リウマチ治療におけるメトトレキサート (MTX) 診療ガイドライン2011年版 (日本リウマチ学会MTX診療ガイドライン策定小委員会編), 羊土社, 2011.
 
P.431 掲載の参考文献
1) Smolen JS, et al:EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69(6):964-975, 2010.
PubMed
2) Smolen JS, et al:Treating rheumatoid arthritis to target:recommendations of an international task force. Ann Rheum Dis 69:631-637, 2010.
PubMed
3) Aletaha D, Smolen JS:Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints. Arthritis Rheum 63:3702-3711, 2011.
 
4) Felson DT, et al:American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 63:573-586, 2011.
PubMed
5) Grigor C, et al:Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study):a single-blind randomised controlled trial. Lancet 364:263-269, 2004.
PubMed
6) Verstappen SM, et al:Intensive treatment with methotrexate in early rheumatoid arthritis:aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 66:1443-1449, 2007.
PubMed
7) Fuchs HA, et al:Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol 16:585-591, 1989.
 
8) Van Doornum S, et al:Accelerated atherosclerosis:an extraarticular feature of rheumatoid arthritis? Arthritis Rheum 46:862-873, 2002.
PubMed
9) Smolen JS, et al:Treating rheumatoid arthritis to target:recommendations of an international task force. Ann Rheum Dis 69:631-637, 2010.
PubMed
10) Haraoui B, et al:Treating Rheumatoid Arthritis to Target:multinational recommendations assessment questionnaire. Ann Rheum Dis 70(11):1999-2002, 2011.
PubMed
11) Haraoui B, et al:Treating rheumatoid arthritis to target:a Canadian physician survey. J Rheumatol 39:949-953, 2012.
 
12) Khan NA, et al.:Determinants of discordance in patients' and physicians' rating of rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken) 64:206-214, 2012.
PubMed
13) Studenic P, et al:Discrepancies between patients and physicians in the perception of rheumatoid arthritis disease activity. Arthritis Rheum 64:2814-2823, 2012.
PubMed
P.435 掲載の参考文献
1) 津谷喜一郎ほか:生物学的製剤の費用対効果. Medical Practice 27:2085-2087, 2010.
Medical*Online
2) Rau R, et al:Radiographic outcome after three years of patients with early erosive rheumatoid arthritis treated with intramuscular methotrexate or parenteral gold. Extention of a one-year doubleblind study in 174 patients. Rheumatology (Oxford) 41:196-204, 2002.
 
3) Edwards CJ, et al:The changing use of disease-modifying anti-rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research Database. Rheumatology (Oxford) 44:1337-1338, 2005.
 
4) RESEARCH SUB-COMMITTEE OF THE EMPIRE RHEUMATISM COUNCIL:Gold Therapy in Rheumatoid Arthritis:Final Report of a Multicentre Controlled Trial. Ann Rheum Dis 20:315-334, 1961.
PubMed
5) Cooperating Clinics Committee of American Rheumatism Association:A controlled trial of gold salt therapy in rheumatoid arthritis. Arthritis Rheum 16:353-358, 1973.
 
6) Rau R, et al:Comparison of intramuscular methotrexate and gold sodium thiomalate in the treatment of early erosive rheumatoid arthritis:12 month data of a double-blind parallel study of 174 patients. Br J Rheumatol 36:345-352, 1997.
PubMed
7) Lehman AJ, et al:A 48-week, randomized, double-blind, double observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis. Results of the METGO study. Arthritis Rheum 52:1360-1370, 2005.
PubMed
8) Rau R:Have traditional DMARDs had their day? Effectiveness of parenteral gold compared to biologic agents. Clin Rheumatol 24:189-202, 2004.
PubMed
9) Nandi P, et al:Disease-modifying antirheumatic drugs other than methotrexate in rheumatoid arthritis and seronegative arthritis. Curr Opin Rheumatol 20:251-256, 2008.
PubMed
10) Klinkhoff AV, Teufel A:How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions. J Rheumatol 22:1657-1659, 1995.
 
11) Almarzouqi M, et al:Gold therapy in women planning pregnancy:outcomes in one center. J Rheumatol 34:1827-1831, 2007.
 
12) Buckley WA, et al.:Gold sodium thiomalate for the treatment of rheumatoid arthritis in a patient with hepatitis B. Ann Pharmacother 45:e23, 2011.
 
13) Medeira JM, et al:The biological activity of auranofine:implications for novel treatment of diseases. Inflammopharmacology 20:297-306, 2012.
 
14) Wood PL, et al:Mechanism of action of the disease-modifying anti-arthritic thiol agents D-penicillamine and sodium aurothiomalate:restoration of cellular free thiols and sequestration of reactive aldehydes. Eur J Pharmacol 580(1-2):48-54, 2008.
 
15) Munro R, Capell HA:Penicillamine. Br J Rheumatol 36:104-109, 1997.
PubMed
P.440 掲載の参考文献
1) Silverstein FE:Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis:The CLASS study:A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284:1247-1255, 2000.
PubMed
2) 慢性関節リウマチの上部消化管傷害に関する疫学調査委員会:非ステロイド抗炎症薬による上部消化管傷害に関する疫学調査. リウマチ 31:96-111, 1991.
 
3) Lanas A, et al:Risk factors associated with a decrease ≧2g/dL in haemoglobin and/or ≧10% haematocrit in osteoarthritis patients taking celecoxib or a nonselective NSAID plus a PPI in a large randomised controlled trial (CONDOR). Aliment Pharmacol Ther 36:485-492, 2012.
 
4) 天野祐二ほか:NSAIDs大腸粘膜障害の診断・治療. 日本臨牀 65:1879-1884, 2007.
 
5) Fujimori S, et al:Distribution of small intestinal mucosal injuries as a result of NSAID administration. Eur J Clin Invest 40:504-510, 2010.
PubMed
6) Fujimori S, et al:Prevention of traditional NSAID-induced small intestinal injury:recent preliminary studies using capsule endoscopy. Digestion 82:167-172, 2010.
PubMed
7) Mukherjee D:Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286:954, 2001.
PubMed
8) Kirwan JR, et al.:Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 1:CDOO6356, 2007.
PubMed
9) Van Staa TP, et al:Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993-1000, 2000.
PubMed
10) Wolfe F, et al:Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia:associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 54:628-634, 2006.
PubMed
11) Smolen JS, et al:EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69:964-975, 2010.
PubMed
P.444 掲載の参考文献
1) 鈴木康夫:抗リウマチ薬の適応と副作用. よくわかる関節リウマチのすべて (宮坂信之編), p158-168, 永井書店, 2009.
 
2) van der Heijde DM:Radiographic imaging ; the "gold standard" for assessment of disease progression in rheumatoid arthritis. Rheumatology 39:9-16, 2000.
PubMed
3) Lard LR, et al:Early versus delayed treatment in patients with recent-onset rheumatoid arthritis:comparison of two cohorts who received different treatment strategies. Am J Med 11:446-451, 2001.
 
4) Anderson JJ, et al:Factors influencing response to treatment in rheumatoid arthritis ; the importance of disease duration. Arthritis Rheum 43:22-29, 2000.
 
5) Boers M:Understanding the window of opportunity concept in early rheumatoid arthritis. Arthritis Rheum 48:1771-1774, 2003.
PubMed
6) Quinn MA Emery P:Window of opportunity in early rheumatoid arthritis ; possibility of altering the disease process with early intervention. Clin Exp Rheumatol 21:S154-S157, 2003.
PubMed
7) Ortendahl M, et al:Factors influencing length of time taking methotrexate in rheumatoid arthritis. J Rheumatol 27:1139-1147, 2000.
PubMed
8) O'Dell JR, et al:Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med 369:307-318, 2013.
PubMed
9) Rich E, et al:Paucity of radiographic progression in rheumatoid arthritis treated with methotrexate as the first disease modifying anti-rheumatic drug. J Rheumatol 26:259-261, 1999.
PubMed
10) Visser K, et al:Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis:integrating systematic literature research and expert opinion of a broad intemational panel of rheumatologists in the 3E initiative. Ann Rheum Dis 68:1086-1093, 2009.
 
11) Jones G, et al:The effect of treatment on radiological progression in rheumatoid arthritis:a systematic review of randomized placebo-controlled trials. Rheumatology (Oxford) 42:6-13, 2003.
PubMed
12) Capell HA, et al:Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine:results from the double-blind placebo-controlled MASCOT study. Ann Rheum Dis 66:235-241, 2007.
PubMed
13) Tanaka Y, et al:Prevention of joint destruction by tacrolimus in patients with early rheumatoid arthritis:a post hoc analysis of a double-blind, randomized, placebo-controlled study. Mod Rheumatol 23:1045-1052, 2013.
PubMed
14) Kremer JM, et al:Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexate:a six-month, open-label study. Arthritis Rheum 48:2763-2768, 2003.
PubMed
15) Morita Y, et al:Efficacy of low-dose tacrolimus added to methotrexate in patients with rheumatoid arthritis in Japan:a retrospective study. Mod Rheumatol 18:379-384, 2008.
PubMed
P.449 掲載の参考文献
1) Horikoshi M, et al:Efficacy of mizoribine pulse therapy in patients with rheumatoid arthritis who show a reduced or insufficient response to infliximab. Mod Rheumatol 19:229-234, 2009.
PubMed
2) Tanaka Y, et al.:Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis:RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 69:1286-1291, 2010.
PubMed
3) Takeuchi T, et al:Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis:results from the RISING study. Mod Rheumatol 19:478-487, 2009.
 
4) Sakai R, et al:Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules. Ann Rheum Dis 71(11):1820-1826, 2012.
PubMed
5) Kameda H, et al:Continuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis:52-week results from the JESMR study. J Rheumatol 38(8):1585-1592, 2011.
PubMed
6) Iwamoto N, et al:Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population. Mod Rheumatol 19(5):488-492, 2009.
 
7) 伊藤聡:病診連携の進め方. 実験治療 710:23-26, 2013.
 
8) Umeda N, et al:A patient with rheumatoid arthritis who had a normal delivery under etanercept treatment. Intern Med 49(2):187-189, 2010.
PubMed
9) Smolen JS, et al:Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE):a randomised controlled trial. Lancet 381(9870):918-929, 2013.
 
10) Burmester G, et al:Efficacy, pharmacokinetics, and safety of different doses of methotrexate in combination with adalimumab:results from the CONCERTO trial. Ann Rheum Dis 72(Suppl 3):72, 2013.
 
11) Ito S, et al:Effectiveness of adalimumab in the treatment of rheumatoid arthritis depends on the dose of methotrexate. Ann Rheum Dis 72(Suppl 3):437, 2013.
 
12) Singh JA, et al:2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 64:625-639, 2012.
PubMed
13) Takeuchi T, et al:Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis:the HOPEFUL 1 study. Ann Rheum Dis 73:536-543, 2014.
PubMed
14) Palframan R, et al:Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immun Methods 348:36-41, 2009.
 
15) Keystone EC, et al:Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis. Arthritis Rheum 60:3319-3329, 2008.
 
16) Keystone EC, et al:Sustained efflcacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis:2-year results from the RAPID 1 trial. Rheumatology (Oxford) 51:1628-1638, 2012.
PubMed
17) Takeuchi T, et al:Clinical response at 12 weeks predicts long-term remission and the extent of radiographic progression in Japanese patients with rheumatoid arthritis treated with certolizumab pegol with and without methotrexate coadministration. Arthritis Rheum 64(Suppl 10):S563, 2012.
 
18) Singh JA, et al:Adverse effects of biologics:a network meta-analysis and Cochrane overview (Review). Cochrane Database of Systematic Reviews Issue 4, 2013.
 
P.454 掲載の参考文献
1) Hirano T:Interleukin 6 in autoimmune and inflammatory diseases. Proc Jpn Acad Ser B Phys Biol Sci 86:717-730, 2010.
PubMed
2) Toh ML, et al:Role of interleukin 17 in arthritis chronicity through survival of synoviocytes via regulation of synoviolin expression. PLoS One 15:e13416, 2010.
 
3) Boilard E, et al:Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science 327:580-583, 2010.
PubMed
4) Lin J, et al:Cyr61 induces IL-6 production by fibroblast-like synoviocytes promoting Th17 differentiation in rheumatoid arthritis. J Immunol 188:5776-5784, 2012.
PubMed
5) Hirabayashi Y:The role of tocilizumab in the treatment of rheumatoid arthritis. In:Rheumatoid Arthritis-Treatment (ed by Lemmey AB), p51-70, InTech Open Access Company, Rijeka, Croatia, 2011.
 
6) Hirabayashi Y, et al:The DAS28-ESR cutoff value necessary to achieve remission under the new Boolean-based remission criteria in patients receiving tocilizumab. Clin Rheumatol 32:123-127, 2013.
PubMed
7) Tanaka T, Kishimoto T:Targeting interleukin-6:all the way to treat autoimmune and inflammatory diseases. Int J Biol Sci 8:1227-1236, 2012.
PubMed
8) Finzel S, et al:Interleukin-6 receptor blockade induces limited repair of bone erosions in rheumatoid arthritis:a micro CT study. Ann Rheum Dis 72:396-400, 2013.
PubMed
9) Swerdlow DI, et al:The interleukin-6 receptor as a target for prevention of coronary heart disease:a mendelian randomisation analysis. Lancet 379:1214-1224, 2012.
PubMed
10) Mori S, et al:Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis. Ann Rheum Dis 71:2006-2010, 2012.
 
11) Momohara S, et al:Analysis of perioperative clinical features and complications after orthopaedic surgery in rheumatoid arthritis patients treated with tocilizumab in a real-world setting:results from the multicentre TOcilizumab in Perioperative Period (TOPP) study. Mod Rheumatol 23:440-449, 2013.
 
12) Korkaya H, et al:Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell 47:570-584, 2012.
PubMed
13) Nishimoto N, et al:Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study. Mod Rheumatol 24:17-25, 2014.
PubMed
14) Nishimoto N, et al:Retreatment effiicacy and safety of tocilizumab in patients with rheumatoid arthritis in recurrence (RESTORE) study. Mod Rheumatol 24:26-32, 2014.
 
15) McFarland-Mancini MM, et al:Differences in wound healing in mice with deficiency of IL-6 versus IL-6 receptor. J Immunol 184:7219-7228, 2010.
PubMed
P.460 掲載の参考文献
1) 田中良哉, 森嶋洋輔:関節リウマチ患者の実態調査-アンメット・メディカル・ニーズの把握-. 新薬と臨牀 62(4):758-777, 2013.
Medical*Online
2) Yamaoka K, et al:The Janus kinases (Jaks). Genome Biol 5(12):253, 2004.
PubMed
3) Russell SM, et al:Mutation of Jak3 in a patient with SCID:essential role ofJak3 in lymphoid development. Science 270(5237):797-800, 1995.
 
4) Changelian PS, et al:Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302(5646):875-878, 2003.
PubMed
5) Meyer DM, et al:Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690, 550, in rat adjuvant-induced arthritis. J Inflamm (Lond) 7:41, 2010.
PubMed
6) Tanaka Y, et al:Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken) 63(8):1150-1158, 2011.
 
7) Vieira MC, et al:Tofacitinib versus biologic treatments with and without methotrexate in patients with active rheumatoid arthritis who have had an inadequate response to traditional disease modifying anti-rheumatic drugs-a network meta-analysis. Ann Rheum Dis 71(Suppl 3):375, 2012.
 
8) Kremer J, et al:Tofacitinib (CP-690,550), an oral Janus kinase inhibitor:Analyses of efficacy endpoints by subgroups in a pooled phase 2 and 3 rheumatoid arthritis study population. Ann Rheum Dis 71(Suppl 3):203, 2012.
 
9) Fleischmann RM, et al:Improvements in disease activity score by baseline status:pooled analysis of five phase 3 studies with tofacitinib (CP-690,550) in patients with active rheumatoid arthritis. Ann Rheum Dis 71(Suppl 3):207, 2012.
 
10) Desiree vdH, et al:Tofacitinib (CP-690,550), an Oral Janus Kinase Inhibitor, in Combination with Methotrexate Reduced the Progression of Structural Damage in Patients With Rheumatoid Arthritis:a 24-Month Phase 3 Study. Arthritis Rheum 63(Suppl 10):S1017-1018, 2011.
 
11) Lee EB, et al:Radiographic, Clinical and Functional Comparison of Tofacitinib Monotherapy Versus Methotrexate in Methotrexate-Naive Patients with Rheumatoid Arthritis. Arthritis Rheum 64(Suppl 10):S1049, 2012.
 
12) Genovese MC, et al:24-Week Results of a Blinded Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis. Arthritis Rheum 64(Suppl 10):S1049, 2012.
 
P.464 掲載の参考文献
1) Willemze A, et al:The innuence of ACPA status and characteristics on the course of RA. Nat Rev Rheumatol 8:144-152, 2012.
PubMed
2) Kobari Y, et al:T cells accumulating in the inflamed joints of a spontaneous murine model of rheumatoid arthritis become restricted to common clonotypes during disease progression. Int Immunol 16:131-138, 2004.
PubMed
3) Sarker S, et al:Targeting IL-17 and Th17 cells in rheumatoid arthritis. Rheum Dis Clin North Am 36:345-366, 2010.
 
4) van der Helm-van Mil AH, et al:Genetic variants in the prediction of rheumatoid arthritis. Ann Rheum Dis 69:1694-1696, 2010,
PubMed
5) Ma J, et al:Autoimmune lpr/lpr mice deficient in CD40 ligand:spontaneous Ig class switching with dichotomy of autoantibody responses. J Immunol 157:417-426, 1996.
PubMed
6) Fujio K, et al:Nucleosome-specific regulatory T cells engineering by triple gene transfer suppress a systemic autoimmune disease. J Immunol 173:2118-2125, 2004.
PubMed
7) Law SC, et al:T-cell autoreactivity to citrullinated autoantigenic peptides in rheumatoid arthritis patients with carrying HLA-DRB1 shared epitope alleles. Arthritis Res Ther 14:R118, 2012.
PubMed
8) Gottenberg JE, et al:Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept:data from the 'Orencia and Rheumatoid Arthritis' registry. Ann Rheum Dis 71:1815-1819, 2012.
PubMed
9) Bathon L, et al:Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept:2-year outcomes. Ann Rheum Dis 70:1949-1956, 2011.
 
10) Genabt HK, et al:Abatacept inhibits progression of structural damage in rheumatoid arthritis:results from the long-term extension of the AIM trial. Ann Rheum Dis 67:1084-1089, 2008.
 
11) Genovese MC, et al:Abatacept for rheumatoid arthritis refractory to tumor necrosis factorαinhibition. N Engl J Med 353:1114-1123, 2005.
 
12) Axmann R, et al:CTLA-4 directly inhibits osteoclast formation. Ann Rheum Dis 67:1603-1609, 2008.
PubMed
13) Genovese MC, et al:Subcutaneous abatacept versus intravenous abatacep.:a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum 63:2854-2864, 2011.
PubMed
14) Weinblatt M, et al:Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis:findings of a phase IIIb, multinational, prospective, randomised study. Arthritis Rheum 65:28-38, 2012.
 
15) Davis PM, et al:Abatacept modulates human dendritic cell-stimulated T-cell proliferation and effector function independent of IDO induction. Clin Immunol 126:38-47, 2008.
PubMed
P.470 掲載の参考文献
1) Shourt CA, et al:Orthopedic surgery among patients with rheumatoid arthritis 1980-2007:a population-based study focused on surgery rates. sex, and mortality. J Rheumatol 39(3):481-485, 2012.
PubMed
2) Kolling C, et al:Changes in surgical intervention patterns in rheumatoid arthritis over 10 years in one centre. Ann Rheum Dis 68(8):1372-1373, 2009.
PubMed
3) Jamsen E, et al:The decline in joint replacement surgery in rheumatoid arthritis is associated with a concomitant increase in the intensity of anti-rheumatic therapy:a nationwide register-based study from 1995 through 2010. Acta Orthop 84(4):331-337, 2013.
PubMed
4) Ward MM:Decreases in rates of hospitalizations for manifestations of severe rheumatoid arthritis, 1983-2001. Arthritis Rheum 50(4):1122-1131, 2004.
PubMed
5) Louie GH, Ward MM:Changes in the rates of joint surgery among patients with rheumatoid arthritis in California, 1983-2007. Ann Rheum Dis 69(5):868-871, 2010.
PubMed
6) Jain A, et al:Total joint arthroplasty in patients with rheumatoid arthritis:a United States experience from 1992 through 2005. J Arthroplasty 27(6):881-888, 2012.
PubMed
7) Aaltonen KJ, et al:Do biologic drugs affect the need for and outcome of joint replacements in patients with rheumatoid arthritis? A register-based study. Semin Arthritis Rheum 43(1):55-62, 2013.
PubMed
8) Momohara S, et al:Declining use of synovectomy surgery for patients with rheumatoid arthritis in Japan. Ann Rheum Dis 68(2):291-292, 2009.
PubMed
9) Momohara S, et al:Decrease in orthopaedic operations, including total joint replacements, in patients with rheumatoid arthritis between 2001 and 2007:data from Japanese outpatients in a single institute-based large observational cohort (10RRA). Ann Rheum Dis 69(1):312-313, 2010.
 
10) Momohara S, et al:Recent trends in orthopedic surgery performed in Japan for rheumatoid arthritis. Mod Rheumatol 21(4):337-342, 2011.
PubMed
11) Yano K, et al:Proximal rotational closing-wedge osteotomy of the first metatarsal in rheumatoid arthritis:clinical and radiographic evaluation of a continuous series of 35 cases. Mod Rheumatol 23(5):953-958, 2013.
PubMed
12) Kawakami K, et al:Complications and features after joint surgery in rheumatoid arthritis patients treated with tumour necrosis factor-alpha blockers:perioperative interruption of tumour necrosis factor-alpha blockers decreases complications? Rheumatology (Oxford) 49(2):341-347, 2013.
 
13) Momohara S, et al:Prosthetic joint infection after total.hip or knee arthroplasty in rheumatoid arthritis patients treated with nonbiologic and biologic disease-modifying antirheumatic drugs. Mod Rheumatol 21(5):469-475, 2011.
PubMed
14) Momohara S, et al:Analysis of perioperative clinical features and complications after orthopaedic surgery in rheumatoid arthritis patients treated with tocilizumab in a real-world setting:results from the multicentre TOcilizumab in Perioperative Period (TOPP) study. Mod Rheumatol 23(3):440-449, 2013.
 
15) Saag KG, et al.:American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59(6):762-784, 2008.
PubMed
P.475 掲載の参考文献
1) Larsen A, et al:Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn (Stockh) 18(4):481-491, 1977.
PubMed
2) 金子敦史:寛解とは何か:生物学的製剤による大関節破壊の抑制効果について. 日整会誌 86(5):389-393, 2012.
Medical*Online
3) Sotelo-Garza A, Charnley J:The results of Charnley arthroplasty of hip performed for protrusio acetabuli. Clin Orthop Relat Res 132:12-18, 1978.
PubMed
4) Thomason HC 3 rd, Lachiewicz PF:The influence of technique on fixation of primary total.hip arthroplasty in patients with rheumatoid arthritis. J Arthroplasty 16(5):628-634, 2011.
 
5) Zwartele RE, et al:Cementless total hip arthroplasty in rheumatoid arthritis:a systematic review of the literature. Arch Orthop Trauma Surg 132(4):535-546, 2012.
PubMed
6) 安田義ほか:RAの臼蓋底突出症に対する臼蓋再建プレートを用いたTHA. 関節外科 20:568-574, 2001.
 
7) da Silva E, et al:Declining use of orthopedic surgery in patients with rheumatoid arthritis? Results of a long-term, population-based assessment. Arthritis Rheum 49(2):216-220, 2003.
PubMed
8) Weiss RI, et al:Orthopaedic surgery of the lower lmbs in 49,802 rheumatoid arthritis patients:results from the Swedish National Inpatient Registry during 1987 to 2001. Ann Rheum Dis 65(3):335-341, 2006.
 
9) Hekmat K et al.:Decrease in the incidence of total hip arthroplasties in patients with rheumatoid arthritis-results from a well defined population in south Sweden. Arthritis Res Ther 13(2):R67, 2011.
PubMed
10) Momohara S, et al:Recent trends in orthopedic surgery performed in Japan for rheumatoid arthritis. Mod Rheumatol 21(4):337-342, 2011.
PubMed
11) Seki E, et al:Radiographic progression in weight-bearing joints of patients with rheumatoid arthritis after TNF-blocking therapies. Clin Rheumatol 28(4):453 -460, 2009.
 
12) 松下功ほか:生物学的製剤の時代におけるこれからの外科的治療のあり方 HAQの視点からの考察 大関節の機能を維持する外科的治療のタイミング. 臨床リウマチ 22:438-443, 2011.
 
13) Momohara S, et al:Reparative radiological changes of a large joint after adalimumab for rheumatoid arthritis. Clin Rheumatol 30(4):591-592, 2011.
PubMed
P.481 掲載の参考文献
1) 史賢林, 橋本淳:関節リウマチに対する手術治療:現状と今後の展望. 臨床リウマチ 22:25-31, 2010.
 
2) 厚生労働研究班 (編):関節リウマチの診断マニュアル (改訂版). 診断マニュアルとEBMに基づく治療ガイドライン, 財団法人日本リウマチ財団, 2004.
 
P.487 掲載の参考文献
1) Toyama S, et al:Rheumatoid arthritis of the hand:a five-year longitudinal analysis of clinical and radiographic findings. Mod Rheumatol 24(1):69-77, 2014.
PubMed
2) Stein AB, Terrono AL:The rheumatoid thumb. Hand Clin 12(3):541-550, 1996.
PubMed
3) Terrono A, et al:Boutonniere rheumatoid thumb deformity. J Hand Surg Am 15(6):999-1003, 1990.
PubMed
4) Nalebuff EA, Millender LH:Surgical treatment of the swan-neck deformity in rheumatoid arthritis. Orthop Clin North Am 6(3):733-752, 1975.
PubMed
5) Nalebuff EA:The rheumatoid swan-neck deformity. Hand Clin 5(2):203-214, 1989.
PubMed
6) Nalebuff EA Millender LH:Surgical treatment of the boutonniere deformity in rheumatoid arthritis. Orthop Clin North Am 6(3):753-763, 1975.
PubMed
7) Fearnley GR:Ulnar deviation of the fingers. Ann Rheum Dis 10(2):126-136, 1951.
PubMed
P.491 掲載の参考文献
1) Grondal L, et al:The foot:still the most important reason for walking incapacity in rheumatoid arthritis:distribution of symptomatic joints in 1,000 RA patients. Acta Orthop 79:257-261, 2008.
PubMed
2) Rojas-Villaraga A, et al:The impact of rheumatoid foot on disability in Colombian patients with rheumatoid arthritis. BMC Musculoskeletal Disorder 10:67, 2009.
 
3) Wechalekar MD, et al:Active foot synovitis in patients with rheumatoid arthritis:applying clinical criteria for disease activity and remission may result in underestimation of foot joint involvement. Arthritis Rheum 64:1316-1322, 2012.
PubMed
4) Naredo E, et al:Ultrasound joint inflammation in rheumatoid arthritis in clinical remission:how many and which joints should be assessed? Arthritis Care Res 65:512-517, 2013.
PubMed
5) Hennesy K et al:Chemotherapy waste disposal:asafe and practical method. Arthritis Care Res 64:311-320, 2012.
 
6) Siddle HJ, et al:Debridement of painful forefoot plantar callosities in rheumatoid arthritis:the CARROT randomised controlled trial. Clin Rheumatol 32:567-574, 2013.
PubMed
7) 村澤章:足部の関節炎 (リウマチ性疾患, 結核). 関節外科 13:37-47, 1994.
 
8) Thomas S. et al:Long-term results of the modified Hoffman procedure in the rheumatoid forefoot. J Bone Joint Surg Am 87:748-752, 2005.
PubMed
9) Coughlin MJ, et al:Rheumatoid forefoot reconstruction. A long-term follow-up study. J Bone Joint Surg Arn 82:322-341, 2000.
 
10) Hanyu T, et al:Flexible hinge toe implant arthroplasty for rheumatoid arthritis of the first metatarsophalangeal joint:long-term results. J Orthop Sci 6:141-147, 2001.
PubMed
11) 田中康仁:外反母趾. 図説 足の臨床, 改訂3版 (高倉義典監, 田中康仁, 北田力編), p137-148, メジカルビュー社, 2010.
 
12) Nagashima M, et al:A modified Hohmann method for hallux valgus and telescoping osteotomy for lesser toe deformities in patients with rheumatoid arthritis. Clin Rheumatol 28:39-42, 2007.
 
13) Roukis TS, et al:Scarf and Weil metatarsal osteotomies of the lateral rays for correction of rheumatoid forefoot deformities:a systematic review. J Foot Ankle Surg 49:390-394, 2010.
PubMed
14) 大脇肇:中足骨骨切り術. 関節外科 24:140-147, 2005.
Medical*Online
15) Niki H, et al:Combination joint-preserving surgery for forefoot deformity in patients with rheumatoid arthritis. J Bone Joint Surg Br 92:380-386, 2010.
PubMed
P.498 掲載の参考文献
1) Sweeney SE, et al:Clinical features of rheumatoid arthritis. In:Kelley's Textbook of Rheumatology, 9th ed (ed by Firestein GS, et al), p1109-1136, Elsevier Saunders, Philadelphia, 2013.
 
2) Abe A, et al:Disease activity and the course of elbow joint deterioration over 10 years in the patients with early rheumatoid arthritis. Clin Rheumatol 27:867-872, 2008.
 
3) Morrey BF, et al:A biomechanical study of normal functional elbow motion. J Bone Joint Surg Am 63:872-877, 1981.
 
4) 石川肇, 東千夏:関節リウマチ患者の日常生活動作に関する研究. 平成24年度厚生労働科学研究費補助金 難治性疾患等克服研究事業 (免疫アレルギー疾患等予防・治療研究事業) 研究報告書 第3分冊, p82-85, 2013.
 
5) 石井清一ほか:日本整形外科学会肘機能評価法. 日整会誌 66:591-603, 1992.
 
6) Hanyu T, et al:Reliability, validity, and responsiveness of the Japanese version of the patient-rated elbow evaluation. J Orthop Sci 18(5):712-719, 2013.
PubMed
7) Morrey BF, An KN:Functional evaluation of the elbow. In:The Elbow and Its Disorders, 3rd ed (ed by Morrey BF), p82, WB Saunders, Philadelphia, 2000.
 
8) Imaeda T, et al:Validation of the Japanese Society for Surgery of the Hand version of the disability of the arm, shoulder, and hand (DASH-JSSH) questionnaire. J Orthop Sci 10:353-359, 2005.
PubMed
9) 森俊仁ほか:工藤type-5人工肘関節の適応と限界. 日整会誌 84:882-889, 2010.
Medical*Online
10) 石川肇, 松野博明:上肢の手術療法. 関節リウマチの診療マニュアル (改訂版) 診断のマニュアルとEBMに基づく治療ガイドライン (厚生労働省研究班編), p107-119, 日本リウマチ財団, 2004.
 
11) 加藤博之:人工肘関節の歴史的変遷と現状. 日整会誌 84:875-881, 2010.
Medical*Online
12) 荒井勝光ほか:MNSK人工肘関節置換術の臨床成績. 日肘関節会誌 19:159-161, 2012.
 
13) Neviaser RJ, et al:Abductor pollicis longus transfer for replacement of first dorsal interosseous. J Hand Surg Am 5:53-57, 1980.
PubMed
P.502 掲載の参考文献
1) Fujiwara K, et al:A long-term follow-up study of cervical lesions in rheumatoid arthritis. J Spinal Disord 13(6):519-526, 2000.
PubMed
2) Blom M, et al:Long-term follow-up of the cervical spine with conventional radiographs in patients with rheumatoid arthritis. Scand J Rheumatol 42(4):281 -288, 2013.
 
3) Heywood AWB, Meyers OL:Rheumatoid arthritis of the thoracic and lumbar spine. J Bone Joint Surg Br 68:362-368, 1986.
 
4) Nishioka J, et al:Rheumatoid arthritis of the thoracic and lumbar spine. J Orthop Traum Surg 38:209-218, 1995.
 
5) Kawaguchi Y, et al:Radiologic findings of the lumbar spine in patients with rheumatoid arthritis, and a review of pathologic mechanisms. J Spinal Disord Tech 16:38-43, 2003.
 
6) Koakutsu T, et al:Lumbar radiculopathy caused by foraminal stenosis in rheumatoid arthritis. Upsala J Med Sci 116:133-137, 2011.
PubMed
7) Harms J, Melcher RP:Posterior C1-C2 fusion with polyaxial screw and rod fixation. Spine 26:2467-2471, 2001.
PubMed
8) Wright NM:Posterior C2 fixation using bilateral, crossing C2 laminar screws:case series and technical note. J Spinal Disord Tech 17:158-162, 2004.
PubMed
9) Tanouchi T, et al:Neurological improvement and prognosis after occipito-thoracic fusion in patients with mutilating-type rheumatoid arthritis. Eur Spine J 21:2506-2511, 2012.
PubMed
10) Inaoka M, et al:Problems of posterior lumbar interbody fusion (PLIF) for the rheumatoid spondylitis of the lumbar spine. Orthop Trauma Surg 122:73-79, 2002.
PubMed
11) Crawford III CH, et al:Lumbar fusion outcomes in patients with rheumatoid arthritis. Eur Spine J 17:822-825, 2008.
 
12) Nishimoto N, et al:Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI):evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 66:1162-1167, 2007.
 
13) Kanayama Y, et al:Radiographic progression of cervical lesions in patients with rheumatoid arthritis receiving infliximab treatment. Mod Rheumatol 20:273-279, 2010.
PubMed
14) Kaito T, et al:Effect of biological agents on cervical spine lesions in rheumatoid arthritis. Spine 15:1742-1746, 2012.
PubMed
15) Momohara S, et al.:Analysis of perioperative clinical features and complications after orthopaedic surgery in rheumatoid arthritis patients treated with tocilizumab in a real-world setting:results from the multicentre TOcilizumab in Perioperative Period (TOPP) study. Mod Rheumatol 23:440-449, 2013.
 
P.508 掲載の参考文献
1) 櫻井好美, 前田眞治:オーバービュー-物理療法の現状と課題. 臨床リハ 22:752-756, 2013.
 
2) 村澤章:関節リウマチに対する理学療法. MB Orthopaedics 22:67-71, 2009.
 
3) 岡島康友:物理療法. 現代リハビリテーション医学 (千野直一編), p237-243, 金原出版, 2010.
 
4) Korman P, et al.:Temperature changes in rheumatoid hand treated with nitrogen vapors and cold air. Rheumatol Int 32:2987-2992, 2011.
PubMed
5) Brosseau L, et al:Low level laser therapy for osteoarthritis and rheumatoid arthritis:metaanalysis. J Rheumatol 27:1961-1969, 2000.
PubMed
6) 田中信行:温泉入浴と循環機能. 新温泉医学 (日本温泉気候物理医学会編), p171-177, 2004.
 
7) 武藤芳照:水中運動の特性と利点. 運動療法 (黒澤尚編), p73-79, 金原出版, 2009.
 
8) 真塩清:骨関節疾患の温泉療法. 臨床リハ 22:148-154, 2013.
 
9) 厚生労働省研究班編:関節リウマチの診療マニュアル (改訂版) 診断のマニュアルとEBMに基づく治療ガイドライン, 日本リウマチ財団, 2004.
 
10) 水落和也:関節リウマチのリハビリテーション. リハビリテーション医学白書 (リハビリテーション医学白書委員会編), p209-217, 医歯薬出版, 2013.
 
P.512 掲載の参考文献
1) 川島司朗ほか:血漿交換による自己抗体, 免疫複合体の選択的除去. 日本臨牀 62(増刊号5):334-337, 2004.
 
2) 建部一夫, 津田裕士:関節リウマチ. 日本臨牀 62(増刊号5):563-567, 2004.
Medical*Online
3) Seror R, et al:Plasma exchange for rheumatoid arthritis. Transfus Apher Sci 36:195-199, 2007.
PubMed
4) Dwosh IL et al:Plasmapheresis therapy in rheumatoid arthritis. A controlled, double-blind, cross-over trial. N Engl J Med 308:1124-1129, 1983.
 
5) Rothwell RS, et al:A controlled study of plasma exchange in the treatment of severe rheumatoid arthritis. Arthritis Rheum 23:785-790, 1980.
PubMed
6) Felson DT, et al:The Prosorba column for treatment of refractory rheumatoid arthritis:a randomized, double-blind, sham-controlled trial. Arthritis Rheum 42:2153-2159, 1999.
PubMed
7) Hidaka T, et al:Filtration leukocytapheresis therapy in rheumatoid arthritis:a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 42:431-437, 1999.
PubMed
8) Yu X, et al:A controlled study of double filtration plasmapheresis in the treatment of active rheumatoid arthritis. J Clin Rheumatol 13:193-198, 2007.
 
9) Yu X, et al:Effects of double filtration plasmapheresis, leflunomide, and methotrexate on inflammatory changes found through magnetic resonance imaging in early rheumatoid arthritis. J Rheumatol 39:1171-1178, 2012.
PubMed
10) 山路健:アフェレシス療法. 日本臨牀 67:606-611, 2009.
Medical*Online
P.516 掲載の参考文献
1) 山本一彦:関節リウマチ-病態, 臨床所見, 診断. リウマチ病学テキスト (一般社団法人日本リウマチ学会生涯教育委員会, 財団法人日本リウマチ財団教育研修委員会編), p90-105, 診断と治療社, 2010.
 
2) 高崎芳成:悪性関節リウマチ. リウマチ病学テキスト (一般社団法人日本リウマチ学会生涯教育委員会, 財団法人日本リウマチ財団教育研修委員会編), p132-136, 診断と治療社, 2010.
 
3) Saydain G, et al:New therapies:plasmapheresis, intravenous immunoglobulin, and monoclonal antibodies. Crit Care Clin 18:957-975, 2002.
PubMed
4) Jaffe IE:Comparison of the effect of plasmapheresis and penicillamine on the level of circulating rheumatoid factor. Ann Rheum Dis 22:71-76, 1963.
 
5) Wallace DJ, et al:Plasmapheresis and lymphoplasmapheresis in the management of rheumatoid arthritis. Arthritis Rheum 22:703-710, 1979.
PubMed
6) 高橋孝喜ほか:慢性関節リウマチにおける血漿交換療法の検討 血漿交換療法と疎水性アミノ酸吸着剤による血漿浄化療法の比較検討. 日内会誌 75(3):58-70, 1986.
 
7) Hirata N, et al:Immusorba TR and PH. Ther Apher Dial 7(1):85-90, 2003.
PubMed
8) 竹中良則:関節リウマチに対する免疫吸着療法 <基礎>. Biomedical Perspectives 6(3):263-268, 1997.
 
9) Yamazaki Z, et al:Efficiency and biocompatibility of new immunoadsorbent. Trans Am Soc Artif Intern Organs 28:318-323, 1982.
PubMed
10) 熊谷宗士, 井上昇:慢性関節リウマチ-免疫吸着剤 (IM-P350) を用いた臨床治験-. Immunohaematology 7(4):448-451, 1985.
 
11) Gendreau RM ; Prosorba Clinical Trial Group:A randomized double-blind sham-controlled trial of the Prosorba column for treatment of refractory rheumatoid arthritis. Ther Apher 5(2):79-83, 2001.
 
P.520 掲載の参考文献
1) Onuma S, et al:Investigation of the clinical effect of large volume leukocytapheresis on methotrexate-resistant rheumatoid arthritis. Ther Apher Dial 10:404-411, 2006.
PubMed
2) Yamaji K, et al:Fluctuations in peripheral blood leukocyte and platelet counts and leukocyte recruitment with large volume leukocytapheresis in healthy volunteers. Ther Apher Dial 10:396-403, 2006.
PubMed
3) Singh JA, et al:2012 Update of the 2008 American College of Rheumatology Recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 64:625-639, 2012.
PubMed
4) van Vollenhoven RF:Unresolved issues in biologic therapy for rheumatoid arthritis. Nat Rev Rheumatol 7:205-215, 2011.
PubMed
5) Hidaka T, Suzuki K:Leukocytapheresis for rheumatic disease. Ther Apher Dial 7:161-164, 2003.
PubMed
6) 長瀬和子, 福永健:II-4. 血球除去・採取法 II-4-1. 白血球・顆粒球除去療法. クリニカルエンジニアリング別冊 アフェレシスマニュアル, 改訂第3版 (一般社団法人日本アフェレシス学会編), p139-148, 廣済堂, 2010.
 
7) Hidaka T, Suzuki K:The mechanism of the efficacy of leukocytapheresis on rheumatoid arthritis. Ther Apher 1:215-218, 1997.
PubMed
8) Hidaka T, et al:Dynamic changes in cytokine levels in serum and synovial nuid following filtration leukocytapheresis therapy in patients with rheumatoid arthritis. J Clin Apher 16:74-81, 2001.
 
9) Hidaka T, et al:Filtration leukocytapheresis therapy in rheumatoid arthritis:a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 42:431-437, 1999.
PubMed
10) Hohtatsu K, et al:Effect of various anticoagulant agents on large-volume leukocytapheresis using new Cellsorba CS-180S Filter. Ther Apher Dial 15:355-359, 2011.
PubMed
11) 斎藤和義, 田中良哉:関節リウマチに対する大量血球処理白血球除去療法. 日アフェレシス会誌 28:218-223, 2009.
 
12) Kempe K, et al:Filtration leukocytapheresis therapy in the treatment of rheumatoid arthritis patients resistant to or failed with methotrexate. Ther Apher Dial 8:197-205, 2004.
PubMed
13) Eguchi K, et al:Enhanced effect of high-dose leukocytapheresis using a large filter in rheumatoiud arthritis. Mod Rheumatol 17:481-485, 2007.
PubMed
14) 植木幸孝:血液浄化法の臨床111薬物療法抵抗性関節リウマチ. 腎と透析Vol.65 2008年増刊号血液浄化療法2009, p532-536, 東京医学社, 2008.
 
15) Takeshita Y, et al:A case report of leukocytapheresis for refractory leg ulcers complicated with rheumatoid arthritis. Ther Apher Dial 10:419-424, 2006.
PubMed
P.524 掲載の参考文献
1) 木村幸弘ほか:Syk阻害薬. 日本臨牀 71:1248-1252, 2013.
Medical*Online
2) 羽溪朋子, 定清直:Syk阻害薬. 炎症と免疫 7:530-537, 2009.
 
3) http://ir.rigel.comより引用.
 
4) Weinblatt ME, et al:An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med 363:1303-1312, 2010.
PubMed
5) Sada K et al:Structure and function of Syk protein-tyrosine kinase. J Biochem 130:177-186, 2001.
PubMed
6) Mocsai A, et al:The Syk tyrosine kinase:a crucial player in diverse biological functions. Nat Rev Immunol 10:387-402, 2010.
PubMed
7) Gross O, et al:Syk kinase signaling couples to the Nlrp3 inflammasome for anti-fungal host defence. Nature 459:433-437, 2009.
 
8) Podolanczuk A, et al:Of mice and men:an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood 113:3154-3160, 2009.
PubMed
9) Nakashima K, et al:Inhibition of hepatitis C virus replication through AMP-activated protein kinase-dependent and-independent pathways. Microbiol Immunol 55:774-782, 2011.
PubMed
10) Coopman PJ, et al.:The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells. Nature 406:742-747, 2000.
PubMed
11) Zhang J, et al:A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature 481:329-334, 2012.
 
12) Pechloff K, et al:The fusion kinase ITK-SYK mimics a T cell receptor signal and drives oncogenesis in conditional mouse models of peripheral T cell lymphoma. J Exp Med 207:1031-1044, 2010.
 
P.529 掲載の参考文献
1) Han J, et al.:A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 265:808-811, 1994.
 
2) Lee JC, et al:A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372:739-746, 1994.
PubMed
3) Ge B, et al:MAPKK-independent activation of p38α mediated by TAB1-dependent autophosphorylation of p38α. Science 295:1291-1294, 2002.
 
4) Salvador JM, et al:Alternative p38 activation pathway mediated by T cell receptor-proximal tyrosine kinases. Nat Immunol 6:390-395, 2005.
 
5) Dean JLE, et al:The involvement of AU-rich element-binding Proteins in p38 mitogen-activated protein kinase pathway-mediated mRNA stabilization. Cell Signal 16:1113-1121, 2004.
PubMed
6) Zhao W, et al:P38α stabilizes interleukin-6 mRNA via multiple AU-rich elements. J Biol Chem 283:1778-1785, 2008.
 
7) Nakae S, et al:Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 171:6173-6177, 2003.
PubMed
8) Huang G, et al:Signaling via the kinase p38α programs dendritic cells to drive TH17 differentiation and autoimmune inflammation. Nat Immunol 13:152-161, 2012.
 
9) Jirmanova L, et al:Lack of the T cell-specific alternative p38 activation pathway reduces autoimmunity and inflammation. Blood 118:3280-3289, 2011.
 
10) Noubade R, et al:Activation of p38 MAPK in CD4 T cells controls IL-17 production and autoimmune encephalomyelitis. Blood 118:3290-3300, 2011.
PubMed
11) Namiki K, et al:Mechanism for p38α-mediated experimental autoimmune encephalomyelitis. J Biol Chem 287:24228-24238, 2012.
 
12) Wilson KP, et al:Crystal structure of p38 mitogen-activated protein kinase. J Biol Chem 271:27696-27700, 1996.
PubMed
13) Tanoue T, et al:A conserved docking motif in MAP kinases common to substrates, activators and regulators. Nat Cell Biol 2:110-116, 2000.
PubMed
14) Wrobleski ST, Doweyko AM:Structural Comparison of p38 inhibitor-protein complexes:A review of recent p38 inhibitors having unique binding interactions. Curr Top Med Chem 5:1005-1016, 2005.
PubMed
15) Pergellis C, et al:Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol 9:268-272, 2002.
 
16) Le-Niculescu H, et al:Withdrawal of survival factors results in activation of the JNK pathway in neuronal cells leading to Fas ligand induction and cell death. Mol Cell Biol 19:751-763, 1999.
 
17) Schett G, et al:The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis. Ann Rheum Dis 67:909-916, 2008.
PubMed
18) Bohm C, et al:The α-isoform of p38 MAPK specifically regulates arthritic bone loss. J Immunol 183:5938-5947, 2009.
 
P.533 掲載の参考文献
1) Hla T, et al:Lysophospholipids:receptor revelation. Science 294:1875-1878, 2001.
PubMed
2) Sanchez T, Hla T:Stractural and fUnctional characteristics of SIP receptors. J Cell Biochem 92:913-922, 2004.
 
3) Schwab SR, et al:Lymphocyte sequestration through SIP lyase inhibition and disruption of S1P gradients. Science 309:1735-1739, 2005.
 
4) Kitano M, et al:Sphingosine 1-phosphate/sphingosine 1-phosphate receptor 1 signaling in rheumatoid synovium. Regulation of synovial proliferation and inflammatory gene expression. Arthritis Rheum 54:742-753, 2006.
PubMed
5) Pi X, et al:Sphingosine kinase 1-mediated inhibition of Fas death signaling in rheumatoid arthritis B lymphoblastoid cells. Arhtritis Rheum 54:754-764, 2006.
 
6) Ishii M, et al:Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis. Nature 458:524-538, 2009.
PubMed
7) Mandala S, et al:Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296:346-349, 2002.
PubMed
8) Kataoka H, et al:FIY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell Mol Immunol 2:439-448, 2005.
PubMed
9) Chiba K, et al:Fingolimod (FTY720), sphingosine 1-phosphate receptor modulator, shows superior efficacy as compared with interferon-β in mouse experimental autoimmune encephalomyelitis. Int Immunopharmacol 11:366-372, 2011.
 
10) Choi JW, et al:FTY720 (fingolimod) efiiicacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci USA 108:751-756, 2011.
 
11) Kappos L, et al ; FREEDOMS Study Group:A placebo-controlled trlal of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362:387-401, 2010.
 
12) Cohen JA, et al ; TRANSFORMS Study Group:Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362:402-415, 2010.
PubMed
13) Saida T, et al:A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. Mult Scler 18:1269-1277, 2012.
PubMed
14) Tsunemi S, et al:Effects of the novel immunosuppressant FTY720 in a murine rheumatoid arthritis model. Clin Immunol 136:197-204, 2010.
 
15) Sato C, et al:Sphingosine 1-phosphate receptor activation enhances BMP-2-induced osteoblast differentiation. Biochem Biophys Res Commun 423:200-205, 2012.
PubMed
P.540 掲載の参考文献
1) Schett G, David JP:The multiple faces of autoimmune-mediated bone loss. Nat Rev Endocrinol 6:698-706, 2010.
PubMed
2) Compston J:Management of glucocorticoid-induced osteoporosis. Nat Rev Rheumatol 6:82-88, 2010.
PubMed
3) Yasuda H, et al:Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597-3602, 1998.
PubMed
4) Kong YY, et al:OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315-323, 1999.
PubMed
5) Dougall WC, et al:RANK is essential for osteoclast and lymph node development. Genes Dev 13:2412-2424, 1999.
PubMed
6) Takayanagi H, et al:Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 43:259-269, 2000.
PubMed
7) Rachner TD, et al:Osteoporosis:now and the future. Lancet 377:1276-1287, 2011.
PubMed
8) Cohen SB, et al:Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis:a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 58:1299-1309, 2008.
PubMed
9) Dore RK, et al:Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis 69:872-875, 2010.
PubMed
10) Tezuka K, et al:Molecular cloning of a possible cysteine proteinase predominantly expressed in osteoclasts. J Biol Chem 14:1106-1109, 1994.
 
11) Gelb BD, et al:Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 273:1236-1238, 1996.
PubMed
12) Asagiri M, et al:Cathepsin K-dependent toll-like receptor 9 signaling revealed in experimental arthritis. Science 319:624-627, 2008.
PubMed
13) Zerbini CA, McClung MR:Odanacatib in postmenopausal women with low bone mineral density:a review of current clinical evidence. Ther Adv Musculoskelet Dis 5:199-209, 2013.
PubMed
14) Langdahl B, et al:Odanacatib in the treatment of postmenopausal women with low bone mineral density:five years of continued therapy in a phase 2 study. J Bone Miner Res 27:2251-2258, 2012.
 
15) Nakamura T, et al:Effect of the cathepsin K inhibitor odanacatib administered once weekly on bone mineral density in Japanese patients with osteoporosis-a double-blind, randomized, dose-finding study. Osteoporos Int 25:367-376, 2014.
 
P.543 掲載の参考文献
1) Mertens M, Singh JA:Anakinra for rheumatoid arthritis. Cochrane Database Syst Rev CD005121, 2009.
PubMed
2) Bresnihan B, et al:Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis. Extension of a 24-week randomized, placebo-controlled trial. J Rheumatol 31:1103-1111, 2004.
 
3) Bresnihan B, et al:Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 41:2196-2204, 1998.
PubMed
4) Jiang Y, et al:A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis:radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 43:1001-1009, 2000.
 
5) Nuki G, et al:Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis:extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46:2838-2846, 2002.
PubMed
6) Cohen S, et al:Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate:results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46:614-624, 2002.
PubMed
7) Cohen SB, et al:A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 63:1062-1068, 2004.
 
8) Cohen SB, et al:Interleukin 1 receptor antagonist anakinra improves functional status in patients with rheumatoid arthritis. J Rheumatol 30:225-231, 2003.
PubMed
9) Genovese MC, et al:Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 50:1412-1419, 2004.
PubMed
10) Buch MH, et al:Lack of response to anakinra in rheumatoid arthritis folloWing failure of tumor necrosis factor alpha blockade. Arthritis Rheum 50:725-728, 2004.
PubMed
11) Ruperto N, et al:Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 367:2396-2406, 2012.
PubMed
12) Ruperto N, et al:A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum 64:557-567, 2012.
PubMed
13) Schlesinger N, et al:Canakinumab for acute gouty arthritis in patients with limited treatment options:results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 71:1839-1848, 2012.
PubMed
14) Alten R, et al:Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis:results of a 12-week, phase II, dose-finding study. BMC Musculoskelet Disord 12:153, 2011.
PubMed
15) Singh JA, et al:A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis:a Cochrane overview. CMAJ 181:787-796, 2009.
PubMed
P.550 掲載の参考文献
1) Sell S, Max EE (ed):All about B cells. In:Immunology, Immunopathology, and Immunity, 6th ed, p101, ASM Press, Washington DC, 2001.
 
2) Reff ME, et al:Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435-445, 1994.
PubMed
3) Edwards JC, et al:Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350:2572-2581, 2004.
PubMed
4) Emery P, et al:The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment:results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54:1390-1400, 2006.
PubMed
5) Cohen SB, et al:Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy:Results of a multicenter, randomized, double-blind. placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54:2793-2806, 2006.
PubMed
6) Rubbert-Roth A, et al:Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis:results of a phase III randomized study (MIRROR). Rheumatology (Oxford) 49:1683-1693, 2010.
PubMed
7) Emery P, et al:Efficacy and safety of different doses and retreatment of rituximab:a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis 69:1629-1635, 2010.
 
8) Tak PP, et al:Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis:2-year results from the randomised controlled trial IMAGE. Ann Rheum Dis 71:351-357, 2012.
PubMed
9) Clynes RA, et al:Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6:443 -446, 2000.
 
10) Melet J, et al:Rituximab-induced T cell depletion in patients with rheumatoid arthritis:association with clinical response. Arthritis Rheum 65:2783-2790, 2013.
PubMed
11) Soliman MM, et al:Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken) 64:1108-1115, 2012.
 
12) Smolen JS, et al:EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69:964-975, 2010.
PubMed
13) Singh JA, et al:2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 64:625-639, 2012.
PubMed
14) Buch MH, et al:Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 70:909-920, 2011.
PubMed
15) van Vollenhoven RF, et al:Long-term safety of rituximab in rheumatoid arthritis:9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 72:1496-1502, 2013.
PubMed
P.554 掲載の参考文献
1) Burgess AW, et al:Purification and properties of colony-stimulating factor from mouse lung-conditioned medium. J Biol Chem 252:1998-2003, 1977.
PubMed
2) Hamilton JA, Anderson GP:GM-CSF biology. Growth Factors 22:225-231, 2004.
PubMed
3) Hamilton JA:Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol 8:533-544, 2008.
PubMed
4) Cairo MS:Review of G-CSF and GM-CSF. Effects on neonatal neutrophil kinetics. Am J Pediatr Hematol Oncol 11:238-244, 1989.
PubMed
5) Cornish AL, et al:G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol 5:554-559, 2009.
PubMed
6) Stanley E, et al:Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci USA 91:5592-5596, 1994.
PubMed
7) Kitamura T, et al:Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. J Exp Med 190:875-880, 1999.
PubMed
8) Hercus TR, et al:The granulocyte-macrophage colony-stimulating factor receptor:linking its structure to cell signaling and its role in disease. Blood 114:1289-1298, 2009.
PubMed
9) Campbell IK, et al:Protection from collagen-induced arthritis in granulocyte-macrophage colony-stimulating factor-deficient mice. J Immunol 161:3639-3644, 1998.
PubMed
10) Cook AD, et al:Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF):requirement for GM-CSF in the effector phase of disease. Arthritis Res 3:293-298, 2001.
PubMed
11) de Vries EG, et al:Flare-up of rheumatoid arthritis during GM-CSF treatment after chemotherapy. Lancet 338:517-518, 1991.
PubMed
12) Hazenberg BP, et al:Correction of granulocytopenia in Felty's syndrome by granulocyte-macrophage colony-stimulating factor. Stimulataneous induction of interleukin-6 release and flare-up of the arthritis. Blood 74:2769-2770, 1989.
 
13) Burmester GR, et al:Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Ann Rheum Dis 72:1445-1452, 2013.
PubMed

IX 関節リウマチの合併症

P.560 掲載の参考文献
1) Allain J, et al:Prevalence of symptomatic bronchiectasis in patients with rheumatoid arthritis. Rev Rhum Engl Ed 64:531-537, 1997.
PubMed
2) 中島洋:関節リウマチの呼吸器病変. 呼吸器科 8:432-436, 2005.
 
3) Perez T, et al:Airways involvement in rheumatoid arthritis:clinical, functional, and HRCT findings. Am J Respir Crit Care Med 157:1658-1665, 1998.
PubMed
4) Swinson DR, et al:Decreased survival in patients with co-existent rheumatoid arthritis and bronchiectasis. Br J Rheumatol 36:689-691, 1997.
PubMed
5) Tsuchiya Y, et al:Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome. Eur Respir J 37:1411-1417. 2011.
PubMed
6) Geri G, et al:Risk of infections in bronchiectasis during disease-modifying treatment and biologics for rheumatic diseases. BMC Infect Dis 11:304-311, 2011.
PubMed
7) Penny WJ, et al:Obliterative bronchiolitis in rheumatoid arthritis. Ann Rheum Dis 41:469-472, 1982.
PubMed
8) Geddes DM, et al:Airway obstruction in rheumatoid arthritis. Ann Rheum Dis 38:222-225, 1979.
PubMed
9) Geddes DM, et al:Progressive airway obliteration in adults and its association with rheumatoid disease. Q J Med 46:427-444, 1977.
PubMed
10) Yousem SA, et al:Follicular bronchitis/bronchiolitis. Hum Pathol 16:700-706, 1985.
PubMed
11) 杉山幸比古:膠原病に関連した細気管支病変. 呼吸 27:289-293, 2008.
Medical*Online
12) Homma S, et al:Comparative clinicopathology of obliterative bronchiolitis and diffuse panbronchiolitis. Respiration 73:481-487, 2005
PubMed
P.565 掲載の参考文献
1) Kim EJ, et al:Rheumatoid arthritis-associated interstitial lung disease:the relevance of histopathologic and radiographic pattern. Chest 136:1397-1405, 2009.
PubMed
2) de Lauretis A, et al:Review series:Aspects of interstitial lung disease:connective tissue diseaseassociated interstitial lung disease:how does it differ from IPF? How should the clinical approach differ? Chron Respir Dis 8:53-82, 2011.
PubMed
3) 北市正則:膠原病に伴う肺病変の病理組織学的所見. びまん性肺疾患の臨床 (第4版), p171, 金芳堂, 2012.
 
4) 榎本達治ほか:慢性関節リウマチ患者における肺病変の解析. アレルギー 46:1156-1162, 1997.
Medical*Online
5) 奥田恭章ほか:高分解能CTによる慢性関節リウマチにおける間質性肺炎/肺線維症の検討. リウマチ 33:12-19. 1993.
 
6) Nakamura Y, et al:Rheumatoid lung disease:prognostic analysis of 54 biopsy-proven cases. Respir Med 106:1164-1169, 2012.
PubMed
7) Raghu G, et al:An official ATS/ERS/JRS/ALAT statement:idiopathic pulmonary fibrosis:evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183:788-824, 2011.
PubMed
8) Suda T, et al:Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases. Respir Med 103:846-853, 2009.
PubMed
9) Park IN, et al:Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. Chest 132:214-220, 2007.
PubMed
10) Fischer A, et al:Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease. Respir Med 106:1040-1047, 2012.
PubMed
11) Keir GJ, et al:Severe interstitial lung disease in connective tissue disease:rituximab as rescue therapy. Eur Respir J 40:641-648, 2012.
PubMed
12) Park JH, et al:Prognosis of fibrotic interstitial pneumonia:idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 175:705-711, 2007.
PubMed
13) Tsuchiya Y, et al:Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome. Eur Respir J 37:1411-1417, 2011.
PubMed
P.569 掲載の参考文献
1) Bongartz T, et al:Incidence and mortality of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum 62:1583-1591, 2010.
PubMed
2) Olson AL, et al:Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med 183:372-378, 2010.
PubMed
3) American Thoracic Society ; European Respiratory Society:American Thoracic Society/European Respiratory Society International Multidisciplinary Concensus Classification of the ldiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiraory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 165:277-304, 2002.
 
4) Kim DS:Interstitial lung disease in rheumatoid arthritis:recent advances. Curr Opin Pulm Med 12:346-353, 2006.
PubMed
5) Katzenstein A, Fiorelli RF:Nonspecific interstitial pneumonia/fibrosis. Histopathologic features and clinical significance. Am J Surg Pathol 18:136-147, 1994.
 
6) Yoshinouchi T, et al:Nonspecific interstitial pneumonia pattern as pulmonary involvement of rheumatoid arthritis. Rheumatol Int 26:121-125, 2005.
PubMed
7) Kinder BW, et al:Idiopathic nonspecific interstitial pneumonia lung manifestation of undifferentiated connective tissue disease? Am J Respir Crit Care Med 176:691-697, 2007.
PubMed
8) Lee HK, et al:Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest 127:2019-2027, 2005.
PubMed
9) Kim EJ, et al:Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 35:1322-1328, 2010.
PubMed
10) Tsuchiya Y, et al:Lung disease directly associated with rheumatoid arthritis and their relationship to outcome. Eur Respir J 37:1411-1417, 2011.
PubMed
P.573 掲載の参考文献
1) Brown KK:Rheumatoid lung disease. Proc Am Thorac Soc 4:443-448, 2007.
PubMed
2) Young A, et al:Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischemic heart disease and pulmonary fibrosis. Rheumatology 46:350-357, 2007.
PubMed
3) Tsuchiya Y, et al:Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome. Eur Respir J 37:1411-1417, 2011.
PubMed
4) American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 165:277-304, 2002.
PubMed
5) Yousem SA, et al:Lung biopsy in rheumatoid arthritis. Am Rev Respir Dis 131:770-777, 1985.
PubMed
6) Tanaka N, et al:Rheumatoid arthritis-related lung diseases:CT findings. Radiology 232:81-91, 2004.
PubMed
7) Suda T, et al:Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases. Respir Med 103:846-853, 2009.
PubMed
8) Park IN, et al:Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. Chest 132:214-220, 2007.
PubMed
9) Parambil JG, et al:Diffuse alveolar damage. Chest 130:553-558, 2006.
PubMed
10) Lamblin C, et al:Interstitial lung diseases in collagen vascular diseases. Eur Respir J 18(Suppl 32):69s-80s, 2001.
 
11) Kim EA, et al:Interstitial lung diseases associated with collagen vascular diseases:radiologic and histopathologic findings. Lungs 22:S151-S165, 2002.
PubMed
12) Kondoh Y, et al:Prognostic factors in rapidly progressive interstitial pneumonia. Respirology 15:257-264, 2010.
PubMed
13) Gutsche M, et al:Connective tissue disease-associated interstitial lung disease:A review. Curr Respir Care Rep 1:224-232, 2013.
 
14) 日本呼吸器学会呼吸器疾患治療用薬品の適正使用を目的としたガイドライン作成委員会:特発性間質性肺炎の診断・治療ガイドライン. 日呼吸会誌 43:179-207, 2005.
 
15) Abe S, et al:Neutrophil adsorption by polymyxin B-immobilized fiber column for acute exacerbation in patients with interstitial pneumonia:a pilot study. Blood Purif 29:321-326, 2010.
PubMed
P.576 掲載の参考文献
1) 千葉茂樹, 海老名雅仁:剥離性間質性肺炎, 呼吸細気管支炎関連性間質性肺炎, 気腫合併肺線維症. 間質性肺炎を究める (滝澤始編), p190-195, メジカルビュー社, 2012.
 
2) 審良正則:剥離性間質性肺炎desquamative interstitial pneumonia:DIP, 呼吸細気管支炎関連間質性肺疾患 respiratory bronchiolitis-associated interstitial lung disease:RB-ILDと喫煙関連間質性肺炎. 胸部のCT (村田喜代史編), p437-439, メディカル・サイエンス・インターナショナル, 2011.
 
3) Attili AK, et al:Smoking related interstitial lung disease:radiologic-clinical-pathologic correlation. Radiographics 28:1383-1398, 2008.
PubMed
4) Akira M, et al.:Serial computed tomographic evaluation in desquamative interstitial pneumonia. Thorax 52:333-337, 1997.
PubMed
5) Hidalgo A, et al:Smoking-related interstitial lung diseases:radiologic-pathologic correlation. Eur Radiol 16:2463-2470, 2006.
PubMed
6) Park JS, et al:Respiratory bronchiolitis-associated interstitial lung disease:radiologic features with clinical and pathologic correlation. J Comput Assist Tomogr 26:13-20, 2002.
PubMed
7) Liebow AA, et al:Desquamative interstitial pneumonia. Am J Med 39:369-404, 1965.
PubMed
8) Ishii H, et al:Desquamative interstitial pneumonia (DIP) in a patients with rheumatoid arthritis:Is DIP associated with autoimmune disorders? Intern Med 48:827-830, 2009.
 
9) Kawabata Y, et al:Eosinophilia in bronchoalveolar lavage fluid and architectural destruction are features of desquamative interstitial pneumonia. Histopathology 52:194-202, 2008.
PubMed
10) Ishii H, et al:Elevated serum levels of lysozyme in desquamative interstitial pneumonia. Intern Med 49(9):847-851, 2010.
PubMed
11) Ishii H, et al:Desquamative interstitial pneumonia-case report and review of literature. 日呼吸会誌 40(2):160-165, 2002.
 
12) 小橋保夫ほか:生検肺病理所見において剥離性間質性肺炎像を認めた7例の検討. アレルギー 58(8・9):1279, 2009.
 
13) Nakamura Y, et al:Rheumatoid lung disease:prognostic analysis of 54 biopsy-proven cases. Respir Med 106(8):1164-1169, 2012.
PubMed
14) 松原絵里佳ほか:関節リウマチ (RA) 男性患者における肺病変. 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集57th-22nd, p304, 2013.
 
P.582 掲載の参考文献
1) 槇野茂樹:各論5.1. びまん性肺疾患の臨床-診断・管理・治療と症例, 第4版 (びまん性肺疾患研究会編), p179-181, 金芳堂, 2012.
 
2) Susan ES:70-Clinical features of rheumatoid arthritis. In:Kelley's Textbook of Rheumatology, 9th ed (ed by Firestein GS, et al), p1109-1136, Elsevier, Philadelphia, 2013.
 
3) Antin-Ozerkis D, et al:Pulmonary manifestations of rheumatoid arthritis. Clin Chest Med 31(3):451-478. 2010.
PubMed
4) Bouros D:Pleural involvement in systemic autoimmune disorders. Respiration 75(4):361-371, 2008.
PubMed
5) Massey M:Thoracic complications of rheumatoid disease. Clin Radiol 68(3):293-301, 2013.
 
P.587 掲載の参考文献
1) Kamel OW, et al:Brief report:reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 328:1317-1321, 1993.
PubMed
2) Alarcon GS, et al:Risk-factors for methotrexate-induced lung injury in patients With rheumatoid arthritis:A multicenter, case-control study. Ann Intern Med 127:356-364, 1997.
PubMed
3) Lacaille D, et al:Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum 59:1074-1081, 2008.
PubMed
4) Yamada T, et al:Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan. Ann Rheum Dis 65:1661-1663, 2006.
PubMed
5) Brassard P, et al:Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada. Arthritis Rheum 61:300-304, 2009.
PubMed
P.592 掲載の参考文献
1) Yamada T:Serum amyloid A (SAA):a concise review of biology, assay methods and clinical usefulness. Clin Chem Lab Med 37:381-388, 1999.
 
2) Lachmann HJ, et al:Natural history and outcome in systemic AA amyloidosis. N Engl J Med 356:2361-2371, 2007.
PubMed
3) Baba S, et al:A novel alleic variant serum amyloid A. SAA1γ:Genomic evidence, evolution, frequency, and implication as a risk factor for reactive systemic AA-amyloidosis. Hum Mol Genet 4:1083-1087, 1995.
 
4) Okuda Y et al:Ageing:a risk factor for amyloid A amyloidosis in rheumatoid arthritis. Amyloid 18:108-111, 2011.
PubMed
5) Kobayashi H, et al.:Secondary amyloidosis in patients with rheumatoid arthritis:Diagnostic and prognostic value of gastroduodenal biopsy. Br Soc Rheumatol 35:44-49, 1996.
 
6) Kuroda T, et al:Comparison of gastroduodenal, renal and abdominal fat biopsies for diagnosing amyloidosis in rheumatoid arthritis. Clin Rheumatol 21:123-128, 2002.
PubMed
7) Okuda Y, et al:Amyloidosis in rheumatoid arthritis-clinical study of 124 histologically proven cases. Ryumachi 34:939-946, 1994.
PubMed
8) Gottenberg JE, et al:Anti-tumor necrosisαtherapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides. Arthritis Rheum 48:2019-2024, 2003.
 
9) Kuroda T, et al:Effective anti-TNFα therapy can induce rapid resolution and a sustained decrease of gastroduodenal mucosal amyloid deposits in reactive amyloidosis associated with rheumatoid arthritis. J Rheumatol 36:2409-2415, 2009.
 
10) Nakamura T:et al:Etanercept can induce resolution of renal deterioration in patients with amyloid A amyloidosis secondary to rheumatoid arthritis. Clin Rheumatol 29:1395-1401, 2010.
PubMed
11) Fernandes-Nebro A, et al:Long-term TNF-alpha blockade in patients with amyloid A amyloidosis complicating rheumatic diseases. Am J Med 123:454-461, 2010.
 
12) Okuda Y, Takasugi K:Successful use of a humanized anti-interleukin-6 receptor antibody, Tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum 54:2997 -3000, 2006.
 
13) Okuda Y, et al:Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseases. Mod Rheumatol 24:137-143, 2014.
PubMed
14) Okuda Y, et al:Intractable diarrhoea associated with secondary amyloidosis in rheumatoid arthritis. Ann Rheum Dis 56:535-541, 1997.
PubMed
P.597 掲載の参考文献
1) 松尾清一:間質性腎炎. 日本臨牀 60(増刊号1):486-492, 2002.
Medical*Online
2) 御手洗哲ほか:第105回日本内科学会講演会 教育講演 12. 間質性腎炎の基礎と臨床. 日内会誌 9:2297-2302, 2008.
 
3) Nakano M, et al:Analysis of renal pathology and drug history in 158 Japanese patients with rheumatoid arthritis. Clin Nephrol 50:154-160, 1998.
PubMed
4) 乳原善文ほか:腎障害. 日本臨牀 63(増刊号1):245-252, 2005.
Medical*Online
5) 寺井千尋, 桜井正:Sjogren症候群の腎病変. 日内会誌 94:871-875, 2005.
 
6) Hayakawa S, et al:Tubulointerstitial immune complex nephritis in a patient with systemic lupus erythematosus:role of peritubular capillaritis with immune complex deposits in the pathogenesis of the tubulointerstitial nephritis. Clin Exp Nephrol 10:146-151, 2006.
 
7) Goto A, et al:Rheumatoid arthritis complicated with myeloperoxidase antineutrophil cytoplasmic antibody (MPO-AMCA)-associated vasculitis:case report. Mod Rheumatol 15:118-122, 2005.
 
8) Nakabayashi K, et al:Tubulointerstitial nephritis without glomerular lesions in three patients with myeloperoxidase-ANCA-associated vasculitis. Clin Exp Nephrol 13:605-613, 2009.
PubMed
9) Szilasi M, et al:Association of ANCA-associated vasculitis-rheumatoid arthritis overlap syndrome in four patients:rituximab may be the right choice? Autoimmunity 45:304-309, 2012.
PubMed
10) 三村俊英:関節リウマチの腎病変. medicina 42:819-821, 2005.
 
11) Ikeda Y, et al:A case of de novo focal segmental.glomerulosclerosis occurred one and half years after kidney transplantation supposed to be caused by calcineurin inhibitor. Clin Transplant 26:76-80, 2012.
PubMed
12) Tong D, et al:New onset sarcoid-like granulomatosis developing during anti-TNF therap.:an under-recognised complication. Intern Med J 42:89-94, 2012.
 
13) Korsten P, et al:Drug-induced granulomatous interstitial nephritis in a patient with ankylosing spondylitis during therapy with adalimumab. Am J Kidney Dis 56:e17-e21, 2010.
 
14) Watanabe H, et al:A case of emphysematous pyelonephritis in a patient with rheumatoid arthritis taking corticosteroid and low-dose methotrexate. Int J Rheum Dis 13:180-183, 2010.
 
15) Lei PS, et al:Acute renal failure:unusual complication of Epstein-Barr virus-induced infectious mononucleosis. Clin Infect Dis 31:1519-1524, 2000.
PubMed
P.601 掲載の参考文献
1) Kooi LM:Histomorphological variations in systemic AA amyloidosis:clue of AA protein polymophism. Histopathology 14:111-120, 1989.
 
2) Uda H, et al:Two distinct clinical courses of renal involvement in rheumatoid patients with AA amyloidosis. J Rheumatol 33:1482-1487, 2006.
PubMed
3) Verine J, et al.:Clinical and histological characteristics of renal AA amyloidosis:a retrospective study of 68 cases with a special interest to amyloid-associated inflammatory response. Hum Pathol 38:1798-1809, 2007.
PubMed
4) Ueno T, et al:Remission of proteinuria and preservation of renal function in patients with renal AA amyloidosis secondary to rheumatoid arthritis. Nephrol Dial Transplant 27:633-639, 2011.
PubMed
5) Lachmann HJ, et al:Natural history and outcome in systemic AA amyloidosis. N Engl J Med 356:2361-2371, 2007.
PubMed
6) Gottenberg JE, et al:Anti-tumor necrosisαtherapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides. Arthritis Rheum 48:2019-2024, 2003.
 
7) Kuroda T, et al:Effective anti-TNFα therapy can induce rapid resolution and a sustained decrease of gastroduodenal mucosal amyloid deposits in reactive amyloidosis associated with rheumatoid arthritis. J Rheumatol 36:2409-2415, 2009.
 
8) Nakamura T, et al:Etanercept can induce resolution of renal deterioration in patients with amyloid Aamyloidosis secondary to rheumatoid arthritis. Clin Rheumatol 29:1395-1401, 2010.
 
9) Fernandes-Nebro A, et al:Long-term TNF-alpha blockade in patients with amyloid A amyloidosis complicating rheumatic diseases. Am J Med 123:454-461, 2010.
 
10) Hagihara K, et al:IL-6 plays a critical role in the synergistic induction of human amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system. Biochem Biophys Res Commun 314:363 -369, 2004.
 
11) Hagihara K, et al:Essential role of STAT3 in cytokine-driven NF-kappaB-mediated serum amyloid A gene expression. Genes Cells 10:1051-1063, 2005.
PubMed
12) Okuda Y, Takasugi K:Successful use of a humanized anti-interleukin-6 receptor antibody, Tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum 54:2997-3000, 2006.
PubMed
13) Okuda Y, et al:Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseases. Mod Rheumatol . published online:05 March, 2013.
 
14) Dember LM, et al:Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med 356:2349-2360, 2007.
PubMed
P.605 掲載の参考文献
1) Symmons DP, et al:Long term mortality outcome in patients with rheumatoid arthritis:early presenters continue to do well. J Rheumatol 25:1072-1077, 1998.
 
2) Helin HJ, et al:Renal biopsy findings and clinicopathologic correlations in rheumatoid arthritis. Arthritis Rheum 38:242-247, 1995.
PubMed
3) Nakano M, et al:Analysis of renal pathology and drug history in 158 Japanese patients with rheumatoid arthritis. Clin Nephrol 50:154-160, 1998.
PubMed
4) Makino H, et al:Renal involvement in rheumatoid arthritis:analysis of renal biopsy specimens from 100 patients. Mod Rheumatol 12:148-154, 2002.
PubMed
5) IgA腎症診療指針 (第3版). 日腎会誌 53:123-135, 2011.
 
6) Maeda I, et al:Tonsillectomy has beneficial effects on remission and progression of IgA nephropathy independent of steroid therapy. Nephrol Dial Transplant 27:2806-2813, 2012.
PubMed
7) Kawano M, et al:Simultaneous, clonally identical T cell expansion in tonsil and synovium in a patient with rheumatoid arthritis and chronic tonsillitis. Arthritis Rheum 48:2483-2488, 2003.
 
8) Zarza LP, et al:Membranous glomerulonephritis in rheumatoid arthritis unrelated to gold, D-penicillamine or other connective tissue disease. Clin Rheumatol 15:385-388, 1996.
PubMed
9) ネフローゼ症候群診療指針 (完全版), p59-64, 東京医学社, 2012.
 
10) 竹内孝男ほか:エタネルセプト投与中に微小変化型ネフローゼ症候群を来した関節リウマチの1症例. 日臨免疫会誌 31:178-182, 2008.
 
11) Goto A, et al:Rheumatoid arthritis complicated with myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA) -associated vasculitis. Mod Rheumatol 15:118-122, 2005.
PubMed
12) 中村正ほか:半月体形成性糸球体腎炎を合併した慢性関節リウマチの1例. リウマチ 37:476, 1997.
 
13) 竹田陽子ほか:関節リウマチに合併したGoodpasture症候群の1例. 日腎会誌 51:897-903, 2009.
 
14) 急速進行性腎炎症候群の診療指針 第2版. 日腎会誌 53:509-555, 2011.
 
15) Kaneko K, et al:Etanercept-induced necrotizing crescentic glomerulonephritis in two patients with rheumatoid arthritis. Mod Rheumatol 20:632-636, 2010.
PubMed
P.611 掲載の参考文献
1) Jaffe ES, et al (ed):WHO Classification of Tumors:pathology and genetics of tumours of the haematopoietic and lymphoid tissues, p270, IARC Press, Lyon, 2001.
 
2) Isomtiki HA, et al:Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis 31(11):691-696, 1978.
 
3) Smitten AL, et al:A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 10(2):R45, 2008.
PubMed
4) Baecklund E, et al:Disease activity and risk of lymphoma in patients with rheumatoid arthritis:nested case-control study. BMJ 317(7152):180-181, 1998.
PubMed
5) Hellgren K, et al:Do rheumatoid arthritis and lymphoma share risk factors?:acomparison of lymphoma and cancer risks before and after diagnosis of rheumatoid arthritis. Arthritis Rheum 62(5):1252-1258, 2010.
 
6) Baecklund E, et al:Association of chronic inflammation. not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54(3):692-701, 2006.
 
7) 住田孝之:Sjogren症候群の病態と治療. 日内会誌 100(10):3055-3063, 2011.
 
8) Kojima M, et al:Benign, atypical and malignant lymphoproliferative disorders in rheumatoid arthritis patients. Biomed Pharmacother 60(10):663-672, 2006.
PubMed
9) Wolfe F, Michaud K:The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19, 562 patients during 89,710 person-years of observation. Arthritis Rheum 56(5):1433-1439, 2007.
 
10) Swerdlow SH, et al (ed):WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed, IARC Press, Lyon, 2008.
 
11) Ikeda T, et al:Rheumatoid arthritis complicated with immunodeficiency-associated lymphoproliferative disorders during treatment with adalimumab. Mod Rheumatol 22:458-462, 2012.
PubMed
12) Wolfe F, Michaud K:Lymphoma in rheumatoid arthritis:the effect of methotrexate and anti-tumor necrosis factor therapy in 18, 572 patients. Arthritis Rheum 50:1740-1751, 2004.
PubMed
13) Hoshida Y, et al:Lymphoproliferative disorders in rheumatoid arthritis:clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol 34:322-331, 2007.
PubMed
14) Mariette X, et al ; Investigators of the Club Rhumatismes et lnflammation:Lymphomas in rheumatoid arthritis patients treated with methotrexate:a 3-year prospective study in France. Blood 99:3909-3915, 2002.
 
P.616 掲載の参考文献
1) Genta MS, et al:Systemic rheumatoid vasculitis:a review. Semin Arthritis Rheum 36:88-98, 2006.
PubMed
2) Coremans IE, et al:Antilactoferrin antibodies in patients with rheumatoid arthritis are associated with vasculitis. Arthritis Rheum 35:1466-1475, 1992.
PubMed
3) Puechal X, et al:Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis. Ann Rheum Dis 67:880-884, 2008.
PubMed
4) Puechal X, et al:Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis:results from the autoimmunity and rituximab registry. Arthritis Care Res 64:331-339, 2012.
PubMed
5) Avina-Zubieta JA, et al:Risk of incident cardiovascular events in patients with rheumatoid arthritis:a meta-analysis of observational studies. Ann Rheum Dis 71:1524-1529, 2012,
PubMed
6) Nakajima A, et al:Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, IORRA. Scand J Rheumatol 39:360-367, 2010,
PubMed
7) Asanuma YF, et al:Serum osteoprotegerin concentration is associated with carotid atherosclerotic plaque in patients with rheumatoid arthritis. Mod Rheumatol 23:269-275, 2013.
PubMed
8) Kumeda Y, et al:Increased thickness of arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis. Arthritis Rheum 46:1489-1497, 2002.
PubMed
9) Solomon DH, et al:Cardiovascular risk in rheumatoid arthritis:comparing TNF-α blockade with nonbiologic DMARDs. Am J Med 126:730. e9-730. e17, 2013.
 
10) Peters MJ, et al:EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69:325-331, 2010.
PubMed
11) Solomon DH, et al:Unresolved questions in rheumatology:motion for debate:the data support evidence-based management recommendations for cardiovascular disease in rheumatoid arthritis. Arthritis Rheum 65:1675-1683, 2013.
PubMed
P.620 掲載の参考文献
1) 生活習慣病骨折リスクに関する診療ガイド (日本骨粗鬆症学会 生活習慣病における骨折リスク評価委員会編), ライフサイエンス出版, 2011.
 
2) 骨粗鬆症の予防と治療ガイドライン2011年版 (骨粗鬆症の予防と治療ガイドライン作成委員会編), ライフサイエンス出版, 2011.
 
3) Vis M, et al:Can bone loss in rheumatoid arthritis be prevented? Osteoporos Int 24:2541-2553, 2013.
PubMed
4) 中山久徳:関節リウマチでみられる骨粗鬆症の臨床的実態. Osteoporosis Japan 19:151-155, 2011.
Medical*Online
5) 宗圓聰:糖質コルチコイド. The Bone 27:175-179, 2013.
Medical*Online
6) van Staa TP, et al:Oral corticosteroids and fracture risk:relationship to daily and cumulative doses. Rheumatology 39:1383-1389, 2000.
PubMed
7) Redlich K, Smolen JS:Inflammatory bone loss:pathogenesis and therapeutic intervention. Nat Rev Drug Discov 11:234-250, 2012.
PubMed
8) Haugeberg G, et al:Bone loss in patients with active early rheumatoid arthritis:infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study. Ann Rheum Dis 68:1898-1901, 2009.
PubMed
9) Hoff M, et al:Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis:explorative analyses from the PREMIER study. Ann Rheum Dis 68:1171-1176, 2009.
PubMed
10) Deodhar A, et al:Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients. Arthritis Care Res 62:569-574, 2010.
PubMed
11) Naumann L, et al:Quantification of periarticular demineralization and synovialitis of the hand in rheumatoid arthritis patients. Osteoporos Int 23:2671-2679, 2012.
PubMed
12) Alves C, et al:Periarticular osteoporosis:a useful feature in the diagnosis of early rheumatoid arthritis? Reliability and validity in a cross-sectional diagnostic study using dual-energy X-ray absorptiometry. Rheumatology 50:2257-2263, 2011.
 
13) Hoff M, et al:Cortical hand bone loss after 1 year in early rheumatoid arthritis predicts radiographic hand joint damage at 5-year and 10-year follow-up. Ann Rheum Dis 68:324-329, 2009.
PubMed
14) Bejarano V, et al:Relationship between early bone mineral density changes and long-term function and radiographic progression in rheumatoid arthritis. Arthritis Care Res 64:66-70, 2012.
PubMed
P.625 掲載の参考文献
1) 日本呼吸器学会薬剤性肺障害の診断・治療の手引き作成委員会 (編):薬剤性肺障害の診断・治療の手引き, 第1版, メディカルレビュー社, 2012.
 
2) Camus P, et al:Interstitial lung disease induced by drugs and radiation. Respiration 71:301-326, 2004.
PubMed
3) 萩原清文ほか:メトトレキサートに対するリンパ球刺激試験:関節リウマチ患者を対象とした特異度の検討と考察. アレルギーの臨床 26:46-50, 2006.
 
4) 根岸雅夫ほか:Bucillamineによる肺障害-全国アンケート調査を基にして-. リウマチ 32:135-139, 1992.
 
5) Barrera P, et al:Methotrexate-related pulmonary complications in rheumatoid arthritis. Ann Rheum Dis 53:434-439, 1994.
PubMed
6) Ohosone Y, et al:Clinical characteristics of patients with rheumatoid arthritis and methotrexate induced pneumonitis. J Rheumatol 24:2299-2303, 1997.
PubMed
7) Alarcon GS, et al:Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. Ann Intern Med 127:356-364, 1997.
 
8) Golden MR, et al:The relationship of preexisting lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis. J Rheumatol 22:1043-1047, 1995.
 
9) Searles G, McKendry RJ:Methotrexate pneumonitis in rheumatoid arthritis:potential risk factors. Four case reports and a review of the literature. J Rheumatol 14:1164-1171, 1987.
 
10) Shidara K, et al:Incidence of and risk factors for interstitial pneumonia in patients with rheumatoid arthritis in a large Japanese observational cohort, IORRA. Mod Rheumatol 20:280-286, 2010.
 
11) リウマトレックス(R)適正使用情報vol.19, ファイザー株式会社, 2013年5月.
 
12) Tokuda H, et al:Clinical and radiological features of Pneumocystis pneumonia in patients with rheumatoid arthritis, in comparison with methotrexate pneumonitis and Pneumocystis pneumonia in acquired immunodeficiency syndrome:a multicenter study, Intern Med 47:915-923, 2008.
PubMed
13) Imokawa S, et al:Methotrexate pneumonitis:review of the literature and histopathological findings in nine patients. Eur Respir J 15:373-381, 2000.
PubMed
14) Sawada T, et al:Leflunomide-induced interstitial lung disease:prevalence and risk factors in Japanese patients with rheumatoid arthritis. Rheumatology 48:1069-1072, 2009.
PubMed
15) アラバ錠 全例調査の最新状況. サノフィ・アベンティス株式会社 社内資料 (ARA301-40), 2012.
 
16) Sakai F, et al:Leflunomide-related lung injury in patients with rheumatoid arthritis:imaging features. Mod Rheumatol 15:173-179, 2005.
PubMed
17) リマチル(R)錠 副作用のまとめ 第8版, 参天製薬株式会社, 2013.
 
18) Inokuma S, et al:Bucillamine induced pulmonary injury occurs with immunoglobulin decrease. J Rheumatol 23:1282-1285, 1996.
PubMed
19) Takeuchi T, et al:Post-marketing surveillance of the safety and effectiveness of tacrolimus in 3267 Japanese patients with rheumatoid arthritis. Mod Rheumatol 24:8-16, 2014.
 
20) Takeuchi T, et al:Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 67:189-194, 2008.
PubMed
21) Koike T, et al:Post surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. Mod Rheumatol 21:343-351, 2011.
 
22) Koike T, et al:Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients:Postmarketing surveillance report of 7740 patients. Mod Rheumatol , 2013. [Epub ahead of print]
 
23) Koike T, et al:Effectiveness and safety of tocilizumab:Postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan. J Rheumatol 41:15-23, 2014.
PubMed
24) オレンシア(R)適正使用情報vol.4, 最終報告概要. ブリストルマイヤーズ株式会社 小野薬品工業株式会社, 2013.
 
25) Yamanaka H, et al:Management of rheumatoid arthritis:the 2012 perspective. Mod Rheumatol 23:2-7, 2013.
 
26) Carson CW, et al:Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate. Semin Arthritis Rheum 16:186-195, 1987.
PubMed
27) Kremer JM, et al:Clinical, laboratory, radiographic, and histopathologic features of methotrexateassociated lung injury in patients with rheumatoid arthritis:a multicenter study with literature review. Arthritis Rheum 40:1829-1837, 1997.
PubMed
28) 金澤實:薬剤性肺疾患:診断と治療の進歩 IV. 治療指針 1. 治療方針. 日内会誌 96:1156-1162, 2007.
 
P.630 掲載の参考文献
1) 大園恵幸:腎障害. 日本臨牀 70(増刊号6):69-73, 2012.
 
2) Kawai S, et al:Recent advances in nonsteroidal anti-inflammatory drugs. Allergol Int 54:209-215, 2005.
 
3) Honkanen E, et al:Membranous glomerulonephritis in rheumatoid arthritis not related to gold or D-penicillamine therap.:a report of four cases and review of the literature. Clin Nephrol 27:87-93, 1987.
 
4) Radford MG Jr, et al:Reversible membranous nephropathy associated with the use of nonsteroidal anti-inflammatory drugs. JAMA 276:466-469, 1996.
PubMed
5) Sugiyama T, et al:Analysis of clinical features and renal biopsy findings in Japanese patients with Sjogren's syndrome. In:Sjogren's Syndrome. State of the Art (ed by Honma M, et al), p441-443, Kugler Publications, Amsterdam, New York, 1994.
 
6) Becker-Cohen R, Frishberg Y:Severe reversible renal failure due to naproxen-associated acute interstitial nephritis. Eur J Pediatrl 60:293-295, 2001.
 
7) Inoue M, et al:Successful relatively low-dose corticosteroid therapy for diclofenac-induced acute interstitial nephritis with severe renal failure. Clin Exp Nephrol 12:296-299, 2008.
PubMed
8) Segasothy M, et al:Chronic renal disease and papillary necrosis with the long-term use of nonsteroidal anti-inflammatory drugs as the sole or predominant analgesic. Am J Kidney Dis 24:17-24, 1994.
PubMed
9) 黒木亜紀ほか:ネフローゼ症候群. 日本臨牀 70(増刊号6):419-422, 2012.
Medical*Online
10) Hall CL:The natural course of gold and penicillamine nephropathy:a longterm study of 54 patients. Adv Exp Med Biol 252:247-256, 1989.
PubMed
11) Hoshino J, et al:Outcome and treatment of bucillamine-induced nephropathy. Nephron Clin Pract 104:15-19, 2006.
 
12) 杉山隆夫ほか:潰瘍性大腸炎の経過中にびまん性増殖性ループス腎炎を発症した1例. リウマチ 36:651-655, 1996.
 
13) 杉山隆夫ほか:慢性関節リウマチの経過中に巣状糸球体硬化症によるネフローゼ症候群と急性腎不全を合併した1例. 日腎誌 39:426-430, 1997.
 
14) Stokes MB, et al:Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant 20:1400-1406, 2005.
PubMed
P.638 掲載の参考文献
1) 滝川一ほか:DDW-J 2004ワークショップ 薬物性肝障害診断基準の提案. 肝臓 46:85-90, 2005.
 
2) 日本リウマチ学会MTX診療ガイドライン策定小委員会:関節リウマチ治療におけるメトトレキサート (MTX) 診療ガイドライン2011年版 羊土社, 2011.
 
3) ファイザー株式会社:リウマトレックス(R)適正使用情報Vol.19, 副作用および死亡症例の発現状況, 2013年5月.
 
4) Salliot C, van der Heijde D:Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis:systemic literature research. Ann Rheum Dis 68(7):1100-1104, 2009.
PubMed
5) Curtis JR, et al:Elevated liver enzyme tests among rheumatoid arthritis and psoriatic arthritis patients treated with methotrexate and/or leflunomide. Ann Rheum Dis 69(1):43-47, 2010.
PubMed
6) Hara M, et al:Long-term safety study of iguratimod in patients with rheumatoid arthritis. Mod Rheumatol 17:10-16, 2007.
PubMed
7) エーザイ株式会社:イグラチモド適正使用情報Vol.3.
 
8) 中外製薬株式会社:アクテムラ(R)点滴静注用80mg, 200mg, 400mg全例調査最終報告「関節リウマチ」「多関節に活動性を有する若年性特発性関節炎」
 
9) 厚生労働省科学研究費補助金 肝炎等克服緊急対策研究事業「免疫抑制薬, 抗悪性腫瘍薬によるB型肝炎ウイルス再活性化の実態解明と対策法の確立」平成23年度研究成果報告.
 
10) 日本リウマチ学会:B型肝炎ウイルス感染リウマチ性疾患患者への免疫抑制療法に関する提言 (2012年9月5日再改訂). [http://www.ryumachi-jp.com/info/news120905.html]
 
P.643 掲載の参考文献
1) Wolfe F, et al:Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia. Arthritis Rheum 54:628-634, 2006.
PubMed
2) Bombardieri S, et al:Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology 46:1191-1199, 2007.
PubMed
3) Harigai M, et al:Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med 357(18):1874-1876, 2007.
PubMed
4) 渡辺彰:生物学的製剤使用時の肺炎および結核の合併頻度とその対策. 医学のあゆみ 221:405-409, 2007.
Medical*Online
5) Yamada T, et al:Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan. Ann Rheum Dis 65:1661-1663, 2006.
PubMed
6) 有限責任中間法人日本リウマチ学会リウマチ性疾患 治療薬検討委員会:関節リウマチ (RA) に対するTNF阻害療法施行ガイドライン (改訂版). 日本リウマチ学会ホームページ [http://www.ryumachi-jp.com/info/080201.html], 2008年2月1日.
 
P.649 掲載の参考文献
1) Deschemin JC, Vaulont S:Role of hepcidin in the setting of hypoferremia during acute inflammation. PLoS One 8(4):e61050, 2013.
PubMed
2) Ganz T, Nemeth E:Hepcidin and disorders of iron metabolism. Annu Rev Med 62:347-360, 2011.
PubMed
3) Ganz T:Hepcidin and iron regulation, 10 years later. Blood 117(17):4425-4433, 2011.
PubMed
4) Faquin WC, et al:Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 79(8):1987-1994, 1992.
PubMed
5) Papadaki HA, et al:Bone marrow progenitor cell reserve and function and stromal cell function are defective in rheumatoid arthritis:evidence for a tumor necrosis factor alpha-mediated effect. Blood 99 (5):1610-1619, 2002.
PubMed
6) Esplin BL, et al:Chronic exposure to a TLR ligand injures hematopoietic stem cells. J Immunol 186(9):5367-5375, 2011.
PubMed
7) Ma YD, et al:Defects in osteoblast function but no changes in long-term repopulating potential of hematopoietic stem cells in a mouse chronic inflammatory arthritis model. Blood 114 (20):4402-4410, 2009.
 
8) Oduro KA Jr, et al:Myeloid skewing in murine autoimmune arthritis occurs in hematopoietic stem and primitive progenitor cells. Blood 120(11):2203-2213, 2012.
PubMed
9) Fujii H, et al:Telomerase insufficiency in rheumatoid arthritis. Proc Natl Acad Sci USA 106(11):4360-4365, 2009.
PubMed
10) Yokota T, et al:Soluble frizzled-related protein 1 is estrogen inducible in bone marrow stromal cells and suppresses the earliest events in lymphopoiesis. J Immunol 181(9):6061-6072, 2008.
PubMed
11) Sabattini E, et al:WHO classification of tumours of haematopoietic and lymphoid tissues in 2008:an overview. Pathologica 102(3):83-87, 2010.
PubMed
12) Mariette X, et al:Lymphomas in rheumatoid arthritis patients treated with methotrexate:a 3-year prospective study in France. Blood 99(11):3909-3915, 2002.
PubMed
13) 中尾眞二ほか:再生不良性貧血. 特発性造血障害疾患の診療の参照ガイド 平成22年度改訂版 (小澤敬也編), p3-32, 厚生労働科学研究費補助金難治性疾患克服研究事業 特発性造血障害に関する調査研究班 (平成20-22年度), 2010.
 
P.653 掲載の参考文献
1) Borchers AT, et al:Immune-mediated adverse effects of biologicals used in the treatment of rheumatic diseases. J Autoimmun 37:273-288, 2011.
PubMed
2) Pumphrey RS, Roberts IS:Postmortem findings after fatal anaphylactic reactions. J Clin Pathol 53:273-276, 2000.
PubMed
3) Johansson SG, et al:Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the WOrld Allergy Organization, October 2003. J Allergy Clin Immunol 113:832-836, 2004.
PubMed
4) Lieberman P, et al:The diagnosis and management of anaphylaxis practice parameter:2010 update. J Allergy Clin Immunol 126:477-480. e1-42, 2010.
 
5) Kounis NG:Kounis syndrome (allergic angina and allergic myocardial infarction):a natural paradigm? Int J Cardiol 110:7-14, 2006.
PubMed
6) Simons FE:World Allergy Organization survey on global availability of essentials for the assessment and management of anaphylaxis by allergy-immunology specialists in health care settings. Ann Allergy Asthma Immunol 104:405-412, 2011.
 
7) Sampson HA, et al:Second symposium on the definition and management of anaphylaxis:summary report-Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 117:391-397, 2006.
PubMed
8) Campbell RL, et al:Evaluation of national institute of allergy and infectious diseases/food allergy and anaphylaxis network criteria for the diagnosis of anaphylaxis in emergency department patients. J Allergy Clin Immunol 129:748-752, 2012.
PubMed
9) Payne-V, Kam PC:Mast cell tryptase:a review of its physiology and clinical significance. Anaesthesia 59:695-703, 2004.
PubMed
10) Mertes PM, et al:Perioperative anaphylaxis. Med Clin North Am 94:761-789, xi, 2010.
PubMed
11) Vanden Hoek TL, et al.:Part 12:cardiac arrest in special situations:2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 122:S829-861, 2010.
PubMed
12) Kemp SF, Lockey RF:Anaphylaxis:a review of causes and mechanisms. J Allergy Clin Immunol 110:341-348, 2002.
PubMed
13) Oswalt ML, Kemp SF:Anaphylaxis:office management and prevention. Immunol Allergy Clin North Am 27:177-191, vi, 2007.
PubMed
14) Winbery SL, Lieberman PL:Histamine and antihistamines in anaphylaxis. Clin Allergy Immunol 17:287-317, 2002.
PubMed
15) Schummer C, et al:The pivotal role of vasopressin in refractory anaphylactic shock. Anesth Analg 107:620-624, 2008.
PubMed
P.658 掲載の参考文献
1) Warrington TP, BostWick JM:Psychiatric adverse effects of corticosteroids. Mayo Clin Proc 81:1361-1367, 2006,
PubMed
2) Lewis DA, Smith RE:Steroid-induced psychiatric syndromes. A report of 14 cases and a review of the literature. J Affect Disord 5:319-332, 1983.
 
3) Cade R, et al:Comparison of azathioprine, prednisone, and heparin alone or combined in treating lupus nephritis. Nephron 10:37-56, 1973.
PubMed
4) Gagliardi Jp. et al:When Steroids Cause Psychosis-Medical management of this side effect is complicated in rheumatology patients. The Rheumatol ogist, 2010. [http://www.the-rheumatologist.org/details/article/867939/When_Steroids_Cause_Psychosis.html]
 
5) American Psychiatric Association:Diagnostic and Statistical Manual of Mental Disorders, 4th ed, American Psychiatric Association, Washington, 1994.
 
6) Sirois F:Steroid psychosis:a review. Gen Hosp Psychiatry 25:27-33, 2003.
PubMed
7) Naber D, et al:Psychopathological and neuropsychological effects of 8-days corticosteroid treatment:a prospective study. Psychoneuroendocrinology 21:25-31, 1996.
PubMed
8) Boston Collaborative Drug Surveillance Program:Acute adverse reactions to prednisone in relation to dosage. Clin Pharmacol Ther 13:694-698, 1972.
 
9) Mullen RS, Romans-Clarkson SE:Behavioral sensitization and steroid-induced psychosis. Br J Psychiatry 162:549-551, 1993.
PubMed
10) Bhangle SD, et al:Corticosteroid-induced neuropsychiatric disorders:review and contrast with neuropsychiatric lupus. Rheumatol Int 3:1923-1932, 2013.
 
11) Turktas I, et al:Medication-induced psychotic reaction. J Am Acad Child Adolesc Psychiatry 36:1017-1018, 1997.
 
12) Wolkowitz OM, et al:Glucocorticoids:mood, memory, and mechanisms. Ann NY Acad Sci 1179:19-40, 2009.
 
13) Hirohata S, et al:A patient with systemic lupus erythematosus presenting both central nervous system lupus and steroid induced psychosis. J Rheumatol 15:706-710, 1988.
PubMed
14) 廣畑俊成, 有沼良幸:シンポジウム4 リウマチ性疾患の合併症. 克服を日指して. Topic 1 ステロイド精神病-リウマチ専門医-. 第57回日本リウマチ学会総会・学術集会抄録集, p151, 2013.
 
15) Nishimura K, et al:Blood-brain barrier damage as a risk factor for corticosteroid-induced psychiatric disorders in systemic lupus erythematosus. Psychoneuroimmunology 33:395-403, 2008.
 
P.662 掲載の参考文献
1) Sakaguchi M, et al:Impact of oral corticosteroid use for idiopathic osteonecrosis of the femoral head:A nationwide multicenter case-control study in Japan. J Orthop Sci 15:185-191, 2010.
PubMed
2) 廣田良夫ほか:特発性大腿骨頭壊死症の分析疫学. 別冊整形外科 35:8-15, 1999.
 
3) Hirota Y, et al:Association of alcohol intake, cigarette smoking, and occupational status with the risk of idiopathic osteonecrosis of the femoral head. Am J Epidemiol 137:530-538, 1993.
PubMed
4) Yamaguchi R, et al:Incidence of non-traumatic osteonecrosis of the femoral head in the Japanese population. Arthritis Rheum 63:3169-3173, 2011.
 
5) Fukushima W, et al:Nationwide epidemiologic survey of idiopathic osteonecrosis of the femoral head. Clin Orthop Relat Res 468:2715-2724, 2010.
PubMed
6) Kaneshiro Y, et al:Low hepatic cytochrome P450 3A activity is a risk for corticosteroid-induced osteonecrosis. Clin Pharmacol Ther 80:396-402, 2006.
PubMed
7) Kubo T, et al:Initial MRI findings of non-traumatic osteonecrosis of the femoral head in renal allograft recipients. Magn Reson Imaging 15(9):1017-1023, 1997.
PubMed
8) Nagasawa K, et al:Very early development of steroid-associated osteonecrosis of femoral head in systemic lupus erythematosus:prospective study by MRI. Lupus 14(5):385-390, 2005.
PubMed
9) Sugano N, et al:Multicenter study of diagnostic criteria for nontraumatic osteonecrosis of the femoral head. J Bone Joint Surg 81B:590-595, 1999.
 
10) Shimizu K, et al:Prediction of collapse with magnetic resonance imaging of avascular necrosis of the femoral head. J Bone Joint Surg Am 76(2):215-223, 1994.
PubMed
11) Motomura G, et al:Combined effects of an anticoagulant and a lipid-lowering agent on the prevention of steroid-induced osteonecrosis in rabbits. Arthritis Rheum 50:3387-3391, 2004.
 
12) Ichiseki T, et al:Oxidative stress and vascular permeability in steroid-induced osteonecrosis model. J Orthop Sci 9:509-515, 2004.
 
13) Kuribayashi M, et al.:Vitamin E prevents steroid-induced osteonecrosis in rabbits. Acta Orthop 81:206-212, 2010.
 
14) Nishida K, et al:Pitavastatin may reduce risk of steroid-induced osteonecrosis in rabbits:a preliminary histological study. Clin Orthop Relat Res 466:1054-1058, 2008.
 
15) Yamaguchi R, et al:Effects of an anti-platelet drug on the prevention of steroid-induced osteonecrosis in rabbits. Rheumatology 51:789-793, 2012.
PubMed
P.670 掲載の参考文献
1) 鈴木康夫, 佐藤慎二:ステロイド性骨粗髪症の特異性. Clinical Calcium 20(5):645-653, 2010.
 
2) Kirigaya D, et al:Management and treatment of osteoporosis in patients receiving long-term glucocorticoid treatment:current status of adherence to clinical guidelines and related factors. Intern Med 50(22):2793-2800, 2011.
PubMed
3) 鈴木康夫:ステロイド誘発骨粗鬆症-疫学・病態・予防治療ガイドライン (第4回日本骨粗鬆症学会サテライトシンポジウム:ステロイド性骨粗鬆症の薬物療法). Osteoporosis Japan 11(3):427-436, 2003.
 
4) van Staa TP, et al:The epidemiology of conicosteroid-induced osteoporosis. A meta-analysis. Osteoporos Int 13(10):777-787, 2002.
PubMed
5) Nawata H, et al:Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004). J Bone Miner Metab 23(2):105-109, 2005.
PubMed
6) Saag KG, et al:Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357(20):2028-2039, 2007.
 
7) Kanis JA, on behalf of the World Health Organization Scientific Group:Assessment of osteoporosis at the primary health care level. WHO Collaborating Centre for Metabolic Bone Diseases, University of Scheffield, 2007.
 
8) Grossman JM, et al:American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 62(11):1515-1526, 2010.
PubMed
9) Lekamwasam S, et al:A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int 23(9):2257-2276, 2012.
PubMed

X 関節リウマチの予後因子

P.676 掲載の参考文献
1) Sokka T, et al:Mortality in rheumatoid arthritis:2008 update. Clin Exp Rheumatol 26:S35-61, 2008.
PubMed
2) Nakajima A, et al:Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, IORRA. Scand J Rheumatol 39:360-367, 2010.
PubMed
3) Young A, et al:Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology (Oxford) 46:350-357, 2007.
PubMed
4) Dadoun S, et al:Mortality in rheumatoid arthritis over the last fifty years:systematic review and meta-analysis. Joint Bone Spine 80:29-33, 2013.
PubMed
5) Leombruno JP, et al:The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis:meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 68:1136-1145, 2009.
PubMed
6) Carmona L, et al:All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 66:880-885, 2007.
 
7) Jacobsson LT, et al:Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 66:670-675, 2007.
PubMed
8) Lunt M, et al:No evidence of association betWeen anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis:results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 62:3145-3153, 2010.
PubMed
9) Thyagarajan V, et al:Risk of mortality, fatal infection, and fatal malignancy related to use of anti-tumor necrosis factor-alpha biologics by rheumatoid arthritis patients. Semin Arthritis Rheum 42:223-233, 2012.
PubMed
10) Nakajima A, et al:No increased mortality in patients with rheumatoid arthritis treated with biologics:results from the biologics register of six rheumatology institutes in Japan. Mod Rheumatol 23:945-952, 2013.
PubMed
11) Charlson ME, et al:A new method of classifying prognostic comorbidity in longitudinal studies:development and validation. J Chronic Dis 40:373-383, 1987.
PubMed
12) Charlson M, et al:Validation of a combined comorbidity index. J Clin Epidemiol 47:1245-1251, 1994.
PubMed
13) Norton S, et al:A study of baseline prevalence and cumulative incidence of comorbidity and extra-articular manifestations in RA and their impact on outcome. Rheumatology (Oxford) 52:99-110, 2013.
 
14) Scire CA, et al:Early remission is associated with improved survival in patients with inflammatory polyarthritis:results from the Norfolk Arthritis Register. Ann Rheum Dis, 2013. [Epub ahead of print]
 
P.682 掲載の参考文献
1) 厚生労働科学研究費補助金 (免疫アレルギー疾患等予防・治療研究事業) 研究代表報告書 関節リウマチの関節破壊機序の解明と関節破壊「ゼロ」を目指す治療法確立に関する研究 平成23年度 総括・研究分担報告書 田中良哉.
 
2) Courvoisier N, et al:Prognostic factors of 10-year radiographic outcome in early rheumatoid arthritis:a prospective study. J Rheumatol 38(1):44-52, 2011.
 
3) Markatseli TE, et al:Prognostic factors of radiological damage in rheumatoid arthritis:a 1-year retrospective study. J Rheumatol 38(1):44-52, 2011.
PubMed
4) Jansen LM, et al:Predictors of radiographic joint damage in patients with early rheumatoid arthritis. Ann Rheum Dis 60(10):924-927, 2001.
PubMed
5) Saag KG, et al:American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59:762-784, 2008.
PubMed
6) Aletaha D, Smolen JS:Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints. Arthritis Rheum 63(12):3702-3711, 2011.
 
7) Felson T, et al:American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials. Ann Rheum Dis 70:404-413, 2011.
 
8) Takeuchi T, et al:Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan:one-year outcome of joint destruction (RECONFIRM-2J). Mod Rheumatol 18(5):447-454, 2008.
 
9) de Vries-Bouwstra JK, et al:Progression of joint damage in early rheumatoid arthritis:association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies. Arthritis Rheum 58(5):1293-1298, 2008.
PubMed
10) Yamanaka H, et al:Serum matrix metalloproteinases as a predictor of the degree of joint destruction during the six months after measurement in patients with early rheumatoid arthritis. Arthritis Rheum 43:852 -858, 2000.
 
11) Houseman M, et al:Baseline serum MMP-3 levels in patients with Rheumatoid Arthritis are still independently predictive of radiographic progression in a longitudinal observational cohort at 8 years follow up. Arthritis Res Ther 14(1):R30, 2012.
 
12) Funck-Brentano T, et al:Prediction of radiographic damage in early arthritis by sonographic erosions and power Doppler signal:a longitudinal observational study. Arthritis Care Res (Hoboken) 65(6):896-902, 2013.
 
13) Dougados M, et al:The ability of synovitis to predict structural damage in rheumatoid arthritis:a comparative study between clinical examination and ultrasound. Ann Rheum Dis 72(5):665-671, 2013.
PubMed
P.687 掲載の参考文献
1) Backdahl M:The caput ulnae syndrome in rheumatoid arthritis:a study of the morphology, abnormal anatomy, and clinical picture. Acta Rheumatol Scand 5:1-75, 1963.
 
2) Taleisnik J:The Sauve-Kapandji procedure. Clin Orthop Relat Res (275):110-123, 1992.
PubMed
3) Nolan WB, 3rd, Eaton RG:A Darrach procedure for distal ulnar pathology derangements. Clin Orthop Relat Res (275):85-89, 1992.
PubMed
4) Murray PM:Radioscapholunate arthrodesis. Hand Clin 21(4):561-566, 2005.
PubMed
5) Williamson SC, Feldon P:Extensor tendon ruptures in rheumatoid arthritis. Hand Clin 11(3):449-459, 1995.
PubMed
6) Sakuma Y, et al:Number of ruptured tendons and surgical delay as prognostic factors for the surgical repair of extensor tendon ruptures in the rheumatoid wrist. J Rheumatol 41(2):265-269, 2014.
PubMed
7) Geldmacher J, et al:Bedeutung der praoperativen Status bei der Auswertung der Ergebnisse der Rekonstruktion der Strecksehnen (in German). Significance of the preoperative status in the evaluation of results of the reconstruction of extensor tendons. Handchir Mikrochir Plast Chir 18:23-29, 1986.
 
8) Ryu J, et al:Risk factors and prophylactic tenosynovectomy for extensor tendon ruptures in the rheumatoid hand. J Hand Surg Br 23(5):658-661, 1998.
 
9) Ishikawa H, et al:Rheumatoid wrist deformity and risk of extensor tendon rupture evaluated by 3DCT imaging. Skeletal Radiol 39(5):467-472, 2010.
PubMed
10) Moore JR, et al:Tendon ruptures in the rheumatoid hand:analysis of treatment and functional results in 60 patients. J Hand Surg Am 12(1):9-14, 1987.
PubMed
11) Nakamura S, et al:Tendon grafting for multiple extensor tendon ruptures of fingers in rheumatoid hands. J Hand Surg Br 27(4):326-328, 2002.
 
12) Mountney J, et al:Free tendon interposition grafting for the repair of ruptured extensor tendons in the rheumatoid hand. A clinical and biomechanical assessment. J Hand Surg Br 23(5):662-665, 1998.
 
13) Chu PJ, et al:Extensor-tendons reconstruction using autogenous palmaris longus tendon grafting for rheumatoid arthritis patients. J Orthop Surg Res 3:16, 2008.
PubMed
14) Shannon FT, et al:Surgery for rupture of extensor tendons in rheumatoid arthritis. Hand 8(3):279-286, 1976.
PubMed
15) Gong HS, et al:Extensor tendon rupture in rheumatoid arthritis:a survey of patients between 2005 and 2010 at five Korean hospitals. Hand Surg 17 (1):43-47, 2012.
PubMed
16) Alderman AK, et al:Effectiveness of rheumatoid hand surgery:contrasting perceptions of hand surgeons and rheumatologists. J Hand Surg Am 28(1):3-11, 2003.
PubMed
P.691 掲載の参考文献
1) Tutuncu Z, et al:Do patients with older-onset rheumatoid arthritis receive less aggressive treatment? Ann Rheum Dis 65:1226-1229, 2006.
PubMed
2) Koller MD, et al:Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients. Rheumatology (Oxford) 48:1575-1580, 2009.
PubMed
3) Lopez-Hoyos M, et al:Clinical utility of anti-CCP antibodies in the differential diagnosis of elderly-onset rheumatoid arthritis and polymyalgia rheumatica. Rheumatology (Oxford) 43:655-657, 2004.
PubMed
4) Caporali R et al:Presenting features of polymyalgia rheumatica (PMR) and rheumatoid arthritis with PMR-like onset:a prospective study. Ann Rheum Dis 60:1021-1024, 2001.
PubMed
5) van der Heijde DM, et al.:Older versus younger onset rheumatoid arthritis:results at onset and after 2 years of a prospective followup study of early rheumatoid arthritis. J Rheumatol 18:1285-1289, 1991.
PubMed
6) Pease CT, et al:Does the age of onset of rheumatoid arthritis influence phenotype?:a prospective study of outcome and prognostic factors. Rheumatology (Oxford) 38:228-234, 1999.
PubMed
7) Bathon JM, et al:Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. J Rheumatol 33:234-243, 2006.
PubMed
8) Sugihara T, et al:Treat-to-Target Strategy Aiming At Achievement of Structural and Functional Remission in Patients with Active Elderly-Onset Rheumatoid Arthritis. Arthritis Rheum 64:S161, 2012.
 
9) Glennas A, et al:Recent onset arthritis in the elderly:a 5 year longitudinal observational study. J Rheumatol 27:101-108, 2000.
PubMed

XI ガイドライン策定の意義

P.703 掲載の参考文献
1) Elliott MJ, et al:Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 36:1681-1690, 1993.
PubMed
2) Singh JA, et al:2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 64(5):625-639, 2012.
PubMed
3) Smolen JS:EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69(6):964-975, 2010.
PubMed
4) Smolen JS, et al:EULAR recommendation for the management of rheumatoid arthritis-2013 update. EULAR 2013, Oral presentation.
 
P.708 掲載の参考文献
1) 熊谷俊一ほか:白己抗体検査の全国サーベイとそれに基づく標準化の検討. 臨床病理 57(1):31-41, 2009.
 
2) Xie F:The need for standardization:A literature review of indirect costs of rheumatoid arthritis and osteoarthritis. Arthritis Rheum (Arthritis Care Res) 59(7):1027-1033, 2008.
 
3) Aletaha D, et al:2010 Rheumatoid arthritis classification criteria:an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62(9):2569-2581, 2010.
PubMed
4) 吉野谷定美ほか:リウマトイド因子測定値の標準化について. リウマチ 36(6):819-829, 1997.
 
5) 厚生労働科学研究費補助金 (医療技術評価総合研究事業) 総括研究報告書, 平成16年度 総括研究報告書 (主任研究者:熊谷俊一), 平成17年 (2005年) 3月.
 
6) 熊谷俊一:RF標準化の問題点とお願い. Laboratory and Clinical Practice 26(1):35-41, 2008.
Medical*Online
7) van der Linden MP, et al.:Toward a data-driven evaluation of the 2010 American College of Rheumatology/European League Against Rheumatism criteria for rheumatoid arthritis:is it sensible to look at Ievels of rheumatoid factor? Arthritis Rheum 63(5):1190-1199, 2011.
 
8) Vastesaeger N, et al:A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology (Oxford) 48(9):1114-1121, 2009.
PubMed
9) 知的基盤創成・利用促進研究開発事業「臨床検査用標準物質の研究開発」平成18年度成果報告書 (作成:独立行政法人新エネルギー・産業技術総合開発機構) 2-4-2-2 リウマトイド因子 (RF) (責任者:島村朗), p320-328, 2007年5月.
 
10) 知的基盤創成・利用促進研究開発事業「臨床検査用標準物質の研究開発」平成19年度成果報告書 (作成:独立行政法人新エネルギー・産業技術総合開発機構) 2-4-2-2 リウマトイド因子 (RF) (責任者:斎藤憲祐), p251-269, 2008年5月.
 
11) 日本リウマチ学会:日本リウマチ学会からのお知らせ. リウマトイド因子標準化のガイドライン (日本臨床検査標準化協議会認証), 2011. [http://www.ryumachi-jp.com/info/news110817.html]
 
12) 林伸英, 熊谷俊一:関節リウマチ診断における自己抗体検査の標準化. 臨床化学 41(2):127-132, 2012.
Medical*Online
13) Ameratunga R, et al:Rheumatoid factor measurement-continuing problems 70 years after discovery. Clin Rheumatol 30(9):1215-1220, 2011.
PubMed
P.713 掲載の参考文献
1) 日本リウマチ学会関節リウマチ超音波標準化委員会:リウマチ診療のための関節エコー撮像法ガイドライン, 2011.
 
2) Colebatch AN, et al:EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Ann Rheum Dis 72:804-814, 2013.
PubMed
3) Backhaus M, et al:Guidelines for musculoskeletal ultrasound in rheumatology. Ann Rheum Dis 60:641-649, 2001.
PubMed
4) D'Agostino MA, et al:The OMERACT ultrasound task force-Advances and priorities. J Rheumatol 36:1829-1832, 2009.
PubMed
5) Naredo E, et al:The OMERACT ultrasound task force-status and perspectives. J Rheumatol 38:2063-2067, 2011.
PubMed
6) Wakefield RJ, et al:Musculoskeletal ultrasound including definitions for ultrasonographic pathology. J Rheumatol 32:2485-2487, 2005.
PubMed
7) Wakefield RJ, et al:After treat-to-target:can a targeted ultrasound initiative improve RA out-comes? Ann Rheum Dis 71:799-803, 2012.
 
8) Guideline development in Europe. An international comparison. Int J Technol Assess Health Care 16:1039-1049, 2000.
PubMed
9) 中山健夫:EBMを用いた診療ガイドライン:作成・活用ガイド, 金原出版, 2004.
 
10) Minds診療ガイドライン選定部会:Minds診療ガイドライン作成の手引き 2007, 医学書院, 2007.
 
11) Nakagomi D, et al:Ultrasound can improve the accuracy of the 2010 American College of Rheumatology/European League against rheumatism classification criteria for rheumatoid arthritis to predict the requirement for methotrexate treatment. Arthritis Rheum 65:890-898, 2013.
PubMed
12) Ikeda K, et al:Correlation of radiographic progression with the cumulative activity of synovitis estimated by power Doppler ultrasound in rheumatoid arthritis:difference betWeen patients treated with methotrexate and those treated with biological agents. J Rheumatol 40:1967-1976, 2013.
PubMed
13) Ogasawara M, et al:Autofeedback from ultrasound images provides rapid improvement in palpation skills for identifying joint swelling in rheumatoid arthritis. J Rheumatol 39:1207-1214, 2012.
PubMed

XII トランスレーショナルリサーチ - 基礎から臨床応用まで -

P.721 掲載の参考文献
1) Evans CH, et al:Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis. Hum Gene Ther 7:1261, 1996.
PubMed
2) Hacein-Bey-Abina S, et al:LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302:415-419, 2003.
PubMed
P.726 掲載の参考文献
1) Okano T, et al.:Mechanism of cell detachment from temperature-modulated, hydrophilic-hydrophobic polymer surfaces. Biomaterials 16:297-303, 1995.
PubMed
2) Okano T. et al:A novel recovery system for cultured cells using plasma-treated polystyrene dishes grafted with poly (N-isopropylacrylamide). J Biomed Mater Res 27:1243-1251, 1993.
PubMed
3) Kaneshiro N, et al:Bioengineered chondrocyte sheets may be potentially useful for the treatment of partial thickness defects of articular cartilage. Biochem Biophys Res Commun 349(2):723-731, 2006.
PubMed
4) Kaneshiro N, et al:Cultured articular chondrocytes sheets for partial thickness cartilage defects utilizing temperature-responsive culture dishes. Eur Cell Mater 13:87-92, 2007.
PubMed
5) Mitani G, et al:The properties of bioengineered chondrocyte sheets for cartilage regeneration. BMC Biotechnol 9:17, 2009.
PubMed
6) Ebihara G, et al:Cartilage repair in transplanted scaffold-free chondrocyte sheets using a minipig model. Biomaterials 33(15):3846-3851, 2012.
PubMed
7) Sato M:Cell sheet technologies for cartilage repair. In:Regenerative Medicine and Biomaterials for the Repair of Connective Tissues, p251-265, Woodhead Publishing Limited, Cambridge, UK, CRC Press LLC, Florida, USA, 2010.
 
8) 佐藤正人ほか:分子レベルからみた整形外科疾患-シリーズ VIII ; 関節軟骨損傷修復のための軟骨細胞シート. 整形・災害外科 53(13):1554-1555, 2010.
 
9) Ito S, et al:Repair of articular cartilage defect with layered chondrocyte sheets and cultured synovial cells. Biomaterials 33(21):5278-5286, 2012.
PubMed
10) Kokubo M, et al:Characterization of chondrocyte sheets prepared using a co-culture method with temperature-responsive culture inserts. J Tissue Eng Regen Med, 2013 Jul 19. doi:10. 1002/term. 1764. [Epub ahead of print]
 
11) Hamahashi K, et al:Studies of the humoral factors produced by layered chondrocyte sheets. J Tissue Eng Regen Med, 2012 Nov 19. DOI:10.1002/term. 1610. [Epub ahead of print]
 
12) Sato M, et al:An atelocollagen honeycomb-shaped scaffold with a membrane seal (ACHMSscaffold) for the culture of annulus fibrosus cells from an intervertebral disc. J Biomed Mater Res A 64(2):248-256, 2003.
PubMed
13) Masuoka K, et al:Tissue engineering of articular cartilage using an allograft of cultured chondrocytes in a membrane-sealed atelocollagen honeycomb-shaped scaffold (ACHMS scaffold). J Biomed Mater Res B 75(1):177-184, 2005.
 
14) Sato M, et al:Effects of growth factors on heparin-carrying polystyrene-coated atelocollagen scaffold for articular cartilage tissue engineering. J Biomed Mater Res B 83(1):181-188, 2007.
 
15) Sato M, et al:An experimental study of the regeneration of the intervertebral disc with an allograft of cultured annulus fibrosus cells using a tissue-engineering method. Spine 28(6):548-553, 2003.
PubMed
16) Sato M, et al:Tissue engineering of the intervertebral disc with cultured annulus fibrosus cells using atelocollagen honeycomb-shaped scaffold with a membrane seal (ACHMS scaffold). Med Biol Eng Comput 41(3):365-371, 2003.
PubMed
17) 国際出願・番号:PCT/JP2006/303759, 国際出願日:2006年2月28日, 国際公開番号:WO2006/093151, 国際公開日:2006年9月8日, 出願人:(株) セルシード, 発明者:佐藤正人ほか.
 
18) Nagai T, et al:Characteristics of a scaffold-free articular chondrocyte plate grown in rotational culture. Tissue Eng Part A 14(7):1183 -1193, 2008.
 
19) Sato M, et al:Recent technological advancements related to articular cartilage regeneration. Med Biol Eng Comput 46(8):735-743, 2008.
PubMed
20) Nagai T, et al:Optimization of allograft implantation using scaffold-free chondrocyte plates. Tissue Eng Part A 14(7):1225-1235, 2008.
PubMed
21) Castellanos MV, et al:Chromosomal abnormalities are related to location and grade of osteoarthritis. Osteoarthritis Cartilage 12:982-985, 2004.
PubMed
22) 厚生労働省発医政1003第3号「ヒト幹細胞臨床研究実施計画について」平成23年10月3日.
 
23) 出願番号:特許出願2011-260318, 出願日:2011.11.29, 出願人:学校法人明治大学, 学校法人東海大学, 株式会社バイオベルテ, 発明者:長嶋比呂志, 佐藤正人ほか.
 
24) Maehara M, et al:Development of a novel vitrification method for chondrocyte sheets. BMC Biotechnol 13:58, 2013.
PubMed
P.731 掲載の参考文献
1) Dong L, et al:Spleen-speciflc suppression of TNF-alpha by cationic hydrogel-delivered antisense nucleotides for prevention of arthritis in animal models. Biomaterials 30:4416-4426, 2009.
 
2) Andreakos E, et al:Amphoteric liposomes enable systemic antigen-presenting cell-directed delivery of CD40 antisense and are therapeutically effective in experimental arthritis. Arthritis Rheum 60:994-1005, 2009.
PubMed
3) Hildner KM, et al:Targeting of the transcription factor STAT4 by antisense phosphorothioate antisense oligonucleotides suppresses collagen-induced arthritis. J Immunol 178:3427-3436, 2007.
PubMed
4) Sewell KL, et al:Phase I trial of ISIS 104838. A 2'-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha. J Pharmacol Exp Ther 303:1334-1343, 2002.
PubMed
5) http://ir.isispharm.com/phoenix.zhtml?c=222170&p=irol-newsArticle_pf&ID=1289726&highlight=
 
6) Maksymowych WP, et al:A randomized, placebo controlled trial of an antisense oligodeoxynucleotide to intercellular adhesion molecule」in the treatment of severe rheumatoid arthritis. J Rheumatol 29(3):447-453, 2002.
 
7) Kumar R, et al:Gene targeting by ribozyme against TNF-alpha mRNA inhibits autoimmune arthritis. Gene Ther 12:1486-1493, 2005.
PubMed
8) Schedel J, et al:Targeting cathepsin L (CL) by specific ribozyme decreases CL protein synthesis and cartilage destruction in rheumatoid arthritis. Gene Ther 11:1040-1047, 2004.
PubMed
9) Rutkauskaite E, et al:Ribozyme that inhibit the production of matrix metalloproteinase 1 reduce the invasiveness of rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 50:1448-1456, 2004.
PubMed
10) Tomita T, et al.:Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor kappa B decoy oligodeoxynucleotides as a gene therapy. Arthritis Rheum 42:2532-2542, 1999.
PubMed
11) Tomita T, et al:Transcription factor decoy for NFkappaB inhibits cytokine and adhesion molecule expressions in synovial cells derived from rheumatoid arthritis. Rheumatology 39(7):749-757, 2000.
PubMed
12) Tomita T, et al:E2F decoy oligodeoxynucleotide ameliorates cartilage invasion by infiltrating synovium derived from rheumatoid arthritis. Int J Mol Med 18(2):257-265, 2006.
PubMed
13) Kunugiza Y, et al:Inhibitory effect of ribbon-type NF-kappaB decoy oligodeoxynucleotides on osteoclast induction and activity in vitro and in vivo. Arthritis Res Ther 8(4):R103, 2006.
PubMed

XIII 特論

P.739 掲載の参考文献
1) Yamamoto T:Cutaneous manifestations associated with rheumatoid arthritis. Rheumatol Int 29:979-988, 2009.
PubMed
2) Yamamoto T:Cutaneous necrobiotic conditions associated with rheumatoid arthritis:Important extra-articular involvement. Mod Rheumatol 23:617-622, 2013.
PubMed
3) Yamamoto T, Ueki H:Koebner phenomenon in rheumatoid arthritis. J Genet Syndr Gene Ther 4:173, 2013.
 
4) Hessian PA, et al:Cytokine profile of the rheumatoid nodule suggests that it is a Th1 granuloma. Arthritis Rheum 48:334-338, 2003.
PubMed
5) Cunnane G, et al:Accerelated nodulosis and vasculitis following etanercept therapy for rheumatoid arthritis. Arthritis Rheum 47:445-449, 2002.
 
6) Sangueza OP, et al:Palisaded neutrophilic granulomatous dermatitis in rheumatoid arthritis. J Am Acad Dermatol 47:251-257, 2002.
PubMed
7) Ramos-Casals M, et al:Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 22:847-861, 2008.
PubMed
8) Mohan N, et al:Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol 31:1955-1958, 2004.
PubMed
9) Srivastava MD, et al:Immunology of cutaneous vasculitis associated with both etanercept and infliximab. Scand J Immunol 61:329-336, 2005.
PubMed
10) Hoshida Y, et al:Lymphoproliferative disorders in rheumatoid arthritis:Clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol 34:322-331, 2007.
PubMed
11) Yamamoto T, et al:Skin manifestations associated with rheumatoid arthritis. J Dermatol 22:324-329, 1995.
PubMed
12) Kikuchi N, et al:Pyoderma gangrenosum possibly triggered by adalimumab. Eur J Dermatol 22:804-805, 2012.
PubMed
13) Merrill JT, et al:Adenosine A1 receptor promotion of multinucleated giant cell formation by human monocytes:A mechanism for methotrexate-induced nodulosis in rheumatoid arthritis. Arthritis Rheum 40:1308-1315, 1997.
PubMed
14) Stephenson SR, et al:Palisaded neutrophilic and granulomatous dermatitis presenting in a patient with rheumatoid arthritis on adalimumab. J Cutan Pathol 38:644-648, 2011.
 
15) Yamamoto T:Postherpetic oral ulcers misdiagnosed as pemphigus in a patient with rheumatoid arthritis under bucillamine therapy. Our Dermatol Online 3(Suppl):625-626, 2013.
 
P.745 掲載の参考文献
1) NICE:Rheumatoid arthritis-adalimumab, etanercept and infliximab (TA130). NICE, 2007. [http://publications.nice.org.uk/.adalimumab-etanercept-and-infliximab-for-the-treatment-of-rheumatoid-arthritis-ta130/]
 
2) CADTH:Common Drug Review Cedac Final Recommendation Adalimumab. CADTH, 2005.
 
3) PBAC:Public Summary Document Infliximab, powder for IV infusion, 100mg, Remicade(R). July 2008. PBAC, 2008.
 
4) Saag KG, et al:American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59(6):762-784, 2008.
PubMed
5) Schoels M, et al:Economic aspects of treatment options in rheumatoid arthritis:a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 69:995-1003, 2010.
PubMed
6) Choi HK et al:A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis. Arthritis Rheum 43:2316-2327, 2000.
PubMed
7) Wong JB, et al:Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am J Med 113:400-408, 2002.
PubMed
8) Choi HK, et al:A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis. J Rheumatol 29:1156-1165, 2002.
PubMed
9) Singh JA, et al:2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken) 64(5):625-639, 2012.
PubMed
10) Schoels M, et al:Economic aspects of treatment options in rheumatoid arthritis:a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 69:995-1003, 2010.
PubMed
P.750 掲載の参考文献
1) 秋山雄次:維持透析中の関節リウマチ患者における抗リウマチ薬の使用法. 日臨免疫会誌 34:485-492, 2011.
 
2) 海津嘉蔵ほか:ブシラミンが有効であった維持透析中の慢性関節リウマチの1例. 透析会誌 27:1505-1510, 1994.
 
3) 杉山敏ほか:血液透析患者におけるD-penicillamineの薬動力学的検討. 透析会誌 21:831-836, 1988.
 
4) 黒田毅:透析中の関節リウマチ治療. 炎症と免疫 21:362-367, 2013.
Medical*Online
5) Al-Hasani H, Roussou E:Methotrexate for rheumatoid arthritis patients who are on hemodialysis. Rheumatol Int 31:1545-1547, 2011.
PubMed
6) 吉富啓之ほか:維持透析中の高齢関節リウマチ患者に対する低用量ミゾリビン間歇投与の経験. 新薬と臨床 61:486-491, 2012.
Medical*Online
7) Yamashita M, et al:Efficacy and safety of tacrolimus treatment for rheumatoid arthritis patients undergoing hemodialysis. Mod Rheumatol 18:296-300, 2008.
PubMed
8) Iwamoto M, et al:Administration of leflunomide to a patient with rheumatoid arthritis on haemodialysis. Scand J Rheumatol 34:410-411, 2005.
PubMed
9) Sugioka Y, et al:Use of etanercept in a patient with rheumatoid arthritis on hemodialysis. Mod Rheumatol 18:293 -295, 2008.
 
10) Senel S, et al:The efficacy and safety of etanercept in patients with rheumatoid arthritis and spondyloarthropathy on hemodialysis. Clin Rheumatol 30:1369-1372, 2011.
PubMed
11) Iwamoto M, et al:Effective and safe administration of tocilizumab to a patient with rheumatoid arthritis on haemodialysis. Rheumatol Int 31:559-560, 2011.
PubMed
12) Okuda Y, Takasugi K:Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum 54:2997-3000, 2006.
PubMed
13) Sumida K, et al:Adalimumab treatment in patients with rheumatoid arthritis with renal insufficiency. Arthritis Care Res 65:471-475, 2013.
PubMed
14) Kirwan JR:The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med 333:142-146, 1995.
 
15) Onuma S, et al:Investigation of the clinical effect of large volume leukocytapheresis on methotrexate-resistant rheumatoid arthritis. Ther Apher Dial 10:404-411, 2006.
PubMed
P.755 掲載の参考文献
1) Hazes JM, et al:Rheumatoid arthritis and pregnancy:evolution of disease activity and pathophysiological considerations for drug use. Rheumatology (Oxford) 50:1955-1968, 2011.
PubMed
2) Scioscia C, et al:Intentional etanercept use during pregnancy for maintenance of remission in rheumatoid arthritis. Clin Exp Rheumatol 29:93-95, 2011.
PubMed
3) Sills ES, et al:Successful ovulation induction, conception, and normal delivery after chronic therapy with etanercept:a recombinant fusion anti-cytokine treatment for rheumatoid arthritis. Am J Reprod Immunol 46:366-368, 2001.
PubMed
4) Roux CH, et al:Pregnancy in rheumatology patients exposed to anti-tumor necrosis factor (TNF)-alpha therapy. Rheumatology (Oxford) 46:695-698, 2006.
PubMed
5) Carter JD, et al:Tumor necrosis factor-alpha inhibition and VATER association:a causal relationship. J Rheumatol 33:1014-1017, 2006.
PubMed
6) Carter JD, et al:A safety assessment of tumor necrosis factor antagonists during pregnancy:a review of the Food and Drug Administration database. J Rheumatol 36:635-641, 2009.
PubMed
7) Ostensen M:Are TNF inhibitors safe in pregnancy? Nat Rev Rheumatol 5:184-185, 2009.
PubMed
8) Berthelot JM, et al.:Exposition to anti-TNF drugs during pregnancy:outcome of 15 cases and review of the literature. Joint Bone Spine 76:28-34, 2009.
PubMed
9) Roux CH, et al:Pregnancy in rheumatology patients exposed to anti-tumor necrosis factor (TNF)-alpha therapy. Rheumatology (Oxford) 46:695-698, 2007.
PubMed
10) Sinha A, et al:Rheumatoid arthritis in pregnancy:successful outcome with anti-TNF agent (Etanercept). J Obstet Gynaecol 26:689-691, 2006.
PubMed
11) Hyrich KL, et al:Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents:results from a national population register. Arthritis Rheum 54:2701-2702, 2006.
PubMed
12) Umeda N, et al:A patient with rheumatoid arthritis who had a normal delivery under etanercept treatment. Intern Med 49:187-189, 2010.
PubMed
13) 古川加奈子ほか:エタネルセプト投与下で妊娠・出産した関節リウマチの一例. 日臨免疫会誌 36:47-51, 2013.
 
14) Murashima A, et al:Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis:drug levels in maternal serum, cord blood, breast milk and the infant's serum. Ann Rheum Dis 68:1793-1794, 2009.
 
15) Mahadevan U, et al:Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 11:286-292, 2013.
PubMed
P.759 掲載の参考文献
1) Smolen JS, et al:EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69:964-975, 2010. doi:10.1136/ard. 2009. 126532.
 
2) Aalbers J:Rheumatoid arthritis management options for 2012. Cardiovasc J Afr 23:355, 2012.
PubMed
3) Davis JM, 3rd, Matteson EL:American College of Rheumatology:European League Against Rheumatism:My treatment approach to rheumatoid arthritis. Mayo Clin Proc 87:659-673, 2012. doi:10.1016/j. mayocp. 2012.03.011.
 
4) Conn DL:Oral glucocorticoids should be included in any recommendation for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis:comment on the article by Singh et al. Arthritis Care Res 64:1622-1623, 2012 ; author reply 1623-1624. doi:10.1002/acr. 21809.
 
5) Porter D, et al:DAS28 and rheumatoid arthritis:the need for standardization. Musculoskeletal Care 9:222-227, 2011. doi:10.1002/msc. 218.
 
6) Grunke M, et al:Use of the 28-joint count yields significantly higher concordance between different examiners than the 66/68-joint count. J Rheumatol 39:1334-1340, 2012. doi:10.3899/jrheum. 110677.
 
7) Wolfe F, Michaud K:The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 56:1433-1439, 2007. doi:10.1002/art. 22579.
 
8) Buchbinder R, et al:Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 59:794-799, 2008. doi:10.1002/art. 23716.
 
9) McDougall JA, et al:Long-term statin use and risk of ductal and lobular breast cancer among women 55 to 74 years of age. Cancer Epidemiol Biomarkers Prev 22:1529-1537, 2013. doi:10.1158/1055-9965. EPI-13-0414.
 

書評

最近チェックした商品履歴

Loading...